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Infertility treatment, more specifically Assisted Reproductive Technology [ART], is available 
worldwide, but in many countries and public clinics, this service is not being offered, mostly due 
to limited resources and funds. Many factors can influence the outcome of ART and insufficient 
funds can have an effect on ovarian stimulation protocols, assisted reproduction procedures, 
laboratory procedures and equipment (i.e. CO₂ incubator). Strategies making ART as affordable 
and accessible as possible is of importance. 
The objective of the study was to investigate which factors in ART treatment might have the most 
significant effect on ART outcome in two ART laboratories – one in the public sector and one in 
the private sector. Two studies, one retrospective and one prospective were conducted.  
The retrospective study (2013 - 2014) investigated the effect of two different CO₂ incubators 
(MINC® benchtop incubator and large conventional Forma® incubator) used at a private fertility 
clinic, on ART outcome. Fertilization, embryo quality and development, and clinical pregnancy 
rate [CPR] outcomes were compared. A strict exclusion criteria was applied to eliminate other 
factors that could have an effect on the outcomes and patients were well paired for the study. 
Three hundred and eighty five (385) cycles were included. No statistical significant difference was 
observed between the two incubators for embryo quality on culture days 2 and 5. For day 3, the 
MINC® incubator showed a significant superiority over the Forma® incubator for the proportion 
of good quality embryos [GQE]/number of ova aspirated (44.58% vs. 39.31%; p < 0.05). There 
was no statistical significant difference in CPR between the incubators (45.43% vs 47.17%; p = 
0.81). 
The prospective study aimed at determining (by means of regression analyses) the possible 
negative or positive impact of female patient profile (specifically number of oocytes, age, body 
mass index [BMI], Anti-Mullerian Hormone [AMH] and female diagnosis - tubal factor and 
endometriosis) in two different ART clinics (public and private fertility clinic) on ART outcome with 
regard to CPR. Eight hundred and twenty (820) cycles (572 in the private clinic; 248 in the public 
clinic) were included. Patient profiles in the two clinics were very different. The most common 
female diagnosis at the private clinic was Advanced Maternal Age compared to Tubal Factor 
Infertility [TFI] at the public clinic. Patients with a high BMI was also much more prevalent in the 
public clinic. No statistically significant association, in both clinics (with pooled and separate data), 
was observed between BMI, AMH, endometriosis or TFI and CPR. The only significant 
association with CPR in the final regression analysis (pooled data) was the Site (clinic) and the 
number of metaphase II oocytes available. Data analysis for the two clinics separately, 
considering all confounding factors investigated, indicated that the number of metaphase II 
oocytes available was the only factor that showed a significant association with CPR - and only 
Stellenbosch University  https://scholar.sun.ac.za
iv 
 
at the private clinic. For the public clinic, none of the factors had a significant association with 
CPR when all factors were included in the analysis. 
Various factors contribute to ART outcome, and these factors may differ in public and private 
clinics as shown in this study. Although the results did not show marked differences in outcome 
between the incubator types, all outcomes were better in the MINC® and its use should be 
encouraged. The result of an independent, significant association between number of MII oocytes 
and CPR is linked to specific ovarian stimulation protocols and potential alternative strategies 
should be investigated to optimize outcome without increasing costs. 
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 OPSOMMING  
Infertiliteit behandeling, meer spesifiek geassisteerde reproduktiewe tegnieke [GRT], word 
wêreldwyd toegepas, maar in baie ontwikkelende lande en staatsklinieke is hierdie diens nie 
beskikbaar nie. Die rede daarvoor is hoofsaaklik beperkte bronne en befondsing. Alhoewel daar  
baie faktore is wat die uitkoms van GRT kan beïnvloed kan ŉ gebrek aan fondse die ovulasie 
stimulasie protokolle, GRT prosedures en beskikbaarheid van  apparaat (bv. CO₂ inkubator) 
affekteer. Strategieë wat GRT so bekostigbaar en toeganklik as moontlik maak is dus van uiterste 
belang. 
Die doel  van hierdie studie was om te bepaal watter faktore moontlik ŉ effek kan hê op die 
uitkoms van GRT behandeling by twee verskillende GRT laboratoriums – een in die staat- en ŉ 
ander in die privaatsektor. Twee afsonderlike studies, een retrospektief en die ander prospektief, 
is gedoen.  
Die retrospektiewe studie (2013 – 2014) het beoog om te bepaal wat die effek van twee 
verkillende inkubators,  (MINC® inkubator “benchtop” en ŉ groot konvensionele  Forma® 
inkubator), op GRT uitkoms by ŉ privaat fertiliteitskliniek is. Bevrugting, embrio kwaliteit en 
ontwikkeling en die kliniese swangerskap uitkoms [KSU] is vergelyk. Om faktore wat moontlik die 
uitkoms van die studie  kon beïnvloed te elimineer, is ŉ streng uitsluitingskriteria toegepas en 
paring van pasiënte was dus voldoende. Drie honderd vyf en tagtig (385) siklusse is ingesluit. 
Geen statisties beduidende verskil ten opsigte van embrio kwaliteit op kultuurdae 2 en 5 is gevind 
tussen die twee inkubators nie. Die MINC® inkubator het egter beter gevaar as die Forma® 
inkubator op kultuurdag 3, en statisties betekenisvol meer  goeie kwaliteit embrio’s/aantal oösiete 
geaspireer is gevind (44.58% teen 39.31%; p < 0.05). Daar is ook geen statisties betekenisvolle 
verskil ten opsigte van kliniese swangerskap uitkoms tussen die twee inkubators waargeneem 
nie (45.43% teen 47.17%; p = 0.81). 
Die prospektiewe studie het beoog om te bepaal (d.m.v. ŉ regressie analise) watter faktore van 
die vroulike pasiëntprofiel (spesifiek die getal oösiete, ouderdom, liggaamsmassa-indeks, Anti-
Mullerian hormoon en vroulike diagnose - buisfaktor infertiliteit en endometriose), moontlik ŉ 
positiewe of negatiewe effek kan hê op die GRT uitkomste, veral kliniese swangerskap [KSU], in 
twee verskillende fertiliteitsklinieke. Agthonderd en twintig (820) siklusse is ingesluit (572 in die 
privaatkliniek; 248 in die staatskliniek) in die studie. Die resultate het aangedui dat daar wel ŉ 
verskil was in die pasiëntprofiele tussen die twee klinieke. Die algemeenste vroulike diagnose in 
die privaatkliniek was gevorderde moederlike ouderdom en by die staatskliniek, buisfaktor 
infertiliteit. Die staatskliniek het ook ŉ hoër insidensie van pasiënte met ŉ hoë BMI getoon. Geen 
statisties beduidende assosiasie, in beide klinieke (met saamgevoegde en aparte data), is 
waargeneem tussen BMI, AMH , endometriose of buisfaktor infertiliteit en KSU nie. Die enigste 
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statisties beduidende interaksie in die finale regressie model vir die saamgevoegde data met 
KSU, was die kliniek (“Site”) en die getal metafase II oösiete beskikbaar. Vir die twee klinieke 
apart, en wanneer al die faktore in ag geneem is, was net aantal metafase II oösiete betekenisvol 
geassosieer met KSU en ook net vir die privaatkliniek. Vir die staatskliniek het geen faktor wat 
ondersoek is, ŉ statistiese beduidende assosiasie met KSU getoon nie. 
Verskeie faktore beïnvloed die uitkomste van ŉ GRT siklus en hierdie faktore mag verskil in die 
staats- en privaatklinieke, soos bewys deur die studie. Alhoewel resultate nie betekenisvolle 
verskille in uitkomstes vir die twee inkubators gewys het nie, was alle uitkomstes beter in die 
MINC® en die gebruik daarvan moet aangemoedig word. Die resultaat van ŉ onafhanklike, 
beduidende assosiasie tussen die aantal metafase II oösiete en KSU is afhanklik van die 
spesifieke ovariale stimulasie protokol en potensiële alternatiewe strategieë moet ondersoek 
word om  uitkomstes te optimaliseer sonder om die kostes te vermeerder.  
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CHAPTER 1 – BACKGROUND INFORMATION AND LITERATURE REVIEW 
1.1 Assisted Reproduction Globally 
For more than three decades, In Vitro Fertilization [IVF] has played a critical role in human 
conception. IVF and other Assisted Reproductive Techniques [ART] have revolutionized the 
possibility of helping childless couples. There have been estimated that more than 5 million 
babies have been born following ART treatment (Franklin, 2013). 
 
Infertility has been clinically defined as a reproductive system disease that causes failure to 
achieve a clinical pregnancy after 12 months or more of unprotected, regular, sexual 
intercourse (Zegers-Hochschild et al., 2009). In 2015, the World Health Organization [WHO], 
acknowledged infertility as a global public health issue (Pantoja et al., 2015). IVF can be 
viewed as a test for reproductive potential, allowing for a detailed assessment of oocytes, 
oocyte-sperm interaction and embryo quality, as well as an effective treatment for most forms 
of subfertility (Ola et al., 2005). 
 
An estimated 10 – 15% of all couples experience at least one period of infertility during their 
lifetime (Revonta et al., 2010). Approximately 50% of infertile couples will require treatment 
with some form of assisted conception in order to achieve a pregnancy and a review article by 
Dyer et al. (2013) reported that 85% of the world’s population are living in countries where 
ART are available (Collins, 2002). Although millions of babies have been born from IVF 
(Franklin, 2013), ART is not widely used in low-resource environments due to the high cost. 
In most countries, the public sector offers limited ART services (Hovatta et al., 2006). The 
overall demand for infertility treatment has been estimated at 56% of the population (Makuch 
et al., 2011). This could be due to the limited attention infertility has received at global and 
regional levels. Vayena et al. (2009) claims two main reasons for the poor attention infertility 
receives in developing countries. Firstly, the wide perception that infertility is a problem limited 
to the developed world and not that of developing countries. The second reason is the belief 
that ART is technically much too demanding for the capacity and expertise available in 
developing countries and too expensive, because their resources are already limited. 
 
1.2 Infertility in Developing Countries 
Technological progress in the field of ART has produced new medical, ethical, social and 
economic issues that require attention from health professionals and society at large. Current 
barriers to reproductive treatment are predominantly financial in nature (Huyser, 2008). In low-
resource countries, especially where the prevalence of infertility is high, financial resources 
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are too scarce to provide affordable services and do not allow for expensive treatment (Pantoja 
et al., 2015). Annual increases in the cost of IVF also put the treatment beyond the reach of 
the majority of infertile couples (Aleyamma et al., 2011).  
 
Although infertility is one of the major health problems individuals are facing in developing 
countries, healthcare systems in developing countries are more focussed on addressing 
overall health at lower costs and other health issues that do not include infertility (Habbema, 
2008). There are numerous ethical concerns regarding ART in developing countries. One of 
the biggest concerns is overpopulation in low-resource countries. Other concerns include; the 
fact that natural resources are extremely limited and the ethical problem of practitioners who 
are not sufficiently trained, but still offer services to unsuspecting and uninformed patients. 
Although findings have indicated that these concerns are not unique to developing countries, 
its prevalence is far greater compared to that of developed countries (Allahbadia, 2013). 
 
Another factor that largely contributes to infertility in developing countries is the prevalence of 
Sexual Transmitted Diseases [STD] and Human Immunodeficiency Virus [HIV], affecting both 
the male and female partner (Ombelet, 2014). Infections, especially pregnancy related, 
abortions that are not performed in a clinical setting or by a healthcare professional, lack of 
STD and HIV awareness and diagnosis are some of the main causes that contribute to 
infertility in developing countries (Ombelet, 2014).  
 
Infertility treatment in developing countries should be prioritized and low-cost options 
drastically needs to be explored to address this problem (Vayena et al., 2009). With available 
lowered cost ART treatment options, governments could be motivated to allocate public funds 
for ART but with the implementation of these services quality control measures should be 
standardised practice to ensure the delivery of appropriate maternal and neonatal health 
services (Dyer & Pennings, 2010). 
 
1.3 Cost of Assisted Reproduction and the South African Context 
 
It is commonly known that ART procedures are expensive, due to various contributing factors 
(Johnson, 2014). Not only are equipment and ovarian stimulation protocols expensive, but 
highly specialized clinicians and scientists/technologists, also essential for this treatment, are 
not available in many hospitals and clinics (Mahajan, 2013).  
 
Similar to other countries, South Africa has limited risk protection against the costs involved 
with regard to ART and assisted reproduction services offered in the private and public sector. 
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The costs of ART treatment are in general not covered by medical aid schemes in the private 
sector (Dyer et al., 2013). In 2012, Huyser and Boyd published an article providing a 
breakdown of the cost per IVF cycle in a large private clinic, where 35% of the cost was for 
laboratory purposes, 29% for clinicians’ fees and consultations, 28% for medication used 
during the cycle and 8% for clinic fees. The cost of ART procedures, in South Africa, in 2012, 
ranged from R7 000 – R14 000 in the public sector and R25 000 – R50 000 in the private 
sector (Huyser & Boyd, 2012). Fee structures have since increased.   
 
Although ART treatment  is available in South Africa in the public sector, a limited number of 
hospitals and clinics across the country offer good quality ART treatment (Huyser & Boyd, 
2013). A possible reason for this could be the limited resources allocated to public sector ART 
treatment, with related concerns regarding shortcomings of other healthcare systems, such 
as HIV and tuberculosis [TB] treatment. Another reason could be the fact that, on a national 
and international level, health strategies have been more focussed on contraception and on 
lowering fertility rates overall (Ombelet et al., 2008). The government subsidizes public sector 
ART treatment, but only to a certain extent, where a segment of the funds have to be provided 
by the patients. Thus, a substantially lower cost option is available when compared to private 
clinics, but by lowering the cost, adaptions have to be made to standard protocols exploring 
options where treatment costs can be reduced (Dyer et al., 2013). 
 
Various studies have explored strategies to lower the cost of ART treatment. Examples of 
these strategies include simplification of standard ART procedures, with adaptions to the ART 
laboratory, application of milder ovarian stimulation strategies and non-IVF ART, which include 
fertility awareness programmes (Ombelet et al., 2008). 
 
Due to the fact that one of the most expensive components of ART is ovarian stimulation 
medication, various experts have proposed milder stimulation protocols, as previously 
mentioned (Mahajan, 2013). Low-cost cycles created in this way, may provide accessibility to 
ART treatment for patients in lower socio-economic environments, who still have the right, 
according to the South African Bill of Rights, to “make decisions concerning reproduction” 
(Constitution of the Republic of South Africa Act, No. 108 of 1996 Chapter 2. Bill of Rights), 
and to be provided with the opportunity to at least one ART treatment cycle (Mahajan, 2013). 
 
As mentioned before, the main contributors to ART costs are; a) ovarian stimulation drugs and 
protocols, b) expensive specialized equipment needed and c) highly specialized and skilled 
clinicians and scientists/technologists. 
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1.4 Role players in ART Outcome 
 
Various factors influence the outcome of an ART cycle. They range from the ART laboratory 
and equipment to the method of female stimulation and also the patient’s fertility profile - with 
female age being a significant factor (Eijkemans et al., 2014; Klitzman, 2016). Patient profile 
specific factors are often related to lifestyle choices or behaviour and include; BMI (Luke et 
al., 2011), smoking habits (Fuentes et al., 2010) and tubal factor infertility (Dun & Nezhat, 
2012).  Equipment - specifically the incubators used for gamete/embryo culturing (Gardner et 
al., 2008:4) - as well as ovarian stimulation (Bosch et al., 2016) – with a wide variety of 
approaches available, not only affect ART outcome but also have a significant impact on the 
final cost of the cycle. 
 
1.4.1 Laboratory Equipment, Culture Conditions & Incubators 
 
Embryo culturing is one of the most important aspects of ART (Gruber & Klein, 2011). For 
optimum embryo culturing, various key environmental variables need to be considered within 
the culture system. The most important variables are; appropriate regulation of culture media 
(especially with regard to pH, temperature and osmolality), air quality inside the laboratory and 
overall sterility (Swain, 2014). As all of these variables can be influenced by the type of culture 
incubator, it can be regarded as the most crucial component of an ART laboratory (Swain, 
2014). One of the most important functions of an embryo culture incubator is to regulate and 
maintain environmental variables such as gas concentrations, specifically carbon dioxide 
[CO₂] and oxygen [O₂] (Guarneri et al., 2015). Regulation of CO₂ is crucial as the 
concentration of the gas plays a vital role in the pH regulation of embryo culture medium and 
the pH of the culture medium is one of the most important variables since it can significantly 
influence gamete function and embryo development (Swain, 2012). 
 
Various types of embryo culture incubators are commercially available. CO₂ incubators differ 
mainly in terms of; size, temperature maintenance and recovery, CO₂ and O₂ monitoring and 
regulation and lastly, pH and gas supply requirements. A few examples of major culture 
incubator differences can be seen in Table 1. Over the last decade incubator functions have 
revolutionized and the most advanced type of incubator can now also provide time-lapse 
images of embryos as they develop over time (Rubio et al., 2015, Kirkegaard et al., 2015, 
Goodman et al., 2016). Regardless of modern modifications, all of these incubators are still 
dependent on a power supply and a trustworthy gas or gas mix supply, thus incubator 
management, maintenance and quality control remains crucial for optimal ART outcomes 
(Higdon et al., 2008) 
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1.4.1.1 Oxygen Concentration 
 
As mentioned previously, gas concentrations play a crucial role with regard to optimal embryo 
culturing and development. In in vivo conditions, embryos are exposed to an O₂ concentration 
of 2 to 8% (Ciray et al., 2009). In the older ART incubators, the O₂ was provided by ambient 
air and was therefore 20%.  Numerous studies have however demonstrated that embryo 
culture in vitro should occur in the same O₂  range as they would physiologically (± 5%), 
contradicting earlier embryo culturing protocols that made use of 20% O₂ concentration 
(Meintjies et al., 2009; Nanassy et al., 2010,  Nastri et al., 2016). 
 
The damaging effect of O₂ at atmospheric concentration (20%) on embryo development has 
been reported widely in previous studies (Thompson et al., 1990; Catt & Henman, 2000; 
Karagenc et al., 2004). The accumulation of reactive oxygen species [ROS] in the cytoplasm 
is most likely the mechanism through which high O₂ concentration reduces developmental 
ability of embryos during in vitro culture (Guarneri et al., 2015). A beneficial effect of lowering 
O₂ concentration in incubators to 5% has been observed for both embryo quality and 
pregnancy rates, mostly in trials where embryos were cultured and transferred at blastocyst 
stage (Guarneri et al., 2015). Other reports also showed that atmospheric O₂ is injurious 
through the generation of free oxygen radicals (Guérin et al., 2001). Atmospheric O₂ 
concentrations preferentially damage the inner cell mass (ICM) of blastocysts, while the 
trophectoderm is less affected or even stays well developed. Experimental evidence however, 
also demonstrates that the ability of embryos to develop into blastocysts does not necessarily 
indicate an absence of O₂ toxicity and its associated anomalies in cell properties, such as 
altered metabolism and gene expression (Bavister, 2004). 
 
In 2008, Kovačič et al. conducted a prospective study to determine the effect of 5% and 20% 
O₂ on prolonged development of embryos. The study reported the effects of the differing O₂ 
concentrations on fertilization rate, proportion of morphologically optimal embryos, blastocysts 
and optimal blastocyst development on day 5. The study was conducted using sibling oocytes 
from routine consecutive stimulated IVF and ICSI cycles. The results for IVF (n=988 oocytes) 
and ICSI (n=928 oocytes) were analysed separately. The results indicated that lower O₂ did 
not influence fertilization rate, however 20% O₂ resulted in a significantly higher proportion of 
optimal quality embryos on day 3 after IVF. In both procedures, IVF and ICSI, the lower O₂ 
concentration improved blastulation rate and increased the proportion of embryos reaching 
the expanded blastocyst stage with a normal inner cell mass on day 5. The conclusion was 
that a lower O₂ concentration in the incubator atmosphere contributed to better embryo 
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morphology and higher blastulation rates (Kovačič et al., 2008). Guarneri et al. (2015) 
conducted a similar retrospective analysis comparing two routine IVF culture strategies. The 
first culture system consisted of atmospheric O₂ concentration (± 20%) until insemination on 
Day 0 for ICSI cycles or until denuding on Day 1 for standard IVF, followed by the use of a low 
(±5%) O₂ concentration for the rest of the culture period to the blastocyst stage until embryo 
transfer. The second culture system consisted of exclusive use of low O₂ concentration. The 
main outcome of the study was determined by the utilization rate defined as the number of 
transferred plus vitrified embryos per inseminated cycle. Other outcomes of the study included 
pregnancy and live birth rates. The results of the study indicated that of the 701 IVF/ICSI 
cycles that were performed, the utilization rate for IVF (38% and 37%; p=0.78) and ICSI (37% 
and 41%; p=0.40) was similar between the two culture systems.  
 
Another study conducted by Kovačič et al. (2010) aimed to assess whether embryo culture at 
different O₂ concentrations had any effect on ICSI outcome. This prospective randomized 
trial’s first outcome was to assess on-going pregnancy rate (OPR) and secondly, the 
cumulative pregnancy rate, implantation and embryo quality for two treatment groups and the 
clinical outcomes for sub-groups (which included; optimal cycles, poor responders and older 
women). The two treatment groups consisted of embryos cultured either at 6% CO₂, 5% O₂, 
and 89% N₂ mix or at 6% CO₂ in air. The findings indicated that although a low O₂ 
concentration resulted in a higher incidence of good quality day 2 embryos and blastocysts, 
the on-going pregnancy rate and implantation rate were similar in both O₂ concentration 
groups. Low O₂ concentration resulted in a higher cumulative pregnancy rate in the main group 
(high O₂ concentration vs. low O₂ concentration) and a higher pregnancy rate in the poor 
responder subgroup with embryo transfers performed mostly on Day 3. The conclusion was 
that the use of reduced O₂ concentration in IVF is reasonable, irrespective of the duration of 
embryo culture. Reduced O₂ concentration not only improved embryo development and 
cumulative pregnancy, but was also recommended for poor responder patients. A very recent 
study by Nastri et al. (2016) conducted a meta-analysis that included 21 studies that compared 
low and atmospheric O₂ concentration for embryo culture. From the results obtained the 
researchers concluded that although a small improvement of approximately 5% in live 
birth/ongoing pregnancy and clinical pregnancy rates was observed. The evidence was of very 
low quality and the best interpretation of the study was that uncertainty remains about 
differences in the comparison between the two O₂ concentrations. 
 
Although the effect of atmospheric O₂ on embryo development is well-known,  
conventional large box incubators using CO₂ in air (20% O₂) are significantly cheaper 
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compared to modern benchtop incubators (5% CO₂ and  5% O₂ gas mix) and the replacement 
of incubators remain a very expensive exercise for low resource laboratories. According to 
Guarneri et al. (2015) scientists at ART clinics tend to overload available low O₂ incubators 
causing an increase in the frequency of the opening and closing of the incubator door, with 
the potential rebound effect for culture conditions and micro-environment maintenance. Since 
the conventional evaluation of embryo morphology at different embryo development stages 
under a microscope necessitates the frequent opening of the incubator door, it results in 
fluctuating O₂ and CO₂ concentrations. Kovačič et al. (2008) suggested an embryo culture 




Internal pH homeostasis is essential for normal development in a preimplantation embryo as 
it plays a crucial role in cellular communication, protein synthesis, cellular division and enzyme 
activity (Lane et al., 1998). During the later stages of embryo development robust regulatory 
mechanisms are in place to regulate internal pH, which does not seem to be the case for 
preimplantation embryos and exposure to culture conditions without optimal intercellular pH 
have shown to result in developmental delay or even arrest (Squirrell et al. 2001; Lane & 
Gardner, 2005). Due to the fact that the pH of embryo culture medium is regulated by the 
balance between bicarbonate and CO₂ (based on the Henderson-Hasselbalch equation), the 
slightest fluctuation in the CO₂ concentration inside the culture incubator can induce significant 
changes within the culture medium, directly influencing the embryo (Lane et al., 2008). The 
optimal pH for embryo culturing is 7.2 to 7.3 (Kelly & Cho, 2014). 
 
Zander-Fox et al. (2010) conducted a study investigating the effect of intracellular pH 
fluctuations on preimplantation embryos. The results concluded that a lowered intracellular pH 
resulted in embryos with a decreased cell number and inner cell mass and increased 
apoptosis. This study contributed to the field of knowledge that intracellular pH fluctuations, 
directly affected by culture media composition, can have detrimental effects on embryo 
development (Zander et al., 2006; Rooke et al., 2007), thus, highlighting the importance of pH 




Temperature plays a pivotal role during embryo development. The fine regulation of 
temperature inside an ART incubator is extremely important when trying to maximize embryo 
development, implantation and pregnancy (Walker et al., 2013).  The optimal temperature for 
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culturing embryos has, since 1969, been determined at 37°C (Kelly & Cho, 2014). Depending 
on the number of patients, every ART laboratory needs at least 2 – 3 CO₂ incubators that need 
to be monitored daily for proper maintenance of correct temperature regulation. Frequent 
opening/closing of the incubator door, overnight power outages or failures as well as 
temperature differences at different locations within the same incubator contribute to 
increased difficulty to maintain a stable temperature (Anifandis, 2013). 
 
Heating systems in incubators differ widely but there are three main options available for CO2 
incubators. The three systems include; water-jacketed, contact heat (not to be confused with 
direct heat) and air-jacketed, also known as direct heat (Swain, 2014; Kelly & Cho, 2014; 
Meintjies, 2014). In a water-jacketed incubator, temperature is maintained through heated 
water (with high heat capacity) within the incubator’s chamber walls giving a consistent interior 
temperature (Kelly & Cho, 2014). The water-jacketed heating system is especially prevalent 
in larger CO₂ incubators and have shown to maintain the interior temperature within the 
incubator chamber four to five times longer (Kelly & Cho, 2014; Swain, 2014) compared to the 
direct heat system in cases of incubator opening or power failure (Meintjies, 2014). Although 
this aspect of a water-jacketed incubator is beneficial, these incubators tend to have high 
power consumption (Swain, 2014). The contact heat heating system, mostly adopted in 
benchtop incubators, consists of heat being transmitted from the warmed incubator surface 
directly onto the culture dish (Meintjies, 2014). Another heating system, direct heat (air-
jacketed) consists of warm air originating from mounted chamber heaters being circulated 
inside the incubator, sometimes with assistance of an internal fan (Meintjies, 2014). With 
evaluation of these different heating systems in terms if temperature recovery, contact heat 
shows superiority (Swain, 2014). Cooke et al. (2002) reported that a benchtop contact heat 
incubator (MINC) showed superior temperature recovery time of 5.5 minutes (from 35°C to 
37°C) compared to > 20 minutes in a conventional water-jacketed incubator. 
 
With regard to optimal temperature regulation and maintenance, several studies have 
indicated that prolonged exposure of embryo culture to temperatures other than the optimal 
37°C, reduces fertilization ability and also the ability of cell division/cleavage, growth, 
implantation potential and subsequently pregnancy rate (Wang  et al., 2002; Hong et al., 
2014). One study indicated that a 1°C drop from optimal temperature reduces the ability of 
embryos to cleave but allows division of nuclei (McCulloh, 2004). This indicates that 
cytokinesis is more temperature sensitive than mitosis. Thus, prolonged exposure of embryos 
to higher temperatures than optimal, has a deleterious effect on cytokinesis in all embryos 
(normal and abnormally fertilized; 1, >2 pronuclei). Human embryos are therefore very 
sensitive to any fluctuation in temperature (Anifandis, 2013). 
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1.4.1.4 Incubator Types and Specifications 
 
As multiple incubator types are available, the decision of selecting a one should be dependent 
on the needs of the specific laboratory. Culture incubators differ in various aspects (Table 1), 
as previously mentioned. Not only are different capacities and sizes available, but the type of 
gas monitoring systems, gas supply and temperature control can differ significantly from one 
incubator to another.   
 
Benchtop incubators are gaining favour among ART laboratories since stringent control and 
recovery of temperature and gas concentrations and therefore pH is possible (Hong et al., 
2014). When considering temperature, benchtop type incubators are capable of direct heat 
transfer compared to larger box-type incubators, which maintain temperature mostly by means 
of a water-jacket (Swain et al., 2016). In 2007, Fujiwara et al., conducted a study to determine 
the effect of micro-environment maintenance on embryo culture and clinical results using two 
types of incubators. They used a benchtop incubator (K-MINC-1000, COOK) and a 
conventional large incubator with a water-jacketed heating system (Personal Multi Gas CO₂ 
incubator, APM-30D, ASTEC). Both incubators used standard O₂ concentrations, 5% was 
used in this specific study. The temperature and O₂ concentration in both incubators were 
compared following a 5 second door opening/closing procedure. Embryos of 30 IVF cases 
were selected randomly and assigned to either one of the incubators. The early-stage good 
quality embryo formation rate and the good blastocyst formation rate were compared as 
indicators for micro-environment maintenance ability. The results indicated that, after the 5 
second door opening/closing, the temperature recovery for the benchtop was approximately 
5 minutes compared to 30 minutes for the conventional incubator. The O₂ concentration 
recovery was significantly better in the benchtop (3.0 minutes ± 0 minutes) compared to the 
conventional incubator (7.8 minutes ± 0.9 minutes). The early-stage good quality embryo rate 
and good blastocyst formation rate for the benchtop (39.5% and 15.1%) were significantly 
higher than the conventional incubator (28.4% and 7.8%). The results confirmed that the 
micro-environment maintenance ability of an incubator influences the rate of successful 
formation of good embryos and the micro-environment can be improved by replacing culture 
equipment (Fujiwara et al., 2007). 
 
Since the bicarbonate in the media and the CO2 concentration in the culture incubator 
determine media pH, maintenance and stability of CO2 extremely important. Although various 
published studies show that embryos can still develop in a medium with fluctuating pH values, 
these variations influence the quality and development of embryos (Zander-Fox et al., 2010).
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Table 1: Comparison of specifications of different incubator types/brands.  
 
*South African supplier 
Specifications Incubator Type/Brand 
K-MINC™ Planer (BT37) Miri® 











ESCO Medical Labotec Labotec ESCO Medical Illex South Africa 
Price ZAR (Incl. VAT) ± 480 000 ± 221 000 ± 435 480 ±  100 000 
Not Available - 
Discontinued 
± 993 000 ±  1 300 000 






Premixed gas (CO₂; 
N₂; O₂) 
Premixed gas 
(CO₂; N₂; O₂) 
Premixed gas (CO₂; N₂; 
O₂) OR Built-in gas 
mixer (CO₂; N₂; ambient 
air) 
CO₂ only CO₂ only 
Built-in gas 
mixer (CO₂; N₂; 
O₂) 
Built-in gas mixer (CO₂; 
N₂; O₂) 
Humidification Yes (Disposable flask) 
Yes (Disposable 
flask) 
Yes (Water reservoir) 
OR No 
Yes (Internal water 
reservoir/pan) 
Yes (Internal water 
reservoir/pan) 
No No 





Infra-red OR Thermal 
Conductivity 
Infra-red  
Temperature Control Direct heat transfer 
Direct heat 
transfer & cooling 
fan 
Direct heat transfer 
(PT1000 sensors) 
Water jacket 





Direct heat transfer 
Air Filter Hydrophobic filter HEPA HEPA / VOC / UV HEPA 0.22 µm filter 
HEPA and VOC 
254 nm UV-C 
with 185nm filter 
HEPA and VOC 
Capacity (Volume In 
Litres) 
0.43 (2 Chambers) 0.43 (2 Chambers) 0.886 (6 chambers) 184 184.1 
n/a - 6 chambers 
(holds 12 
embryos each) 
n/a - 6 chambers (holds 
12 embryos each) 
Recovery Time 
Temperature/CO₂ 
± 5 min / ± 3 min ± 5 min / ± 3 min < 1 min / < 3 min ± 20 min ± 20 min < 1 min < 3 min < 0.2 min / < 5 min 
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Therefore, small benchtop incubators with individual chambers are now the incubators of 
choice since various studies showed a decreased recovery time for both temperature and CO₂ 
compared to the conventional incubators (Fujiwara et al., 2007). 
 
Embryo selection for transfer remains one of the most important aspects of ART. Currently, 
morphological assessment of the embryo remains the method of choice in many ART 
laboratories, which conventionally requires inspection outside the controlled environment of 
the incubator. This leads to exposure of the embryos to undesirable changes in critical 
parameters such as; temperature, pH, humidity and gas concentrations (Meseguer et al., 
2012). A relatively new, but very expensive addition to ART incubators is the time-lapse 
monitoring system (TMS). Time-lapse monitoring overcomes the obstacle of removing 
embryos from the incubator, thus not exposing them to environmental changes. By using time-
lapse imaging of the developing embryo, one also increases the number of morphologic 
observations available to the embryologist for assessing embryo quality. The use of an 
automated time-lapse monitoring system with continuous embryo surveillance provides 
comprehensive data on embryo development kinetics. This system allows the precise 
determination of the onset, duration and intervals between cell divisions (Meseguer et al., 
2012). Results from time-lapse incubator culture are controversial, since comparison with 
other types of incubators is difficult and large randomised controlled studies are lacking. Rubio 
et al. (2014) conducted a prospective study focusing on whether embryo culture in the 
integrated EmbryoScope® time lapse monitoring system [TMS] and selection supported by 
the use of a multivariable morphokinetic model, would improve ART outcome when compared 
to embryo culture in a standard incubator [SI] (conventional large incubator). The results 
indicated that the pregnancy rate per treated cycle was not statistically significant (65.2% and 
61.1% respectively). The only statistical significant difference found were for ongoing 
pregnancy rate (54.5% and 45.3% respectively p = 0.01]. The conclusion was that culturing 
and selecting embryos in the TMS improves ART outcome. A similar study by Kirkegaard et 
al. (2012) aimed to evaluate the development of sibling embryos from oocytes randomized to 
be cultured in either a SI or a TMS The results indicated no significant difference between the 
outcomes of the two incubators and both supported embryonic development equally.  
 
Even though the above-mentioned studies indicate otherwise, comparing the TMS to SI and 
more specifically the larger SI remains a difficult task. A fairer competitor would be a small 
benchtop incubator, as characteristics of the two incubators are similar. Goodman (2016) 
conducted a prospective randomized controlled study to determine whether the addition of 
morphokinetic data would improve ART outcomes in a closed culture system. This was the 
first randomized controlled trial where all the embryos were cultured in a similar manner in the 
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closed TMS.  (Meseguer, 2016). The results of the Goodman study indicated that the time-
lapse morphokinetic data did not significantly improve clinical ART outcomes (Goodman et al., 
2016). 
 
Laboratory equipment, specifically CO₂ incubators in an ART clinic, contributes largely to the 
high cost of the service (Ombelet, 2007). Currently, due to the high cost of incubators 
specifically, other alternatives have been investigated to possibly lower the cost associated 
with gamete and embryo incubation (Ombelet, 2013). Therefore, at the other end of the 
spectrum of CO₂ incubators, a recent study showed comparable IVF outcomes using a 
“simplified embryo culture system” consisting of a very simple and cost effective “single tube 
method” incubator system when compared with the traditional box type incubator (Ombelet, 
2014, Van Blerkom et al., 2014). In the “single tube method” incubator, the correct 
concentration of CO₂ is produced by a controlled chemical reaction between specific amounts 
of sodium bicarbonate and citric acid. The CO₂ gas is produced in a sterile glass test tube and 
relayed via a sterile connection to another sterile test tube containing the embryo culture 
medium – ensuring an optimal pH during embryo development. Van Blerkom et al. (2014) 
conducted a pilot clinical trial using this simplified and cost effective laboratory culture method 
(single tube method incubator) for IVF and found that the fertilization and implantation rates 
were similar to those reported using a high resource and expensive incubator in the same IVF 
program. They observed an embryo implantation rate of 34.8% (8/23), a live birth rate of 30.4% 
(7/23) and one miscarriage at 8 weeks gestation. The results were compared with the Belgian 
IVF registration data (BELRAP) (high resource IVF laboratories using conventional incubators 
and culture strategies). The clinical pregnancy rate per transfer was 34.2% (3403/9929) and 
live birth rate was 29.0% (2808/9680). This indicated that the results obtained by Van Blerkom 
et al. (2014) were almost identical to that of BELRAP. 
 
Thus, there is clearly room and reason for investigation into simplified culture systems. This 
incubation method is not only a simpler incubation method, but also less expensive when 
compared to standard incubation methods and has shown similar outcomes. However, ICSI 
cycles and therefor treatment for patients with severe male factor, are not possible with the 
use of this incubation method.  
 
Another initiative aiming at reducing laboratory costs, the INVOcell® device, consists of 
fertilization of oocytes and early embryo development in a capsule, which is placed into the 
maternal vaginal cavity for incubation, replacing the use of a standard incubator (Frydman & 
Ranoux, 2008). A study conducted by Mitri et al. (2015) aimed to determine if an intravaginal 
culture device [IVC] could provide acceptable embryo development rates compare to standard 
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IVF. The study consisted of 10 women aged 27 to 37 years with an indication for IVF treatment. 
Oocytes were randomized for fertilization using conventional IVF or the IVC device.  The 
results indicated that the fertilization rates in the standard IVF group (68.7% ± 36%) were 
higher compared to the IVC device (40.7% ± 27%). The clinical pregnancy rate for the IVC 
device was 30% compared to 43% in the standard IVF group. Although the IVC device 
produced reasonable pregnancy rates, psychological factors were not investigated (Mitri et 
al., 2015). 
 
Doody et al. (2016) recently conducted a study to compare the efficacy of intravaginal culture 
[IVC] of embryos in INVOcell™ to standard IVF incubation. The results of this prospective 
randomised study indicated that there was no significant difference in the percentage of quality 
blastocysts transferred or live birth rate. A difference was observed in the percentage of total 
good quality embryos, where standard IVF incubators showed superiority compared to IVC 
(50.6% vs. 30.7%; p < 0.05). The researchers concluded that standard IVF culturing resulted 
in higher quality blastocysts compared to IVC, however, both produced identical blastocysts 
for transfer, resulting in similar live birth-rates (Doody et al. 2016). The results of this study 
shows that IVC can be effective and may broaden access to fertility care in selected patient 
populations (Doody et al. 2016). 
 
1.4.1.5 Incubator Management and Quality Control 
 
As previously discussed, the equipment used within an ART laboratory, especially the CO₂ 
incubators, contributes largely to the success rates of the treatment (Higdon et al., 2008). As 
variations among laboratories exist, standard quality control recommendations can be 
considered in optimising ART outcomes. One of the most important means of quality control 
is record keeping of all variables that could influence ART outcomes. These variables include 
regular measurements of temperature, culture media pH and CO₂ and O₂ concentrations 
(Swain, 2014). Other factors to monitor, since they could potentially influence ART outcomes, 
are air quality, humidity and decontamination within the laboratory and CO₂ incubator (Boone 
& Higdon, 2014). 
 
As temperature plays a pivotal role with regard to embryo culturing, temperature maintenance, 
regulation and quality control is of vital importance within the CO₂ incubator.  Frequent opening 
and closing of the CO₂ incubator doors result in temperature fluctuations which should be 
avoided. Incubators offering a contact heat system has been shown to have the most superior 
recovery rates (Cooke et al., 2002; Fujiwara et al., 2007). The use of lids for culturing dishes 
and smaller volumes of culturing medium and oil have also shown to positively influence 
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temperature maintenance and recovery times (Cooke et al., 2002). Temperature within the 
CO₂ incubator should be monitored on a daily basis and records of the measurements should 
be kept. Temperature calibration of an incubator should be ensured before the use thereof 
and must take place within the laboratory the incubator will be used (Meintjies, 2012). 
 
Due to the fact that the culture media pH is regulated by the CO₂ concentration, the gas supply 
of the CO₂ incubator should be adapted for the specific culture media used, as different 
brands/types of culture media require different gas concentrations for the same pH. The 
assumption that the pH is a direct result of the percentage of CO₂ should not be made. The 
pH of culture medium is however, a direct function of the CO₂ partial pressure within the culture 
medium and is affected by the height above sea level, which differs from one laboratory to 
another (Meintjies, 2012). The pH should be verified for each batch of medium and should be 
consistent between incubators used within the same laboratory. pH should be monitored 
regularly and calibration should take place at 37°C (Gardner et al., 2012). Since culture 
medium pH is determined by the CO₂ concentration maintenance and regulation thereof is 
extremely important. Equipment controlling gas concentrations should be sensitive to the 
specific range and monitored on a daily basis (Gardner et al., 2012). CO₂ is mostly supplied 
in gas cylinders, and to ensure that the cylinder does not run empty without a timely switch to 
a new cylinder, it is recommended that the changeover pressure set on the manifold is 50% 
of the original tank pressure (Meintjies, 2014). The cylinder pressure and CO₂ concentration 
within the CO₂ incubator should also be monitored on a daily basis and records thereof should 
be kept. Various measuring tools exist to determine the CO₂ concentration within the CO₂ 
incubator, but an infrared instrument is recommended for improved accuracy (Boone & 
Higdon, 2014).  
 
ART CO₂ incubators, that make use of 20% O₂, obtain their internal air from the external 
environment, which contains particles and volatile organic compounds [VOCs] that need to be 
considered when it comes to incubator management as these compounds can influence 
embryo development (Boone & Higdon, 2014). Due to the fact that the relevant concentrations 
of VOCs within an ART laboratory has not yet been determined, most laboratories have 
implemented air handling systems to increase the air quality. Even though these filtration 
systems can be beneficial for ART outcomes, the air quality inside the culture incubator is also 
of high importance as VOCs have been detected in the gas supply for culture incubators (Hall 
et al., 1998). Filtering of the ART incubator gas supply has mostly become a norm and most 
incubators are supplied with inline filters as it has shown increased ART outcomes (Merton et 
al., 2007). These filters usually contains high efficiency particulate absorption [HEPA] filtration 
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to improve air quality but some incubators also include active carbon filters and an ultra-violet 
[UV] light to remove and ensure degeneration of VOCs (Sharmin & Ray, 2012). 
 
Increased humidity in a culture incubator is important as it decreases evaporation, which is 
directly proportional to the osmolality of the culture media. Osmolality can be increased if an 
increase in evaporation of water within the culture incubator occurs, with potential detrimental 
effect on the embryos (Ozawa et al., 2006). This effect can be overcome with the use of tissue 
culture oil overlay (Swain, 2014). Humidity within a conventional culture incubator can be 
increased with the use of a water pan but maintenance and regular replacement of the water 
supply and water pan is crucial as bacterial and fungal growth can occur (Boone & Higdon, 
2014). An alternative to the water pan is a supplied water bottle/reservoir. 
 
It is clear that maintenance, monitoring and management of culture incubators is extremely 
important when it comes to embryo culture and ultimately pregnancy outcome. Various 
variables need to be regulated and monitored to ensure optimal embryo development and the 
laboratory staff should be adequately trained and informed in terms of quality control and 
incubator management. 
 
Taking all the above mentioned information into consideration, cost analysis remains an 
important factor. Although various studies have indicated a slightly improved outcome in ART 
results when a benchtop incubator was used compared to a conventional large box incubator 
(Fujiwara et al., 2007), various clinics, especially public clinics, do not always have the 
financial capacity to replace conventional incubators with new and improved incubators. This 
is not the case for large private clinics with adequate finances where new improved laboratory 
equipment (i.e. incubators) and the latest developments can easily be implemented. With on-
going advances in technology, multiple CO₂ incubator types exist - with varying capabilities, 
costs and different methods of regulating the internal environment. The selection of a CO₂ 
incubator has become a complex, expensive, but crucial process. 
 
1.5 Female Stimulation in an Assisted Reproductive Treatment Cycle 
 
Conventional standard ovarian stimulation can lead to high cost and the transfer of two or 
more embryos in IVF exhibit a high probability of multiple pregnancies (Polinder et al. 2008). 
Following a mild stimulation protocol is not only less expensive (Matsaseng & Kruger, 2014), 
but there is evidence of increased safety. Mild stimulation protocols can minimize discomfort 
and the risk of complications as well as multiple gestations (Siristatidis et al., 2012).  
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Ferraretti et al. (2015) conducted a prospective cohort study to validate the use of clomiphene 
citrate [CC] in IVF when a mild stimulation protocol is followed to reduce patient risk and 
minimise the cost. The study included  163 good prognosis patients (≤38 years old, normal 
ovarian reserve, normal ovulatory cycles, BMI under 29, no previous ART cycles, no severe 
endometriosis, no history of recurrent miscarriage and no autoimmune or endocrine diseases) 
undergoing IVF. Patients that had undergone surgical procedures for retrieval of sperm were 
also excluded from the study. Mild stimulation was administered by using a fixed protocol of 
CC (100 mg per day from cycle days 3 to 7) in combination with low doses of gonadotropins 
(150 IU of recombinant FSH on cycle days 5, 7 and 9) and GnRH antagonist. The outcomes 
were measured as cumulative delivery rate per patient after three embryos transferred (fresh 
or frozen). After a 2.4 months mean period to pregnancy the cumulative delivery rate per 
patient was 70%. The study confirmed that mild stimulation could be a realistic option for good 
prognosis patients undergoing IVF (Ferraretti et al., 2015). 
 
Matsaseng et al. (2013) asked the important question, whether the ART field is ready for a 
change from conventional ovarian stimulation to mild ovarian stimulation. They conducted a 
met analysis study comparing the efficacy of mild ovarian stimulation and conventional 
stimulation in IVF. The results of the met analysis showed a strong favour towards 
conventional ovarian stimulation (Matsaseng et al., 2013). On a national scale in South Africa, 
various strategies with specific regard to ovarian stimulation have been explored.  Currently, 
the Fertility clinic at Tygerberg Academic Hospital (public) in the Western-Cape implements a 
mild ovarian stimulation protocol that consists of lower doses compared to standard protocols. 
The specific protocol uses 100mg CC from cycle days 3 to 7 in conjunction with 75 IU of 
human menopausal gonadotrophin [hMG] on alternative cycle days, 4, 6 and 8. LH levels are 
tested on day 9 up until administration of human chorionic gonadotrophin [hCG], (Matsaseng 
& Kruger, 2014).  
 
Research indicated that the reason for the introduction of GnRH antagonist and GnRH agonist 
was to decrease the frequency of a premature LH surge, since studies claimed that 
CC/gonadotrophins stimulation increases a premature LH surge with 20 – 25% (Hwang et al., 
2003). A recent study, aimed to determine whether the use of prolonged (8 days) CC 
administration compared to the standard use of 5 days would be an effective method in 
preventing LH surge. The study was a randomized controlled trial consisting of 227 patients 
and the results indicated that prolonged CC administration did not supress a premature LH 
surge compared to the standard administration in the ART program (Matsaseng et al., 2016). 
The biggest issue with a premature LH surge is the possible repercussions thereof; unplanned 
oocyte retrieval, high cycle cancellation rate and insufficient time for oocyte maturation 
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ultimately affecting the pregnancy outcome of a cycle (Matsaseng et al., 2016). To prevent the 
negative outcomes of a LH surge more expensive stimulation drugs are used and contributes 
significantly to ART costs. A premature LH surge can potentially result in cancelation of the 
cycle and starting a new cycle where every step of the treatment has to be repeated with extra 
cost to the patient. 
 
1.6 Factors Possibly Contributing to Infertility 
 
The pathophysiology of infertility could include a very wide range of contributing factors. 
Factors ranging from genetic or chromosomal anomalies, endocrine disorders to congenital 
or infectious malformations throughout the reproductive tract, not only in the female partner 
but also in the male partner. Female factors include advanced maternal age (Jackson et al., 
2015), endometriosis (Mathieu d’ Argent et al., 2010), tubal factors (Zou et al., 2014), 
polycystic ovarian syndrome, diminished ovarian reserve, ovulatory dysfunction, and 
implantation failure or repeated spontaneous abortion (Phillips, 2015).  
 
The incidence of idiopathic infertility is 10 - 15% (Phillips, 2015), with abnormal findings upon 
medical examination occurring minimally. The larger portion of modifiable risk factors 
contributing to idiopathic infertility can be categorized under environmental risk factors 
(Gormack et al., 2015). These factors include; diet (which directly links to Body Mass Index 
[BMI]) (Provost et al., 2016), lifestyle habits (Homan et al., 2007) including alcohol use and 
smoking habits (The Practice Committee of the American Society for Reproductive Medicine, 
2008), medical treatments and environmental factors including exposure to radiation, 
chemicals etc. (Phillips, 2015). 
 
Currently, there are various indications for the use of ART and a number of factors affecting 
the success have been identified. IVF was first reported as a treatment option for women with 
severe tubal disease. With improved efficacy after the introduction of gonadotropin stimulation 
and Intra-cytoplasmic Sperm Injection [ICSI], the indications for IVF have expanded to include 
severe male factor infertility, diminished ovarian reserve, ovulatory dysfunction, severe 
endometriosis and idiopathic infertility. IVF also provides a new means of preconception 
genetic diagnosis and preservation of fertility. IVF is regarded as the most effective treatment 
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1.6.1 Female Factor Infertility 
 
1.6.1.1 Female Age 
 
Fertility is defined as the capacity to produce a baby (Committee of the American Society for 
Reproductive Medicine, 2013). Relative fertility is approximately halved among women in their 
30’s compared to women in their 20’s. Fertility varies among populations and declines with 
age in both men and women, but the effects of age are much more pronounced in women. 
For women, the chance of conception decreases significantly after the age of 35 years. 
Although semen parameters in men also decline detectably after 35 years of age, male fertility 
does not appear to be affected before the approximate age of 50 (Committee of American 
Society for Reproductive Medicine, 2013).  
 
Advanced maternal age has been defined as 35 years or older, given the increased genetic 
and obstetric risk (Jackson, 2015). A classic report on the effect of female age on fertility found 
that the percentage of women not using contraception who remained childless rose steadily 
according to their age at marriage. Six percent (6%) at age 20 – 24, 9% at age 25 – 29, 15% 
at age 30 – 34, 30% at age 35 - 39 and 64% at age 40 - 44 (Committee of American Society 
for Reproductive Medicine, 2006). 
 
Globally, in both high- and low-income countries, there has been a drastic increase in the 
delay of pregnancy among women, especially among those that are more financially secure 
and educated (Chan & Lao, 2008). Not only has a delay in pregnancy onset been observed, 
but also over the last few decades, there has been a drastic decline in the average number of 
offspring born to individual women in developed countries. This can possibly be contributed to 
changes in their social and emotional behaviour (Ehrlich, 2015). As a result of advances in the 
field of medicine and ART, couples are starting to postpone pregnancy to a more optimal or 
convenient time (Sauer, 2015). 
 
Even though obstetric and gynaecological breakthroughs have been made, and the 
prevalence of ART services has increased, there are still many risk factors associated with 
advanced maternal age pregnancy (Carolan & Frankowska, 2011). Aneuploidy (Demko et al., 
2016), pregnancy loss (Spandorfer et al., 2004) and pre-eclampsia (Tandberg et al., 2014) 
are some of the risks associated with advanced maternal age pregnancy. Not only is advanced 
maternal pregnancy a risk for the foetus but there are also various risk factors associated 
maternally (Crawford & Steiner, 2015).  
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Advanced maternal age infertility, has been linked to oocyte abnormalities (The Practice 
Committee of the American Society for Reproductive Medicine, 2006).  A very recent study, 
aimed to determine how the number of euploid embryos are influenced by maternal age. 
Results indicated that in the 22599 day 3 and the 15112 day 5 embryos analysed, the average 
number of euploid embryos per cycle declined from approximately four, for women in their late 
twenties, to less than one, for women older than 42 years (Demko et al., 2016). ). Aneuploid 
embryos are more prevalent in older women and have a higher risk for miscarriage according 
to a retrospective study conducted by Spandorfer et al. (2004). This study aimed to determine 
the relationship between maternal age and foetal loss in IVF pregnancies and results showed 
that there was a significant increase in foetal loss with advanced maternal age. Patients 40 
years and older had a foetal loss rate of 22.2% compared to patients 35 to 39 years with 
12.8%; 31 to 34 years, 7.6% and younger than 30 years, 5.35% (Spandorfer et al., 2004). 
 
The declining of a woman’s fecundability is a natural process of reproductive aging. Age-
related infertility has a multi-factorial cause and there has been demonstrated that there is a 
definite decrease in the ovarian reserve and the number of oocytes, as a women’s age 
increases (Crawford & Steiner, 2015).  
 
1.6.1.2 Anti-Müllerian Hormone and Antral Follicle Count 
 
In females, Anti-Müllerian Hormone [AMH] is assumed to be produced exclusively by follicular 
granulosa cells in the late pre-antral and small antral follicles (Gnoth et al., 2015). AMH seems 
to be derived only from the ovary, since postmenopausal women are associated with 
undetectable AMH concentrations. Granulosa cells of primary follicles show homogenous 
AMH expression, but maximal expression occurs in late pre-antral and small antral follicles 
(Peluso et al., 2014). AMH plays a crucial role in the regulation of folliculogenesis by inhibiting 
the sensitivity of dominant antral follicles to FSH and aromatase, thus, limiting the number of 
primordial follicles that develop (Gnoth et al., 2015). Normal AMH values vary from one 
laboratory to another, thus the establishment of an exact value has been extremely 
challenging, as many studies have demonstrated. The AMH determination test has also 
demonstrated inconsistencies in results as the test is relatively new and standardization of 
protocols are still under investigation. One interpretation of the level of AMH indicates the 
following; high as over 3.0 ng/ml, normal as over 1.0 ng/ml, low normal between 0.7 – 0.9 
ng/ml, low as 0. – 0.6 ng/ml and very low as any value less than 0.3 ng/ml (The American 
Society for Reproductive Medicine, 2013).  
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The serum AMH allows indirect estimating whether the number of available oocytes is above, 
at, or below the expected value for age and therefore attempting to predict reproductive 
longevity (Peluso et al., 2014). Not only can AMH concentrations be used as a prediction tool 
of ovarian reserve, the quantity of the ovarian follicle pool or ovarian response to ovarian 
stimulation (Gnoth et al., 2015), but in clinical practice also as a prognostic tool in 
differentiating the various causes of secondary oligo-amenorrhea (Peluso et al., 2014). A study 
conducted by La Marca et al. (2007) aimed to evaluate whether serum AMH measurement on 
any day of the menstrual cycle could predict ovarian response in women undergoing ART. 
The results demonstrated that women in the lowest AMH quartile (<0.4 ng/mL) were older and 
required a higher dose of recombinant Follicle Stimulating Hormone [FSH] than women in the 
highest quartile (>7 ng/mL). This confirmed their hypothesis that AMH levels can serve as a 
predictable serum marker of ovarian response, which can be measured independently of the 
day of the menstrual cycle (La Marca et al., 2007). 
 
Seifer et al. (2015) conducted a retrospective study on 5087 cycles where AMH was extremely 
low (≤ 0.16 ng/mL) to determine which factors contribute to the outcome of the cycle, cancelled 
or otherwise. The study indicated that the total cancellation rate per cycle was 54% with 38.6% 
of these cycles cancelled before oocyte retrieval and 3.3% of the cycles produced no oocytes 
during follicle aspiration. 50.7% of the cycles where oocytes were retrieved during the 
aspiration, only yielded three or less oocytes. Ultimately, the study showed a live birth-rate of 
9.5% per cycle and when compared to age matched normal AMH cycles, indicated a twofold 
lower live birth rate and a fivefold greater cancellation rate (Seifer et al., 2015). 
 
Various methods have been established to predict IVF response and AMH levels and Antra 
Follicle Count [AFC] are among the most popular tools at the moment, as they could provide 
a tool for predicting ovarian reserve (Tran et al., 2011). AFC is defined as the number of 
follicles within the ovaries on cycle days 2, 3, and 5, that measure 2 to 10 mm in greatest 
diameter, and have been proportionately related to the size of the primordial follicles (Nelson 
et al., 2013). An advantage of AFC measurement is the immediate availability of the results 
as it is done with an ultrasound but this could also be a disadvantage as not all clinics have 
standardized ultrasound equipment and the technique for measuring and determining AFC. 
This also makes comparison of AFC results difficult as AFC thresholds before starting ART 
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1.6.1.3 Tubal Factor Infertility  
 
Tubal factor infertility [TFI] is one of the most common causes of female infertility (Knuttinen 
et al., 2014), and TFI accounts for 30% of involuntary childlessness in women (Huang et al., 
2012). TFI can broadly be defined as obstructed or blocked Fallopian tubes (Grigorescu et al., 
2014) contributing to female infertility.  
 
There are various causes for TFI, as the Fallopian tubes can be extremely vulnerable to 
infection, surgical damage and endometriosis (Kong & Li, 2015). Most commonly, the 
Fallopian tubes are obstructed due to infections such as pelvic inflammatory disease [PID] 
(Kawwass et al., 2015). Other infections that could possibly occlude or disable the Fallopian 
tubes include infections after childbirth or abortions and intra-abdominal infections including 
appendicitis and peritonitis (Grigorescu et al., 2014). Sexually transmitted diseases [STD’s] 
have also been known to play a significant role in infertility, especially with regard to TFI 
(Surana et al., 2012).  One of the most common STD’s is Chlamydial trachomatis infection, 
which is a bacterial infection. There has been shown that C. trachomatis may be the direct 
cause of intraluminal adhesions, hydrosalpinx, pelvic adhesions and fibrosis (Surana et al., 
2012). A study conducted in 2012, aimed to demonstrate the correlation between anti-
chlamydial antibodies and TFI. The results indicated a 60% seropositivity for the anti-
chlamydial IgM antibodies in females that presented with primary infertility and 52% of these 
females presented with bilateral tubal blockage (Surana et al., 2012). 
 
Routinely, as part of an initial work-up, a hysterosalpingography [HSG] is performed to assess 
the uterine cavity and Fallopian tube patency, if a female presents with infertility and can 
indicate the presence of abnormalities such as; hydrosalpinx, adhesions (Asherman’s 
Syndrome, myomas and polyps (Knuttinen et al., 2014). Fallopian tubes that present full of 
fluid is referred to as a hydrosalpinx (Barroso et al., 2001) and various reports have indicated 
the negative impact of hydrosalpinges on ART outcome (Strandell & Linhard, 2002). In 1997, 
an important article was published demonstrating a direct correlation between hydrosalpinx 
and obstructed embryo implantation (Blazar et al., 1997), creating a platform for numerous 
research projects to be conducted proving the same statement. 
 
Various studies have aimed at determining pregnancy prognosis of female patients that 
present with TFI. In a recent study, by Zou et al. (2014), 469 TFI patients were scored pre- 
and post-operatively, classifying TFI (mild, moderate or severe) based on tubal patency, 
adhesions, morphology and structure to determine the correlation between TFI and pregnancy 
outcome. The results indicated an intrauterine pregnancy rate of 43.6% for the mild group, 
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34.0% for the moderate group and 19.4% for the severe group (P < 0.0001), indicating a direct 
correlation between TFI and pregnancy prognosis (Zou et al., 2014). 
 
Before the introduction of IVF, reconstructive tubal surgery was the only treatment option for 
women with tubal obstruction (Huang et al., 2012). Currently, IVF is the treatment of choice 
for women over the age of 35 years with significant tubal disease and those with other co-
existing infertility problems (Huang et al., 2012). In 2005, a study was conducted by Omland 
et al. to determine the pregnancy outcome, with regard to three different infertility diagnoses; 
idiopathic, endometriosis associated and tubal factor after IVF and ICSI. The live birth rate for 
the idiopathic group (78.8%; n=274) indicated superiority over the endometriosis associated 
(66.0%; n=212) and tubal factor infertility groups (66.7%; n=540). 
 
If TFI is diagnosed and treated as a first line infertility treatment, the use of ART may not 
always be necessary, increasing the probability of natural conception and contributing to 
lowering the cost of infertility treatment (Dun & Nezhat, 2012). 
 
1.6.2 Lifestyle Contributors to Infertility 
 
Recurrent IVF failure has multiple known causes but many which are not routinely considered 
as part of the post-treatment analysis or initial work-up when first consulting a couple. There 
are several causes associated with lifestyle and other related pre-existing conditions that have 
only a tenuous or no apparent connection to fertility (Penzias, 2012). 
 
Lifestyle factors have a dramatic impact on general health and also on the capacity to 
reproduce. There is an increasing amount of evidence that lifestyle factors can impact on 
reproductive outcome. Post-Industrial western society has created the potential for increasing 
the exposure to specific lifestyle factors and behaviours that can alter an individual’s 
reproductive capacity. Lifestyle factors include; an abnormal weight, smoking and exposure to 
environmental pollutants and chemicals (Homan et al., 2007). Poor lifestyle habits can 
contribute to infertility in various ways. A recent study by Braga et al. (2015) investigated the 
effect of certain social habits on embryo quality and the likelihood of blastocyst formation. The 
results indicated that the quality of cleavage stage embryos and the probability of blastocyst 
formation correlated negatively with smoking and alcohol consumption. Thus, a correlation 
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1.6.2.1 Female Body Mass Index 
 
Being described as a global phenomenon, obesity is associated with a range of health 
consequences (Rittenberg et al., 2011). Obesity contributes significantly to morbidity and 
mortality worldwide, increasing the prevalence of cardiovascular disease, decreased mobility 
and diabetes (Practice Committee of the American Society for Reproductive Medicine, 2015; 
Goldman et al., 2015). Obesity not only contributes to the above-mentioned health issues but 
also to hypogonadism and other perturbations of the body’s endocrine system that may be 
associated with infertility (Phillips, 2015). An obese female patient also has an increased risk, 
during the course of a pregnancy, towards hypertension, gestational diabetes, spontaneous 
abortion, concomitant delivery complications and foetuses that are larger than the norm for 
their gestational age (Phillips, 2015). 
 
To be categorized as overweight or obese, a person has to have a BMI of 25 – 29.9 kg/m² for 
overweight and >30 kg/m² for obesity. BMI is calculated as weight in kilograms divided by the 
square of height in meters (Orvieto et al., 2009). Compared to women with a normal BMI (18.5 
– 24.9 kg/m²), women with a raised BMI are known to have a threefold greater risk of infertility 
due to disturbances in the hypothalamic-pituitary axis, menstrual cycle alterations and 
anovulation as well as psychological and social factors (Rittenberg et al., 2011). 
 
Obese female patients generally have poor ART outcomes due to various reasons (Phillips, 
2015).  Scientists have tried to determine which factors contribute more to this phenomenon.  
Poor ART outcome among obese females can be due to a poor response to ovarian 
stimulation (Orvieto et al., 2009), leading to a decreased number of retrieved metaphase II 
oocytes and ultimately a decreased fertilization rate (Phillips, 2015). A study examining the 
influence of BMI on IVF outcome found there was a decrease in pregnancy rate among obese 
(27.9%; n=122) compared to non-obese (15.4%; n=12) females, contributing to their 
conclusion that the likelihood of poor responders increased among obese women (Orvieto et 
al., 2009). Decreased ovarian reserve cannot be excluded as a potential contributing factor to 
infertility in obese patients and need to be considered. Bazzano et al. (2015), in an animal 
study, evaluated the effect of obesity on ovarian function and found that diet induced obesity 
alters ovarian function by decreasing serum oestradiol concentrations, prolonging dioestrous 
phases and increasing the number of antral atretic follicles. The results indicated an increase 
in follicular cysts and overall decrease in ovarian reserve as there was a decrease in the COX-
2-positive antral and pre-ovulatory follicles and the number of anti-Mullerian hormone immune-
reactive pre-antral follicles. This lead to the conclusion that diet induced obesity induces 
follicular cyst formation and disrupts ovulation, delaying pregnancy (Bazzano et al., 2015). On 
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the other hand, a recent study by Seidler et al. (2016), showed controversial results, claiming 
that their mouse model indicated that diet induced obesity does not diminish ovarian reserve, 
contributing to the fact that more studies are needed on this specific topic. 
 
Alternatively, various studies have indicated the significant impairment of embryo implantation 
and live birth rates associated with an increasing BMI in female patients (Luke et al., 2011), 
suggesting that the reason for poor reproductive outcomes in these patients may be due to 
uterine activity rather than the oocyte (Goldman et al., 2015). In a large study by Provost et al. 
(2016), the objective was to determine the effect of BMI on IVF outcomes. The study included 
22317 fresh donor ART cycles (2008 to 2010).  Patients with a normal BMI (18.5 to 24.9) were 
used as the reference group. The results demonstrated that the clinical pregnancy rate 
decreased as the patient’s BMI increased; from 59% in the low and normal BMI group to 53.6% 
in the 30 to 34.9 BMI group and 48% in the 45 to 49.9 BMI group. The live birth rate also 
decreased from 51% in the reference group to 40% in the 25 to 34.5 BMI group, demonstrating 
a correlation between a high BMI and pregnancy outcome (Provost et al., 2016). Rittenberg 
et al. (2011) conducted a systematic review and meta-analysis study to determine the effect 
of raised BMI on ART outcome and live birth rate [LBR]. The results of the study indicated that 
women who were overweight or obese (BMI ≥ 30) had significantly lower clinical pregnancy 
and live birth rates and a significantly higher miscarriage rate compared to women with a BMI 
of 25 and under. They concluded that raised BMI is associated with adverse pregnancy 
outcome and lower LBR in women undergoing ART. Controversially, Schliep et al. (2015) 
conducted a prospective cohort study to determine the effect of female BMI on IVF outcome 
and found that there was no significant correlation between BMI and pregnancy outcome.  
 
Obese female patients are not the only ones at risk for fertility challenges. Underweight female 
patients may also be less responsive to ART treatment than patients with a normal BMI 
(Phillips, 2015). These patients have also shown decreased pregnancy rates and fecundity 
(Gormack et al., 2015). Underweight patients are at an increased risk for anovulation and other 
ovulatory dysfunctions, and also pregnancy complications such as premature birth (Phillips, 
2015) and intrauterine growth retardation (Gormack et al., 2015). 
 
Currently, various research studies have indicated controversial results regarding the ultimate 
influence of BMI on pregnancy outcomes, and there is room for more studies to clarify this 









Cigarette smoking is another lifestyle factor that has been associated with reduced pregnancy 
rates in ART and male infertility (Revonta et al., 2010).  
 
Cigarette smoke consists of a well-established mixture of reproductive toxins for both male 
and female patients. Pathology of the reproductive tract may result from a generation of 
reactive oxygen species [ROS] and oxidative stress, vasoconstriction and modifications in 
endocrine signalling (Phillips, 2015). The follicular fluid of smoking female patients have been 
analysed in the past and various studies indicated the presence of toxic compounds found in 
cigarette smoke also to be present in follicular fluid. Some of these compounds include 
polycyclic hydrocarbons, cadmium, benzo[α]pyrene and nicotine metabolite cotinine. The 
accumulation of these toxins in the follicular fluid could potentially influence oocyte growth and 
maturation, induce follicular atresia and interfere with regulation of necessary hormonal 
processes crucial for the initiation and support of meiotic resumption and ovulation (Phillips, 
2015).  
 
Smoking, with regard to female patients, has also been associated with an earlier onset of 
menopause, infertility, premature ovarian failure and spontaneous abortion. Studies have 
shown that smoking female patients undergoing ART do not respond to gonadotropin 
stimulation optimally, produce less oocytes with a decreased developmental potential and 
present with an overall decreased live birth rate (Phillips, 2015). Camlin et al. (2014) stated 
that the results of human research models in the last decade indicate that cigarette smoke 
and exposure to smoke constituents have a negative effect on female fertility, with an increase 
in follicle death and altered hormone output. Results indicated that cessation of smoking can 
extend the age of natural menopause and potentially improve ovarian quality (Camlin et al., 
2014).  
 
 A detailed review on the effects of smoking on fertility from gametogenesis to implantation 
was published in 1982 by Mattison. The study concluded that cigarette smoke had adverse 
effects on many biological mechanisms required for successful reproduction in both animals 
and humans. According to Mattison (1982) cigarette smoking is also associated with an 
increased frequency of menstrual abnormalities and a cigarette dose-related decrease in the 
age of spontaneous menopause.  The study also observed alterations in hypothalamic-
pituitary interrelationships, stimulating growth hormone, cortisol, and vasopressin, release of 
oxytocin and prolactin and inhibition of luteinizing hormone [LH]. Previous findings have 
indicated that cigarette smoke or nicotine alters the receptivity of the female reproductive tract 
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and may impair implantation of an embryo. Both maternal and foetal health risks are increased 
by smoking, including the risk of miscarriage, premature labour, decreased infant birth weight 
and sudden infant death syndrome (Gormack et al., 2015). Concluding from this large meta-
analysis, consisting of 21 studies, the odds of a live birth and clinical pregnancy per cycle are 
significantly lowered in female patients that smoke. The odds of miscarriage and ectopic 
pregnancy are also increased (Gormack et al., 2015). 
 
There has been estimated that approximately 37% of men smoke cigarettes during their 
reproductive age and that toxins from tobacco smoking can potentially affect sperm function 
and development with a harmful effect on semen parameters (Sharma et al., 2016). A study 
by Jong et al. (2014) aimed at investigating the effect of cigarette smoke on sperm parameters. 
The results showed that there was no difference in sperm parameters between the fertile and 
sub-fertile group, indicating that smoking did not affect sperm parameters and ultimately 
pregnancy outcome. 
 
To the contrary, various studies have demonstrated results indicating that men should be 
advised to abstain from smoking in order to improve reproductive outcomes (Kovac et al., 
2015; Dai et al., 2014). Lotti et al. (2015) conducted a retrospective cross-sectional study to 
determine the impact of smoking on seminal, hormonal and male genital tract ultrasound 
parameters in patients seeking fertility treatment. The results indicated that male smokers, 
compared to non-smokers showed a lowered ejaculate and ultrasound derived seminal vesicle 
volume. Similarly, Sharma et al. (2016) conducted a study, including 5865 participants, to 
determine whether cigarette smoking altered semen parameters. From their results, the 
author/s concluded that smoking shows a definite overall negative effect on semen 
parameters, which is directly related to pregnancy outcome.  
 
1.6.2.3 Alcohol Consumption 
 
Severe increased alcohol consumption has generally been associated with poor fertility 
outcomes. In female patients, alcohol consumption has been associated with possible effects 
on the hypothalamus, leading to a decrease in Luteinizing Hormone [LH] and anovulation 
(Phillips, 2015). 
 
In a study by Eggert et al. (2004), the effect of long-term alcohol use on female fertility was 
investigated. The results of the study indicated that out of the 252 study participants, the high 
alcohol consumers had an increased risk of infertility compared to low consumers. The study 
concluded that high alcohol consumption was associated with increased infertility 
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examinations at hospitals and with lower numbers of first and second partus (Eggert et al., 
2004). Gormack et al. (2015) conducted a study to determine what the effect of lifestyle 
choices and dietary aspects on women undergoing ART treatment are. The study included 
250 women (between 20 - 43 years). The results indicated that women who abstained from 
drinking alcohol or merely reduced their alcohol consumption were twice as likely to become 
pregnant than those who maintained their drinking habits prior to fertility treatment.  
 
1.6.3 Male Factor Infertility 
 
Infertility of a couple does not only rely on the female patient profile, but to an equal extent on 
the male patient profile (Brugh et al., 2003). In approximately 20 to 25% of infertility cases, the 
male partner is solely responsible for the infertility problem (Morshedi, 2014).  
 
A semen analysis is generally seen as the cornerstone for evaluating men for infertility or 
subfertility (Kumar & Singh, 2016). The role of the routine semen analysis alone has however 
been challenged as ineffective and unreliable in predicting a male’s fertility status (Barroso et 
al., 1999; Jungwirth et al., 2012). The World Health Organization’s laboratory manual for the 
examination and processing of human semen (2010), regard normal semen parameters with 
Lower References and 95%CI as; semen volume of 1.5 ml (1.4 and 1.7), sperm concentration 
of 15 million per ml (12 and 16) sperm motility at 32% progressive (31 to 34); normal sperm 
morphology of 4% (3 to 5) and vitality of 58% (55 to 63) (WHO, 2010). 
 
Abnormal semen parameters may be a contributing factor in up to 30 - 45% of infertile couples 
(Jungwirth et al., 2012). In cases of oligozoospermia (<15 million motile spermatozoa per mL), 
severe asthenozoospermia (<5% progressive motility) and severe teratozoospermia (<4% 
normal morphology based on the Tygerberg strict criteria), IVF, or a combination of IVF and 
ICSI, should be offered. These semen parameters are associated with poor success in artificial 
insemination (Huang et al., 2012). A study conducted in 1998 by Oehninger et al. aimed to 
investigate the role spermatozoa has on embryo implantation and pregnancy outcome in IVF 
and ICSI. The results indicated that there is not a significant effect of severe male fertility 
(oligo- astheno- teratozoospermia) on implantation and pregnancy outcome (Oehninger et al., 
1998). 
 
With regard to the prediction of pregnancy and the role the male partner plays, several 
possible factors can contribute to the outcome (Brugh et al., 2003). A normal semen analysis 
does not necessarily eliminate a contribution to the fertility problem (Kumar & Singh, 2016) 
since functional tests and genetic integrity of spermatozoa is not evaluated (Zhang et al., 
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2015). Although sperm DNA integrity tests generally correlate with semen analysis outcomes 
and in certain cases, with ultimate pregnancy outcome (Collins et al., 2008) oocyte fertilization 
and embryo development, possibly rely on the inherent integrity of the spermatozoal DNA 
(Practice Committee of the American Society for Reproductive Medicine, 2008). There are 
various causes and contributing factors (intrinsic and external) that play a role in sperm DNA 
damage, and a large portion of these factors are unknown (Collins et al., 2008). Intrinsic 
factors that may predispose to sperm DNA damage include; mutations in relation with DNA 
compaction, oxidative stress caused by leucocytosis or a varicocele, a protamine deficiency 
and genetic disorders (Practice Committee of the American Society for Reproductive 
Medicine, 2008). 
 
Multiple assays have been developed to assess DNA damage (Collins et al., 2008). The sperm 
DNA fragmentation test (DNA Fragmentation Index [DFI]), which evaluates sperm chromatin 
integrity, has been globally adapted, due to its diagnostic capabilities to evaluate male fertility 
potential, and ultimately pregnancy outcome (Zhang et al., 2015). The study by Zhang et al. 
(2015) aimed to estimate and understand the association between the DNA Fragmentation 
Index [DFI] and Pregnancy outcome after IVF and ICSI. Their results indicated that infertile 
couples were more likely to become pregnant if the DFI was below the threshold value of 27% 
DNA fragmentation (Zhang et al., 2015). One could argue that routine semen parameters are 
not sufficient to predict pregnancy outcomes and could potentially be used in conjunction with 
sperm DNA tests (Collins et al., 2008). 
 
When deciding how the male factor should be evaluated for its possible contribution to 
infertility, a semen analysis should be the first line of action, but the test in itself, is not sufficient 
to determine cause or dictate the means of possible therapy (Brugh et al., 2003). To exclude 
other likely causes of male factor infertility, the best approach would be a systematic approach, 
which includes sperm DNA analysis and other necessary characteristics that play a role in 
successful fertilization and will ultimately lead to a full-term pregnancy (Morshedi, 2014). 
 
With regard to lifestyle factors smoking has shown to influence semen parameters (Kovac et 
al., 2015; Dai et al., 2014) but other lifestyle factors such as male BMI also needs to be 
considered. The results from various studies have shown that an increased likelihood of 
abnormal semen parameters and increased risk for subfertility exist among couples in which 
the male partner is obese (Du Plessis et al., 2010). Male partner obesity has been associated 
with a higher prevalence of infertility (Campbell et al., 2015; Nguyen et al., 2007). The 
increasing prevalence of obesity indicates that there is a definite need for clinical awareness 
with regard to male partner obesity and its effects on fertility (Du Plessis et al., 2010). 
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1.7 Infertility in General 
 
As mentioned above, the results obtained by ART depend on diverse factors, not only 
epidemiological (female age, cause of infertility, etc.) or the clinical practice accepted 
(pharmacological treatments, the policy regarding embryo transfer, etc.) but also on the social 
context in which such techniques are practiced. The significance of the role played by each 
factor however, remains unclear. Social context involves a set of social and cultural factors 
that influence clinical practice and the results achieved by different healthcare services. One 
of the most important factors in the field of infertility treatment is the regulation of ART, affecting 
issues such as restrictions on the number of embryos that may be transferred or the handling 
of frozen embryos. Other relevant factors in the social context include the existence of 
competition among clinics and the health care coverage available for infertility treatment, 
which determines the accessibility to such treatment (Castilla, 2009). 
 
In most countries, prioritizing infertility treatments compared to other treatments in healthcare 
is a controversial topic. Although the public sector is available for infertility treatment, the 
private sector predominates in the area of assisted reproduction. Lately, there has been an 
increase in the public sector facilitating ART, both in terms of the volume and the range of 
services offered (Castilla, 2009). Differences in public and private ART clinics do exist in terms 
of the volume of activities, the range of services offered, clinical practice and results achieved. 
Quantifying the intensity of these differences and determining the factors involved could help 
and lead to positive changes, in both sectors, in the procedures followed as well as resources 
available for the management of infertility (Castilla, 2009). 
 
Through analysis of previous applicable literature, findings and study results, it is clear that 
the ART outcomes in an IVF clinic is dependent on a wide variety of contributing factors. To 
be considered when interpreting results are: access to the best and latest equipment (i.e. 
incubators), patient profile (including fertility diagnosis and lifestyle factors) ovarian stimulation 
practises and clinical and laboratory expertise and procedures. For most of these contributing 
factors access to sufficient funds for both the laboratory/clinics and the patients, plays a 
significant role.  In the current study, the researchers aimed to investigate some of the possible 
contributing factors in two different Fertility Clinics. We hypothesise that clinic specific factors 
may have an effect on outcome and included incubator type, oocyte (female) age, number of 
oocytes aspirated, embryo quality, female diagnosis (tubal factor and endometriosis), BMI and  
AMH  in the analyses to determine its possible independent or combined  effect on clinical 
pregnancy outcome.    
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CHAPTER 2 – RESEARCH QUESTIONS 
 
2.1 Research Questions 
 
How does laboratory equipment, specifically two different CO₂ incubator types (COOK 
MINC™ Benchtop Incubator and Forma Scientific CO₂ Incubator Model 3164 - Water 
Jacketed) used, contribute to the embryo quality, development and ultimately the CPR?  
 
Which factors (specifically female) have a significant impact on CPR at a public and private 
fertility clinic?  
 
2.2 Aims & Objectives 
 
The aim of the study was to investigate which factors in ART treatment might have the most 
significant effect on ART outcome in two ART laboratories – one in the public sector and one 
in the private sector. 
 
The study consisted of two different analyses, a retrospective and a prospective analysis. 
 To retrospectively analyse: 
   The effect of two different CO₂ incubators, (COOK MINC™ Benchtop 
Incubator and Forma Scientific CO₂ Incubator Model 3164 - Water Jacketed) used at 
the Drs Aevitas private fertility clinic, on ART outcome (2013-2014).  
 To prospectively analyse: 
 The possible negative or positive impact of female patient profile (specifically 
number of oocytes, age, BMI, AMH and female diagnosis - tubal factor and 
endometriosis) in two different ART clinics public (Tygerberg Hospital Fertility Clinic) 
and private (Drs Aevitas private Fertility clinic) on ART outcome.    
 
2.3 Hypotheses   
 
Retrospective study: Smaller, triple gas, low O₂ concentration, bench top incubators (COOK 
MINC™) will result in improved ART outcome compared to large box, high O₂ concentration 
incubators (Forma Scientific CO₂ Incubator, Water Jacketed - Model 3164). 
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Prospective study: The female patient profiles will be significantly different for the two 
clinics. We hypothesize that BMI, tubal factor infertility and female age will be the main 
factors determining success in the public clinic and the female age will be the main 
contributor determining success in the private clinic – affecting overall success in the clinics.   
 
Important to Note: 
 
Drs Aevitas Fertility Clinic (Private Clinic) referred to as “Site 1” in the Results and 
Discussion sections.   
 
Tygerberg Fertility Clinic (Public Clinic) will be referred to as “Site 2” in the Results and 
Discussion sections.   
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CHAPTER 3 – MATERIALS, METHODS & STATISTICS 
 
3.1  Study Population for the Retrospective Analysis 
 
The retrospective analysis investigated the effect of two different CO₂ incubators on ART 
outcome. The study population for this part of the study was patients that had IVF, ICSI, PICSI, 
IMSI or combinations thereof cycles, during 2013 and 2014, at the private clinic. A total of 
1433 ART cycles were performed during the 2013 and 2014 period. Only 385 cycles were 
included in the final analyses after applying strict exclusion criteria to ensure that results were 
only due to incubator differences. The Health Research Ethics Committee [HREC] of the 
University of Stellenbosch approved this study protocol (Ethics Reference number: 
S15/03/050), for the period 18 June 2015 to 18 June 2016, with a waiver of consent, thus, no 
consent was needed from the patients for this part of the study. 
 
3.2  Patients included in Retrospective Analysis 
  N = 385 ART cycles  
 ART patients, IVF, ICSI, PICSI, IMSI or combinations thereof cycles, at the 
private clinic (2013 – 2014)  - including oocyte donor cycles 
Exclusion criteria: 
 < 3 MII oocytes aspirated  
 <  3 embryos on Day 2 
 Females ≥ 37 years 
 HIV positive female and male patients 
 Oocyte vitrification cycles 
 Frozen embryo transfer [FET] cycles 
 Cycles with crucial missing data 
 Cancelled Cycles 
 
3.3  Data and Information collected (For Retrospective Analysis Only) 
 Female age  
 Specific incubator used (patient specific) 
 Number of mature oocytes 
 Number of fertilized oocytes 
 Day 2, Day 3 and Day 5 embryo quality  
 Number of embryos transferred 
 Day of transfer        
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 Quality of the embryo/s transferred    
 Pregnancy rate (Clinical – foetal sac/ET) 
 
3.4  Data Collection and Ethical Considerations for the Retrospective Analysis 
In this study retrospective data from an existing patient data base was used. Patients were 
not subjected to any additional risks, injury or pain. During collection of data on the password 
protected spread sheet, no patient identity was entered. Each patient’s folder was allocated 
a number and remain anonymous. The patient’s identity and folder were only available to the 
investigators who had access to the files in the normal course of treatment. Waiver of 
consent was granted by the HREC. 
3.5  Study Population for the Prospective Analysis 
The second analysis was prospective and investigated the possible impact (negative or 
positive) of female patient profile on overall ART outcome. The study population for this part 
of the study was patients from both the private and public clinics that had an ART cycle, from 
23rd of June 2015 until 29th of April 2016. The exclusion criteria for this part of the study were 
not as strict as for the retrospective study. For the private clinic, 630 patient cycles were 
captured but only 572 were included in the study.  For the public clinic, 275 patient cycles were 
captured but only 248 were included in the study. Exclusion from the study was mostly due to 
consent form absence. The HREC of the University of Stellenbosch approved this study 
protocol (Ethics Reference number: S15/03/050A), for the period 17 June 2015 to 17 June 
2016. Each patient that underwent ART treatment at both the private and public clinic during 
this period was presented with a consent form (see Appendix XV), approved by the HREC of 
the University of Stellenbosch. The patient could then decide whether they wanted to 
participate or not. Patients who did not give consent or did not receive the consent form were 
excluded from the study. 
 
3.6  Patients included in Prospective Analysis 
 N = 572 cycles for the private clinic and N = 248 for the public clinic 
 2015 - 2016 fertility patients receiving treatment at the private and public clinics -
including oocyte donor cycles 
 IVF, ICSI, PICSI,  IMSI or combinations thereof cycles including FET cycles  
 All female ages 
 All female and male diagnosis 
 
 




 Oocyte vitrification cycles 
 Cycles with crucial missing data 
 Cancelled Cycles 
 Cycles without granted consent 
 Cycles where a consent form was not presented to the patient 
 
Data and Information collected (Independently for both Fertility Clinics) 
 Female and male diagnosis (Male Spermiogram) 
 Female patient & oocyte age  
 BMI 
 AMH 
 Number of oocytes (MI and MII) 
 Number of fertilized oocytes 
 Day 2, Day 3 and Day 5 embryo quality  
 Number of embryos transferred 
 Day of transfer        
 Quality of the embryos transferred    
 Pregnancy outcome (Clinical - foetal sac/ET) 
 
3.7  Data Collection and Ethical Considerations for the Prospective Analysis 
Patients signed informed consent giving permission that their information may be used in the 
study (see Appendix XV). Patients were not subjected to any additional risks, injury or pain. 
During collection of data on the password-protected spreadsheet, no patient identity was 
entered. Each patient’s folder was allocated a number and therefore remained anonymous. 
The patient’s identity and folder were only available to the investigators who had access to the 
files in the normal course of treatment. Participants did not receive remuneration and there 
were no extra costs involved.  
3.8  Procedures and Methods 
Standard IVF, ICSI, PICSI and IMSI protocols for ovarian stimulation, oocyte aspiration, 
insemination, fertilization, embryo culture, embryo evaluation and grading as well as embryo 
transfer were followed for both the retrospective and prospective studies.  Standard semen 
preparation was also followed for both studies. 
See Appendices I – XIV. 
 





3.9.1 Semen Preparation 
The preparation of semen samples were conducted according to standard preparation 
methods, which included wash and swim-up and density gradient centrifugation methods 
(Appendix I). 
 
3.9.2 ART Procedures 
 
Ovulation Induction and Oocyte Aspiration 
Standard ovarian stimulation protocols for each fertility clinic were used. 
 
Private Clinic 
Couples were treated according to a standardized stimulation protocol agreed upon 
by all participating physicians, see Appendix II. 
 
Public Clinic 
Standard, modified stimulation protocols were used – 100mg Clomiphene Citrate 
Clomid®, Letrozole® or Pergonal® for 5 days only on days 3 to day 7 in the cycle and 
± 75IU Menopur® on day 8 and 10 OR 100 mg Clomiphene Citrate for 8 to 10 days 
only on days 3 to 12 in the cycle and ± 75IU Menopur® on day 8 and 10. (4, 6, 8). 
Patients were followed up by doing estradiol determinations as well as serial 
ultrasonographic measurements of the Graafian follicles. Ovulation was induced by 
the administration of human chorionic gonadotrophin [HCG] (Ovitrelle®) as soon as 
the leading follicle reached a diameter of 18mm. 
 
3.9.2.1 Oocyte Retrieval 
A standard method (private and public clinic) was followed (Appendix III – public clinic, 
Appendix IV – private clinic). 
 
3.9.2.2 Insemination Procedure 
 a) IVF  
Metaphase II oocytes were inseminated with 100 000 to 500 000 motile spermatozoa 
each in NUNC 4-well dishes and then incubated in stage specific mediums, in drops 
under oil (see Appendix V). 
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b) ICSI  
Prerequisites for successful injection are immobilization of the sperm cells in PVP and 
mild cytoplasmic aspiration. Each cumulus-free metaphase II oocyte was injected with 
a single initially motile but immobilized spermatozoon. Oocytes were washed in fresh 
fertilization medium drops after injection and then incubated individually in 50µl drops 
of cleavage medium (under oil, 370C, 5 % CO₂, Quinn's – Coopersurgical™). Embryos 
destined for culture to blastocyst stage were transferred into blastocyst medium on day 
3 of culture (under oil, 370C, 5 % CO₂, (Quinn's – Coopersurgical™), see Appendix VI. 
Embryos were transferred to fresh medium on day 1, 3 and 5. 
c) PICSI  
A standard, routine method was followed using commercial PICSI® dishes (Origio, 
Harrilabs, South Africa), see Appendix VII. 
d) IMSI  
A standard, routine method was followed of sperm selection under high magnification 
used for ICSI, see Appendix VIII. 
 
3.9.2.3 Embryo Culture and Evaluation 
For all culture procedures the Quinn’s Advantage™ (Harrilabs, South Africa) culture medium 
range was used - including HEPES buffered medium, sperm preparation medium, 
fertilization/cleavage and blastocyst medium, oil for tissue culture, hyaluronidase, PVP.  
 
Only two CO2 incubator models were used during the retrospective study period (2013-2014) 
at the private clinic; COOK MINC™ Benchtop Incubator and Forma Scientific CO₂ Incubator 
Model 3164 - Water Jacketed. During the study period the private clinic laboratory used four 
MINC™ Benchtop Incubators (purchased in 2010) and four Forma Scientific CO₂ Incubators 
(purchased before and used since the 90’s). Patients were assigned to incubator type 
according to the availability of space.  
 
During the prospective study period (2015 – 2016), the private clinic only used bench top 
incubators for embryo culturing - four MINC™ incubators and four Planer (BT37) bench top 
incubators, introduced in January 2015. These are currently still in use in the laboratory. The 
public clinic laboratory used a Forma Series II Water Jacketed Incubator (model 3111) 
(purchased in 2012) during the study period, but in July 2016 purchased a Miri® benchtop 
incubator that is used for embryo culture after fertilization. 




A standardised, routine method (for both fertility clinics) was used for all patients. 
After incubation for 16-18 hours, oocytes were inspected for fertilization (presence of 2 
pronuclei and 2 polar bodies).  During further embryo development (Day 2 and Day 3 post-
insemination) the embryos were evaluated for embryo quality (blastomere morphology and 
percentage fragmentation).  Culture to the blastocyst stage and subsequent hatching were 
evaluated from day 4 to 7 post insemination, see Appendix IX & XI. 
 
3.9.2.4 Embryo Quality Evaluation  
Embryos were regarded as good quality when they reached the 2 - 4-cell stage at 48h post-
injection/fertilization or at the 6 – 8 cell stage, 72h post-injection/fertilization. They should have 
equal sized blastomeres and minor or no cytoplasmic fragmentation, see Appendix IX. 
 
3.9.2.5 Blastocyst Evaluation  
Blastocysts (day 5/6 culture) were graded according to the Gardner and Schoolcraft Blastocyst 
Grading (Veeck, 2003) method. With this system, blastocysts are given a numerical score 
from 1-6 on the basis of their degree of expansion and hatching. Additionally the development 
of inner cell mass and trophectoderm appearance is also evaluated (see Appendix XI). 
 
3.9.2.6 Embryo Transfer 
A standard embryo transfer method [private and public clinic] was followed.  The transfers 
were sonar guided and patients presented with a full bladder to facilitate an atraumatic 
procedure. The number of embryos transferred varied between the two clinics and also from 
cycle to cycle. In general, no more than three embryos were transferred and each cycle was 
evaluated individually to determine the number of embryos to be transferred considering 
various factors (see Appendix XIV). 
 
3.9.2.7 Cryopreservation and Thawing 
All supernumerary embryos of accepted quality were cryopreserved using an open system 
vitrification protocol (Fertipro VitriFreeze™ - VitriThaw™ kits). The protocol suggested by the 
supplier was used (Appendix XII & XIII). 
 
3.9.2.8 Laboratory Quality Control 
Both the private and public clinic laboratories make use of standard quality control measures. 
The temperature of the incubators and fridges used in both laboratories are checked and 
documented daily with the use of external digital (Temp-Chex Digital II – Streck Inc.) 
thermometers. The CO₂, N₂ and tri –gas mix levels of gas cylinders are also checked and 
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documented daily. The pH of culture medium (Sage cleavage medium) is tested weekly using 
gas tight syringes and a blood gas machine (Gem Premier 3500, Illex South Africa). 
Maintenance for culture incubators and all other laboratory equipment occur annually at both 
laboratories. The private clinic laboratory is equipped with a HEPA filter air system and positive 
pressure. All incubators are also equipped with inline active carbon filters (Gen X – supplied 
by Delfran Pharmaceuticals). The public clinic unfortunately does not have any of these 
measures (positive pressure, HEPA filters and inline filters). 
 
3.9.2.9 Pregnancy 
Pregnancy evaluations are defined as: 
 A biochemical pregnancy - a positive βHCG blood serum value on day 10 or 14 
after embryo transfer – but no foetal sac or heartbeat.  
 A clinical pregnancy - any product of conception 7 weeks (including a gestational 
sac, a positive heartbeat and ectopic pregnancy) post embryo transfer. Note: 
Multiple gestational sacs are counted as one clinical pregnancy per cycle. 
 An ongoing pregnancy - positive foetal heartbeat after 12 weeks. 
 An ectopic pregnancy - a pregnancy where implantation occurs outside the uterine 
cavity. 
 A perinatal death - death of the foetus after 20 weeks. 
 A miscarriage - the premature loss of a foetus up to 23 weeks. A miscarriage will 
have three different sub-categories: 
 1 - If the miscarriage occurred in the first seven weeks 
 2 - If the miscarriage occurred between 7 – 14 weeks 
 3 - If the miscarriage occurred after 14 weeks 
 a live birth - the complete expulsion or extraction from its mother of a product of 
fertilization, irrespective of the duration of the pregnancy, which, after such 
separation, breathes or shows any other evidence of life such as heart beat, 
umbilical cord pulsation, or definite movement of voluntary muscles, irrespective of 
whether the umbilical cord has been cut or the placenta is attached (Zegers-
Hochschild et al., 2009). 
 
For both the retrospective and prospective data analysis for this study, clinical 
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3.10  Statistics 
Statistical analysis of results were conducted at the Biostatistics Unit [BU] of The South African 
Medical Research Council [SAMRC] by Prof Carl Lombard. Prof Lombard was consulted to 
discuss power analysis to ascertain the number of patients to include. All statistical analysis, 
for both retrospective and prospective studies, was performed by prof. C. Lombard. 
 
3.10.1  Statistical Analysis - Retrospective Study  
All of the outcomes are categorical in nature and therefore categorical regression analysis was 
best suitable. Two types of categorical models were thus needed.  
 
For the outcomes: fertilization, embryo quality rate (Day 2 and 3); there are multiple outcomes 
within the same cycle of the participating patients. This correlation or dependence had to be 
accounted for. A mixed effects logistic regression analysis was used to account for the 
clustering.   
 
For the outcomes: clinical pregnancy, live birth and miscarriage, standard logistic regression 
analysis was conducted since the outcome observed is at the cycle level. If there are multiple 
cycles nested within a patient this hierarchical dependence structure was taken into account, 
considering each cycle independently.  
 
In each of the regression models the incubator type was included in the model via two indicator 
variables. Since the variable consists of two types, an overall test, for the significance of the 
variables, was conducted and reported.  The odds ratios of the specific types in relation to the 
reference type were also reported together with 95% confidence intervals. 
 
Since the study was retrospective and observational, the models had to take into account 
possible confounders and effect modifications especially with regard to incubator type. 
Possible confounders considered were:  maternal age at the time point of the cycle, ART 
procedures used, and male reproductive factors. 
 
A sample size of 385 cycles was adequate for the type of analysis used. Basic descriptive 
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3.10.2  Statistical Analysis - Prospective Study 
For the CPR, which is at patient level, analysis was a binomial regression model of the binary 
outcome. The association between clinical pregnancy rate and a set of clinical factors (age of 
oocytes, number of MII oocytes, TFI, endometriosis, BMI and AMH) was investigated.  
  
A pooled analysis was performed on the data of the two study Sites. This was necessary to 
improve the precision of the analysis. To facilitate any Site differences all the factors in the 
model was evaluated for a significant interaction with Site in the regression model. No 
significant interactions were found and Site was included in the main effects model as an 
adjustment factor. The linearity assumption of the continuous factors was investigated by 
graphical plots and by fitting non-linear terms in the model. The linear assumptions were 
confirmed (models not reported). Lowess smooth graphs, which creates a smooth line through 
a scatter plot to indicate the relationship between the variables investigated, were frequently 
used to illustrate and decide which factors should be investigated through regression 
analyses. 
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CHAPTER 4 – RESULTS 
4.1  Results - Retrospective Study  
Objective: To determine the effect of two different incubators, Forma Scientific CO₂ Incubator 
and the MINC™ Benchtop Incubator, on embryo quality and pregnancy outcome during the 
period January 2013 – December 2014. 
 
The incubators used were the MINC™ Benchtop Incubator and the Forma Scientific CO₂ 
Incubator respectively. The private laboratory made use of four MINC™ Benchtop Incubators 
and four Forma Scientific CO₂ Incubators. Important to note is that the incubator used was 
unknown in only three of the total of 388 cycles, and those were excluded from the statistical 
analysis. 
 
The specific grading criteria for good quality embryos used for the purposes of this study can 
be seen in Appendix X. 
 
A limitation of the retrospective results was that – during this specific study period - the Forma 
Scientific CO₂ Incubator was used in more cycles than the MINC™ Benchtop Incubator, 327 
cycles versus 58 cycles, respectively. This is due to the design of the study, which was 
retrospective and observational. Although the cycle numbers significantly differed in the two 
incubators investigated, the statistical significance of the results was not influenced. 
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4.1.1 Descriptive Data 
 
Table 2 presents the descriptive statistics for the variables; procedure, number of ova, age of 
ova (female age), male and female diagnosis, sperm morphology, proportion of fertilized MII 
ova, fertilization rate, quality of embryos and pregnancy outcome. 
 
Only the % of GQE/number of ova on day 3 was significantly increased in the MINC incubator 
compared to the Forma incubator, p = 0.03. 
 
Table 2:   Descriptive data of patient cycles for the two respective incubator types 
investigated. 
Variable 





Number of Cycles  327 58 - 
Age of Ova (years - female age) 30.25 (±4.88) 30.70 (±4.64) 0.29 
Total Ova per Cycle 13.28 (±7.58) 12.59 (±7.77) 0.52 
Sperm Morphology (% normal) 8.41 (±4.60) 9.146 (±4.74) 0.35 
Fertilization rate of MII Oocytes (%) 79.40 79.06 0.88 
Good Quality Embryos 
(GQE/Number of Ova) Day 2 (%) 
55.89 57.44 0.76 
Good Quality Embryos 
(GQE/Number of Ova) Day 3 (%) 
39.31 44.58 0.03 
Good Quality Embryos 
(GQE/Number of Ova) Day 5 (%) 
23.60 21.76 0.90 
Clinical Pregnancy/transfer (%) 45.43 47.17 0.81 
Values are presented as number, percentage or mean (± Standard Deviation) 
 
4.1.1.1 Insemination Procedure  
 
According to Fisher’s Exact test, which had a value of p = 0.43, there was also no difference 
in the distribution of the different ART procedures (ICSI, IVF and combinations thereof) 
between the two incubator types. Although the number of cycles per incubator differs largely, 
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Table 3:  Distribution of all ART procedures in incubators under investigation. 
Procedure 





IVF 10.40 (34) 10.34 (6) 10.39 (40) 
ICSI 64.22 (210) 63.79 (37) 64.16 (247) 
PICSI 7.34 (24) 8.62 (5) 7.53 (29) 
IVF / ICSI 13.76 (45) 12.07 (7) 13.51 (52) 
IVF / PICSI 3.36 (11) 5.17 (3) 3.64 (14) 
FROZEN OVA ICSI 0.61 (2) 0 (0) 0.52 (2) 
ICSI / PGD 0.31 (1) 0 (0) 0.26 (1) 
Total 100 (327) 100 (58) 100 (385) 
Values are presented as percentage (n – number of patients) 
 
4.1.1.2 Oocyte Age  
 
Figure 1 presents the distribution of the age of oocytes in the Forma Scientific CO₂ Incubator 
and the MINC™ Benchtop Incubator, respectively. The average age of oocytes in the Forma 
Scientific CO₂ Incubator was 30.24 years (SD = 4.88) and 30.96 years (SD = 4.64) in the 
MINC™ Benchtop Incubator. A t-test indicated no significant difference among the distribution 














Figure 1:  Boxplot showing the distribution of the age of oocytes (female age) in 
each incubator type the Forma Scientific and the MINC™ Benchtop. 
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4.1.1.3 Oocyte Distribution per Cycle 
 
The boxplot in Figure 2 demonstrates the distribution of the number of oocytes per cycle 
between the two incubator types under investigation. The average number of oocytes cultured 
in the Forma Scientific CO₂ Incubator was 13.28 (SD = 7.58) compared to 12.59 (SD = 7.77) 
in the MINC™ Benchtop Incubator. The p-value of 0.52 indicated no significant difference in 
the distribution of oocytes between the incubators. 
 
Figure 2:  Boxplot showing the distribution of the number of oocytes per cycle 
cultured in each incubator type: the Forma Scientific and the MINC™ 
Benchtop. 
 
4.1.1.4 Male and Female Diagnosis 
 
A Fisher’s Exact Test was also performed to determine whether there was a difference in the 
male and female diagnosis profile between the two incubators investigated.  
 
Table 4 presents the different male diagnoses and their distribution in the Forma Scientific 
CO₂ Incubator and the MINC™ Benchtop Incubator, respectively.  According to the Fisher’s 
Exact Test, which demonstrated a p value of 0.51, the male diagnosis was distributed evenly 
between the two incubators. 
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Table 4:   Distribution of male diagnosis among the two incubator types 
investigated. 
Male Diagnosis 





Normozoospermia 42.57 (126) 37.04 (20) 41.71 (146) 
Oligozoospermia 6.08 (18) 3.70 (2) 5.71 (20) 
Oligo- & Teratozoospermia 2.70 (8) 1.85 (1) 2.57 (9) 
Oligozoospermia (G-Pattern) 1.35 (4) 0 (0) 1.01 (4) 
Oligo- Terato- & 
Asthenozoospermia 
4.73 (14) 5.56 (3) 4.86 (17) 
Oligo- & Asthenozoospermia (G-
Pattern) 
0.68 (2) 3.70 (2) 1.14 (4) 
Teratozoospermia 8.45 (25) 9.26 (5) 8.57 (30) 
G-Pattern 15.54 (46) 24.07 (13) 16.86 (59) 
Immunological Factor 1.01 (3) 0 (0) 0.86 (3) 
Donor Sperm Used 2.70 (8) 0 (0) 2.29 (8) 
Other 6.76 (20) 5.56 (3) 6.57 (23) 
Astheno- & Teratozoospermia 0.34 (1) 0 (0) 0.29 (1) 
Testis Biopsy 6.76 (20) 7.41 (4) 6.86 (24) 
Donor & Own Sperm Used 0.34 (1) 0 (0) 0.29 (1) 
HIV Positive 0 (0) 1.85 (1) 0.29 (1) 
Total 100 (296) 100 (54) 100 (350) 
Values are presented as percentage (n – number of patients) 
 
Table 5 presents the different female diagnoses and their distribution in the Forma 
Scientific CO₂ Incubator and the MINC™ Benchtop Incubator, respectively. A Fisher’s Exact 
Test demonstrated a p value of 0.28, illustrating that the female diagnosis was distributed 
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Table 5:  Distribution of female diagnosis among the two incubator types 
investigated. 
Female Diagnosis 





Idiopathic 61.51 (187) 57.14 (32) 60.83 (219) 
Endometriosis 5.92 (18) 3.57 (2) 5.56 (20) 
Miomas 0.99 (3) 1.79 (1) 1.11 (4) 
Tubal Factor 6.91 (21) 1.79 (1) 6.11 (22) 
Anovulation 7.24 (22) 16.07 (9) 8.61 (31) 
Other 13.49 (41) 19.64 (11) 14.44 (52) 
Premature Ovarian 
Failure 
2.63 (8) 0 (0) 2.22 (8) 
Cervical Factor 0.33 (1) 0 (0) 0.28 (1) 
HIV Positive 0.66 (2) 0 (0) 0.56 (2) 
Normal - Male Factor 0.33 (1) 0 (0) 0.28 (1) 
Total 100 (304) 100 (56) 100 (360) 
Values are presented as percentage (n – number of patients) 
 
Statistical analysis concluded no significant difference in male diagnosis (Fisher’s exact p = 
0.51) or in female diagnosis (Fisher’s exact p = 0.28) between the two incubator types.  These 
factors can therefore be excluded in the ART outcome, emphasizing the effect of the 
incubators only. 
 
4.1.1.5 Sperm Morphology 
 
Patient sperm morphology distribution between the two incubators was shown to be similar 
and did not show a significant difference (p = 0.35) as illustrated in Figure 3. The average 
normal sperm morphology of patients in the Forma Scientific CO₂ Incubator was 8.41 % (SD 
± 0.30) compared to 9.15% (SD ± 0.74) in the MINC™ Benchtop Incubator.  




Figure 3:  Boxplot showing the distribution of patient normal sperm morphology 




Figure 4 represents the fertilization rate of MI and MII oocytes in the two respective incubator 
types. The percentage of MI oocytes fertilized in the Forma Scientific CO₂ Incubator was 
1.13% (SD = 7.09) and 1.25% (SD = 7.90) in the MINC™ Benchtop Incubator (p = 0.93). As 
demonstrated in Figure 4, very few patients had fertilization of MI oocytes.  At Aevitas Fertility 
Clinic there is a policy to inseminate MI oocytes since overnight “maturation” gave similar 
results – unpublished clinic results.  
 
MII oocytes had a much higher fertilization rate [as expected] compared to MI oocytes in both 
the Forma Scientific CO₂ Incubator (79.41% ± 17.94) and the MINC™ Benchtop Incubator 
(79.06% ± 16.77). No significant difference in the fertilization rate of MII oocytes between the 


















Figure 4:  Boxplot showing the fertilization rates of MI and MII oocytes in the two 
incubators under investigation. 
 
4.1.1.7 Embryo Quality - Day 2, 3 and 5 
 
The average number of good quality embryos on day 2, as presented in Figure 5, was 6.94 
(SD = 3.88) in the Forma Scientific CO₂ Incubator compared to 6.67 (SD ± 3.90) in the MINC™ 
Benchtop Incubator. No significant difference was shown in the average number of good 
quality embryos on day 2 (p = 0.62). 
Figure 5:  Boxplot showing the average number of good quality embryos on Day 2 
in the two incubators investigated. 
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Figure 6 illustrates the average number of good quality embryos on day 3. The Forma 
Scientific CO₂ Incubator had an average of 4.79 (SD ± 3.21) good quality embryos on day 3 
compared to 5.29 (SD = 3.51) in the MINC™ Benchtop Incubator.  Although there were more 
good quality day 3 embryos in the MINC incubator compared to the Forma incubator, no 
significant difference was shown in the average number of good quality embryos,  (p = 0.29). 
Figure 6:  Boxplot showing the average number of good quality embryos on Day 3 
in the two incubators investigated. 
 
The average number of good quality embryos on day 5 (Figure 7) also showed no difference 
between the two incubators (p = 0.85). The Forma Scientific CO₂ Incubator had an average 
of 3.14 (SD ± 2.47) compared to the MINC™ Benchtop Incubator which had an average of 












Figure 7:  Boxplot showing the average number of good quality embryos on Day 5 
in the two incubators investigated. 















Figure 8:  Boxplot showing a summary of the average number of good quality 
embryos on Days 2, 3 and 5. 
 
To determine the probability of good quality embryos on days 2, 3 and 5, modelling was 
necessary for the two incubators where the denominator was the total number of ova.  Figure 
9 presents a boxplot of the modelled probability and Table 6 summarizes the outcome. 
 
 
Figure 9:  Boxplot showing the percentage good quality embryos per number of 
oocytes aspirated for day 2, day 3 and day 5. 
 
A significant difference in the percentage of GQE/number of ova between the two incubators 
was shown only for day 3 with the MINC having 44.58% and the Forma 39.31% GQE; p=0.03.  
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Table 6:  Percentage good quality embryos per number of oocytes aspirated 
between the two different incubators. 
Percentage Good Quality 
Embryos (GQE/Number of Ova) 





Day 2 55.89 (318) 57.44 (57) 0.76 
Day 3 39.31 (317) 44.58 (56) 0.03 
Day 5 23.60 (243) 21.76 (40) 0.90 
 
Binomial Regression Model for Variables (Incubator type, Age of oocytes, Donor 
oocytes and MII oocytes) Influencing Quality of Embryos on Day 2, 3 and 5. 
The model was then also adjusted for the age of the oocytes (female age), use of donor 
oocytes and the number of MII oocytes available. Binomial regression was applied estimating 
the risk ratio [rr] for the Forma Scientific CO₂ Incubator compared to the MINC™ Benchtop 
Incubator on embryo culture days; 2, 3 and 5. 
Results are presented in Table 7, showing the risk ratios of the probability of good quality 
embryos on days 2, 3 and 5 in the two incubators. 
For day 2 there was no significant difference in the probability of good quality embryos 
between the two incubators (p = 0.76).  
From Table 6, there was observed that there was a significant difference on day 3 in the 
probability for good quality embryos, rr = 1.15 (95%CI 1.01 to 1.32), p = 0.03. This result 
indicated that the MINC™ Benchtop Incubator has a 15% (relative) higher probability of having 
good quality embryos on day 3 compared to the Forma Scientific CO₂ Incubator.  From the 
descriptive statistics (Table 2) there can be observed that the mean proportion of good quality 
embryos on day 3 is 0.39 in the Forma Scientific CO₂ Incubator compared to 0.45 in the 
MINC™ Benchtop Incubator. The crude ratio is 1.13, which is close to the adjusted ratio from 
the model. 
 
There was no difference between the two incubators with regard to the probability of good 
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Table 7:   Risk ratios of the probability of good quality embryos on Days 2, 3 and 
5.  
  Day 2 Day 3 Day 5 
Incubator  1.01 1.15 1.01 
Age of Oocytes 1.00 0.99 0.99 
Donor Oocytes 0.98 0.95 0.91 
MII Oocytes 0.99 0.98 0.97 
 
4.1.1.8 Pregnancy Outcome 
Clinical Pregnancy Outcome (foetal sac/ET) 
There was no significant difference observed in the clinical pregnancy rate (Table 8) 
observed in patients whose embryos were cultured in the two respective incubator types 
 (47.17% for the MINC and 45.43% for the Forma respectively),   p = 0.81. Of the total of 385 
patients, only 370 patients had a known pregnancy outcome; n = 317 patients from the Forma 
Scientific CO₂ Incubator and n = 53 patients the MINC™ Benchtop Incubator.   
 
Table 8:  Clinical pregnancy rate of patients with embryos cultured in the MINC™ 
Benchtop Incubator and the Forma Scientific CO₂ Incubator.  
Incubator Clinical Pregnancy 
Forma Scientific CO₂ Incubator 45.43 (144) 
MINC™ Benchtop Incubator 47.17 (25) 
Total 45.68 (169) 
Values represented as percentage (number of patients with a positive clinical pregnancy 
outcome), p = 0.81 
Overall Pregnancy Outcome (All Categories) 
No significant difference in any of the other pregnancy outcome categories between the two 
incubators was indicated by the Fisher’s exact test (p = 0.57). All pregnancy category 
outcomes were similar in both the MINC™ Benchtop Incubator and the Forma Scientific CO₂ 
Incubator (Table 9). There were a total of 15 patients with missing pregnancy data. 
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Table 9:   Detailed pregnancy outcome between the MINC™ Benchtop Incubator 







Not Pregnant 40.69 (129) 37.74 (20) 40.27 (149) 
Biochemical 7.57 (24) 9.42 (5) 7.84 (29) 
Blighted Ovum 0.32 (1) 0 (0) 0.27 (1) 
Miscarriage 0.32 (1) 0 (0) 0.27 (1) 
Ectopic 0.95 (3) 0 (0) 0.81 (3) 
Ongoing 4.73 (15) 7.55 (4) 5.14 (19) 
Full Term 35.02 (111) 30.19 (16) 34.32 (127) 
Perinatal Death 1.89 (6) 3.77 (2) 2.16 (8) 
No Embryo Transfer 3.79 (12) 1.89 (1) 3.51 (13) 
No Foetal Heart  0.95 (3) 0 (0) 0.81 (3) 
Miscarriage (< 7 weeks) 1.26 (4) 3.77 (2) 1.62 (6) 
Miscarriage 2 (7 - 14 weeks) 1.58 (5) 5.66 (3) 2.16 (8) 
Miscarriage 3 (> 14 weeks) 0.95 (3) 0 (0) 0.81 (3) 
Total 100 (317) 100 (53) 100 (370) 
Values are presented as percentage (number of patients) 
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4.2  Results – Prospective Study 
 
Objective: To determine the possible (negative or positive),  independent influence/effect of 
specifically female patient profile (including  oocyte age, BMI, AMH and diagnosis) in two 
different ART clinics (one in the public sector and one in the private sector) on ART outcome.  
 
The aim of the study was to investigate which factors in ART treatment might have the most 
significant and independent effect on ART outcome in two ART laboratories. The main 
outcomes investigated with regard to the different laboratories were oocyte age (female age); 
number of MII oocytes aspirated; female diagnosis – specifically tubal factor, endometriosis; 
BMI; AMH and ultimately CPR. 
 
In the private laboratory, the total number of patients during the time of data capturing was 
630. Only the 572 consenting patients were included in the analysis. The 58 excluded patients 
either did not receive a consent form (n = 55) or did not agree to sign consent (n = 3) to 
participate in the study. 
 
The total number of patients that underwent ART treatment at the public clinic was 275. Of the 
275 patients, only 248 could be included in the study. The 27 excluded patients either did not 
receive a consent form (n = 24) or did not agree to sign consent (n = 3) to participate in the 
study. 
 
The statistical analysis presented in the first part of the statistical report made use of pooled 
data from both Sites. Although this was not the initial aim for the prospective data analysis, 
the statistician, prof. C. Lombard, recommended analysis of the pooled data to identify factors 
that might have an effect on CPR and to improve the accuracy of the outcomes.   
 
A limitation of the prospective results was the extensive difference in the number of patients 
between the two Sites although statistical analysis indicated that the results were still 
statistically valid.  
  
Stellenbosch University  https://scholar.sun.ac.za
55 
 
4.2.1 Descriptive Data Results for Site 1 – The Private Fertility Clinic 
 
Table 10 presents the overall descriptive statistics for the variables investigated that could 
potentially influence ART outcomes at Site 1.  
 
Table 10:   Descriptive data of main factors influencing ART outcomes at Site 1. 
Variable N Min p25 p50 p75 Max 
Patient Age (Years) 572 23 34 37 40 54 
Donor Age (Years) 108 19 23 24 28 44 
Oocyte Age (Years) 572 19 30 35 39 46 
AMH (ng/mL) 195 0.08 0.38 1.20 2.53 12.25 
BMI (kg/m²) 468 15.12 20.85 23.31 26.50 45.36 
Number of Oocytes Aspirated  463 0 4 8 13 66 
Number MII Oocytes  460 0 3 6 11 46 
Number of Oocytes Fertilized  472 0 3 5 9 39 
Number of Good Quality Embryos on 
Day 2 
415 0 2 4 7 28 
Number of Good Quality Embryos on 
Day 3 
366 0 2 4 7 22 
Number of Good Quality Embryos on 
Day 4 
44 0 0 1.5 3 10 
Number of Good Quality Embryos on 
Day 5 
247 0 1 3 5 17 
Number of Good Quality Embryos on 
Day 6 
28 0 0 0 1.5 6 
Number of Good Quality Embryos on 
Day 7 
8 0 0 0 0 1 
Day of Embryo Transfer 479 2 3 5 5 7 
Number of Embryos Transferred 533 0 1 2 2 8 
Number of Good Quality Embryos 
Transferred 
478 0 1 2 2 5 
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4.2.1.1 Female Diagnosis  
 
The distribution of female diagnoses at Site 1 is illustrated in Figure 10. The pie chart indicates 
that advanced maternal age; 23% (n = 130), other  (immunological, growths/fibroids, growths 
& myoma’s, myoma, premature ovarian failure myomectomy, uterine factor, HIV positive, poor 
responder, genetic factor, congenital abnormality, cancer, ova vitrification, low AMH value and 
oophorectomy); 21%  (n = 118) and normal (only male factor); 17% (n = 97) were the most 
common diagnoses among the patients. Tubal factor and endometriosis only contributed to 
8% and 11% of the total female factor diagnosis, respectively. 
 





BMI distribution among patients attending Site 1 were categorized into two groups as shown 
in Figure 11. The first group was patients with a BMI < 30 kg/m2 and 90% of the patients (n = 
337) was in this group. The second group was patients with a BMI ≥ 30 kg/m2 and 10% of the 
patients (n = 39) was in this group. The total of the cycles (n = 376) with an indicated BMI 
differs from the total number of cycles that occurred during the time of investigation (n = 572) 









Ideopathic (n = 46)
Endometriosis (n = 63)
Tubal Factor (n = 45)
Anovulation/PCOS (n = 48)
Advanced Maternal Age (n = 130)
Recurrent Miscarriage (n = 25)
Normal - Male Factor (n = 97)
Other (n = 118)




Figure 11:   Pie graph showing the distribution of BMI, grouped, at Site 1 (n = 376). 
 
 
4.2.1.3 Male Diagnosis 
 
Table 11 presents the different male diagnoses and their distribution among the total number 
of cycles at Site 1 (n = 528).  Of the various diagnoses the most predominant was G-Pattern 


































Stellenbosch University  https://scholar.sun.ac.za
58 
 
Table 11:   Distribution of main male diagnoses at Site 1 (n = 528).  
 
 
4.2.1.4 Distribution of Cycles Types 
 
At Site 1, the patient cycle types were grouped to illustrate how many patients made use of 
donor and surrogate cycles (Figure 12). The data indicated that of the total of patients that 
underwent ART treatment at Site 1; 79% (n = 464) used their own ova, 19% (n = 108) made 
use of donor ova and 2% (n = 14) made use of a surrogate. 
Male Diagnosis Number of Patients (n) 
Percentage of 
Patients (%) 
N-Pattern Morphology (>14%) 65 12,31% 
Oligozoospermia 43 8,14% 
Oligo - Teratozoospermia (0 - 4%) 16 3,03% 
Oligozoospermia (G-Pattern 5 - 14%) 12 2,27% 
Oligo- Astheno - P-Pattern Morphology (0 - 
4%) 
13 2,46% 
Oligo- Asthenozoospermia (G-Pattern 5 -
14%) 
2 0,38% 
Oligo- Asthenozoospermia (N-Pattern 
>14%) 
0 0,00% 
P-Pattern Morphology (0 - 4%) 33 6,25% 
G-Pattern Morphology (5 - 14%) 233 44,13% 
Immunological Factor 12 2,27% 
Donor Sperm 18 3,41% 
Other 11 2,08% 
Astheno- Teratozoospermia/G-Pattern (0 - 
4%/5 - 14%) 
3 0,57% 
Retrograde Ejaculation 1 0,19% 
Testis Biopsy 20 3,79% 
Donor And Own Sperm 5 0,95% 
Azoospermia 32 6,06% 
Previous Vasectomy 7 1,33% 
HIV Positive 2 0,38% 
Total 528 100,00% 




Figure 12:   Pie chart showing the distribution of cycle types at Site 1 (n = 572). 
 
 
4.2.1.5 Treatment Distribution 
 
All the different types and combinations of treatment procedures at Site 1 are indicated in 
Table 12. The data showed that the most predominant treatment procedures were; PICSI 







Own Ova (n = 464)
Donor Ova (n = 108)
Surrogate (n = 14)
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Table 12:   Distribution of treatment procedures at Site 1 (n = 572). 
Treatment Type Percentage (n) 
IVF 1,74% (10/572) 
ICSI 9,44% (54/572) 
PICSI 43,53% (249/572) 
IVF/ICSI 0,17% (1/572) 
IVF/PICSI 13,63% (78/572) 
PICSI/IMSI 1,57% (9/572) 
FET 18,70% (107/572) 
FROZEN OVA - PICSI 0,69% (4/572) 
IMSI 0,17% (1/572) 
PICSI - PGD/S 2,97% (17/572) 
OOCYTE VITRIFICATION 5,06% (29/572) 
ICSI/PICSI 0,69% (4/572) 
AI/PICSI 0,17% (1/572) 
ASPIRATED - NO PROCEDURE 1,04% (6/572) 
CYCLE CANCELLED - NO ASPIRATION 0,17% (1/572) 
IVF/FET 0,17% (1/572) 
 
 
4.2.1.6 Cycle Description 
 
Figure 13 presents descriptive data regarding the cycles, at Site 1, during the study period. 
The data indicated that a total of 460 (n = 572 cycles) patients were aspirated (for fresh cycles) 
if the procedure of ova vitrification is included. If the procedure of ova vitrification is excluded 
there were 436 (n = 572 cycles) aspirations eligible for embryo transfer. Of the 436 aspirated 
cycles eligible for embryo transfer (excluding ova vitrification cycles; n = 29), 371 patients 

























































Figure 13:   Distribution of treatment cycle outcomes at Site 1. 
 
In 65 cycles eligible for an embryo transfer, no embryo transfer occurred.   The various 
reasons for no transfer are shown in Figure 14. The most common reasons for a cycle with 
no embryos transferred was poor quality embryos (34%; n = 22) and freeze all cycles for 
PGD/PGS (26%; n = 17). 
Figure 14:  Distribution of cycles with no embryo transfer at Site 1 (n = 65). 
 
4.2.1.7 Overall Pregnancy Outcome  
 
The overall pregnancy outcome per transfer is indicated in Figure 15. At the time of analysis 
61 patients out of 478 patients (that received an embryo transfer) did not have a known 
pregnancy result. In 417 cycles a pregnancy outcome was known. A total of 235 patients were 
not pregnant after ART treatment at Site 1. The number of miscarriages (< 7 weeks and 7-14 
weeks) was 19 and a visible foetal sac/s was present in 113 of the patients. Eleven (11) babies 






Freeze All Cycle (n = 9)
No Fertilization (n = 10)
Poor Quality Embryos (n = 22)
Freeze All Cycle (PGD/PGS) (n = 17)
Other (n = 7)
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Figure 15:   Distribution of pregnancy outcomes (cycle number) at Site 1 (n = 478). 
 
4.2.1.8 Clinical Pregnancy Outcome/ET (of Cycles with a Known Pregnancy Outcome)   
 
Table 13 shows an overview of the clinical pregnancy outcome at Site 1 of cycles with known 
pregnancy outcome (n = 417). The clinical pregnancy rate (CPR) data was subdivided into 
two categories, cycles with an oocyte [female] age ≤ 35 years and > 35 years, respectively.  
The group oocyte age ≤ 35 years had a CPR/ET of 36.01% (n = 103) compared to 27.36% (n 
= 52) in the group oocyte age > 35 years. The overall CPR /ET was 32.56% (n = 155) 
 
 
Table 13:  Clinical Pregnancy Outcome/Transfer at Site 1. 
  
n = ± SD 
Average Number of Oocytes Aspirated 9,57 (± 7,08) 
Average Number of Embryos Transferred 2,07 (± 1,03) 
Average Oocyte [female]  Age (years) 33,88 (± 5,89) 
  Percentage (n) 
Clinical Pregnancy Rate (Foetal Sac)/ET 37.17% (155/417) 
Clinical Pregnancy Rate/ET - Oocyte Age ≤ 35 years 41.53% (103/248) 
Clinical Pregnancy Rate/ET - Oocyte Age > 35 years 30.76% (52/169) 
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4.2.2 Descriptive Data Results for Site 2 – The Public Fertility Clinic 
 
Table 14 presents the descriptive statistics for the variables investigated that could potentially 
influence ART outcomes in the public sector fertility clinic. Table 14 provides an overall 
overview of the patient and cycle demographics at Site 2 during the period of investigation. 
 
Table 14:   Descriptive data of main factors influencing ART outcomes at Site 2. 
Variable N Min p25 p50 p75 Max 
Patient Age (Years) 248 25 32 35 38 45 
Donor Age (Years) 6 20 22 24.5 35 35 
Oocyte Age (Years) 248 20 31 35 38 45 
Anti-Mullerian Hormone [AMH] 
(ng/mL) 
85 0.16 0.72 1.38 3.48 18.88 
BMI (kg/m²) 232 17.80 23.59 26.97 31.075 47.78 
Number of Oocytes Aspirated 241 0 2 3 5 30 
Number MII Oocytes 224 0 2 3 4 30 
Number of Oocytes Fertilized  225 0 1 2 3 28 
Number of Good Quality 
Embryos on Day 2 
198 0 1 2 3 14 
Number of Good Quality 
Embryos on Day 3 
173 0 1 1 2 10 
Number of Good Quality 
Embryos on Day 4 
40 0 0 1 2 4 
Number of Good Quality 
Embryos on Day 5 
19 0 0 1 3 9 
Number of Good Quality 
Embryos on Day 6 
1 0 0 0 0 0 
Number of Good Quality 
Embryos on Day 7 
0 - - - - - 
Day of Embryo Transfer 185 1 3 3 3 6 
Number of Embryos Transferred 248 0 0 2 2 4 
Number of Good Quality 
Embryos Transferred 
185 0 1 2 2 4 
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4.2.2.1 Female Diagnosis 
 
The distribution of female diagnoses at Site 2 is illustrated in Figure 16. Four predominant 
diagnoses were evident as indicated in Figure 16. The most prevalent diagnoses were tubal 
factor infertility; 29% (n = 73), normal female/male only factor infertility; 18% (n = 45) and 
anovulation/PCOS; 14% (n = 34).  
 





The BMI distribution among patients attending Site 2, is shown in Figure 17. The first group 
was patients with a BMI < 30 kg/m2 and 68% of the patients (n = 144) was in this group. The 
second group was patients with a BMI ≥ 30 kg/m2 and 32% (n = 67) was in this group. The 
total of the cycles (n = 211) with an indicated BMI differs from the total number of cycles that 
occurred during the time of investigation (n = 248) due to missing data. 













Endometriosis (n = 22)
Tubal Factor (n = 73)
Anovulation/PCOS (n = 34)
Advanced Maternal Age (n = 23)
Normal - Male Factor (n = 45)
Other (n = 31)
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4.2.2.3 Male Diagnosis 
 
Table 15 demonstrates the male diagnosis distribution among all the cycles at Site 2 (n=248). 
The table indicates that the most frequent male diagnosis among male patients were; 
Normozoospermia (28.63%; n = 71), Teratozoospermia (20.56%; n = 51), Testis Biopsy 
(17.34%; n = 43) and G-Pattern Morphology (13.31%; n = 33). 
 






Percentage of Patients 
(%) 
N-Pattern Morphology (>14%) 7 2.82% 
Oligozoospermia 2 0,81% 
Oligo - Teratozoospermia (0 - 4%) 20 8,06% 
Oligozoospermia (G-Pattern 5 - 14%) 0 0,00% 
Oligo- Astheno - Teratozoospermia (0 - 4%) 8 3,23% 
Oligo- Asthenozoospermia (G-Pattern 5 -
14%) 
1 0,40% 
Oligo- Asthenozoospermia (N-Pattern >15%) 0 0,00% 
P-Pattern Morphology (0 - 4%) 51 20,56% 
G-Pattern Morphology (5 - 14%) 97 39.11% 
Immunological Factor 2 0,81% 
Donor Sperm 8 3,23% 
Other 1 0,40% 
Astheno- Teratozoospermia/G-Pattern (0 - 
4%/5 - 14%) 
2 0,81% 
Retrograde Ejaculation 0 0,00% 
Testis Biopsy 43 17,34% 
Donor And Own Sperm 0 0,00% 
Azoospermia 5 2,02% 
Previous Vasectomy 1 0,40% 
HIV Positive 0 0,00% 
Total 248 100,00% 
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4.2.2.4 Distribution of Cycles Types 
 
Figure 18 shows the distribution of cycle types at Site 2. Of the total number of cycles during 
the time of investigation (n = 248), the female patient made use of her own ova in 98% (n = 
242) of the cycles, compared to 2% (n = 6) of patients making use of donor ova. There were 
no surrogate cycles during this time at Site 2. 
Figure 18:   Pie chart showing the distribution of cycles types at Site 2 (n = 248). 
 
 
4.2.2.5 Treatment Distribution 
 
The treatment procedures applied at Site 2 during the time of investigation are indicated in 
Table 16. The most frequently used procedures were ICSI (58.87%; n = 146) and IVF (31.45%; 






















Own Ova (n = 242)
Donor Ova (n = 6)
Surrogate (n = 0)
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Table 16:   Distribution of treatment procedures at Site 2 (n = 248). 
Treatment Type Percentage (n) 
IVF 31,45% (78/248) 
ICSI 58,87% (146/248) 
PICSI 0,40% (1/248) 
IVF/ICSI 0,00% (0/248) 
IVF/PICSI 0,00% (0/248) 
PICSI/IMSI 0,00% (0/248) 
FET 2,82% (7/248) 
FROZEN OVA - PICSI 0,00% (0/248) 
IMSI 0,00% (0/248) 
PICSI - PGD/S 0,00% (0/248) 
OOCYTE VITRIFICATION 0,00% (0/248) 
ICSI/PICSI 0,00% (0/248) 
AI/PICSI 0,00% (0/248) 
ASPIRATED - NO PROCEDURE 6,45% (16/248) 
IVF/FET 0,00% (0/248) 
 
 
4.2.2.6 Cycle Description  
 
A total of 241 patients were aspirated at Site 2 during the investigation period. The total 
number of cycles were 248, but 7 of the cycles were FET. There were no ova vitrification 
during this period. Of the 241 aspirated cycles, 178 cycles received and embryo transfer, 
excluding Frozen Embryo Transfer [FET] (n = 7), resulting in a transfer rate of 73.85% 
(178/241) as indicated in Figure 19. 
 




Figure 19:   Distribution of treatment cycle outcomes at Site 2. 
 
In 241 cycles eligible for an embryo transfer, 63 of the cycles did not receive an embryo 
transfer. The various reasons for no transfer are shown in Figure 20.  The two main reasons 
for no transfer were no oocyte fertilization (32%; n = 20) and poor quality embryos (29%; n = 
18).  
Figure 20:   Distribution of cycles with no embryo transfer at Site 2 (n = 63). 
 
4.2.2.7 Overall Pregnancy Outcome 
 
The overall pregnancy outcome per transfer of the 185 cycles that received an embryo transfer 
(7 FET’s included) are shown in Figure 21. At the time of analysis 148 of the cycles had a 
negative pregnancy outcome. A foetal heart/s was present in 5 patients and 14 babies have 










































Aspirated - No Ova Retrieved (n = 16)
No Fertilization (n = 20)
Poor Quality Embryos (n = 18)
Other (n = 9)
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Figure 21:   Distribution of pregnancy outcomes (cycle number) at Site 2 (n = 185). 
 
4.2.2.8 Clinical Pregnancy Outcome/ET (of Cycles with a Known Pregnancy Outcome) 
 
Table 17 shows an overview of the clinical pregnancy outcome at Site 2 of cycles with known 
pregnancy outcome (n=185). The clinical pregnancy rate (CPR)/ET for patients with an oocyte 
age of ≤ 35 years was 19.46% (n= 22) compared to 9.72% (n=7) in patients that had an oocyte 
age > 35 years. The overall CPR/ET, regardless of oocyte age, was 15.67% (n=29). 
 
Table 17:  Clinical Pregnancy Outcome/Transfer at Site 2. 
  n = ± SD 
Average Number of Oocytes Aspirated 4,14 (± 3,56) 
Average Number of Embryos Transferred 2,07 (± 1,14) 
Average Oocyte Age (years) 35 (± 4,50) 
 Percentage (n) 
Clinical Pregnancy (Foetal Sac)/ET 15,67% (29/185) 
Clinical Pregnancy/ET - Oocyte Age ≤ 35 years 19,46% (22/113) 
Clinical Pregnancy/ET - Oocyte Age > 35 years 9,72% (7/72) 
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4.2.3 Statistical Analysis for Site 1 and 2 – The Private and Public Fertility Clinic 
Pooled and Separate Data 
 
4.2.3.1 Descriptive Data – Effect of Different Factors on Clinical Pregnancy Rate (CPR) 
 
a) Age of Oocytes (Female Age) 
The Lowess smooth graph (Figure 22) demonstrates the association between oocyte age and 
clinical pregnancy rate (CPR) in both Sites pooled. The results indicated that with an increase 
in oocyte age, CPR declines. There was a 20% difference across the oocyte age range.  
 
Figure 22:  Lowess smooth graph showing the association between CPR and 
oocyte age for both Sites (pooled). 
 
Lowess smooth graph (Figure 23) shows the association between CPR and oocyte age for 
each Site separately. Site 2 had very few cycles that had a relatively young oocyte age, < 26 
years. Overall trends are the same at both Sites confirming results from pooled analysis as 
indicated in Figure 22. No interaction was observed between oocyte age and Site with respect 
to the outcome of CPR.  
 
 






















Figure 23:  Lowess smooth graph showing the association between CPR and 
oocyte age for each Site separately. 
 
b) Endometriosis 
In a pooled analysis of both Sites, the results indicated no significant difference in CPR in 
cycles that had patients presenting with endometriosis (29.41%; n = 20) compared to those 
who did not have endometriosis (29.76% n = 164), p = 0.952.  
 
The CPR, at Site 1, in cycles with patients presenting with endometriosis was 29.41% (n = 15) 
compared to 36.65% (n = 140) in patients that did not have endometriosis (p = 0.31). The CPR 
in patients with endometriosis in Site 2 was also 29.41% (n = 5) compared to 14.20% (n = 24) 
in patients that did not have endometriosis (p = 0.09). 
 
As previously mentioned the CPR for cycles with female patients presenting with 
endometriosis was the same at both Sites; 29.41%. The differential comes in with the CPR in 
the cycles with patients not presenting with endometriosis. Site 2 CPR is 14.20% (n = 24) 
compared to 36.65% (n = 140) at Site 1. This indicated that the results obtained are strongly 
confounded by the patient population in both Sites.  
 
c) TFI 
The results of the pooled data (Site 1 and 2) with regard to the effect of tubal factor infertility 
on CPR indicated that there was no statistical significant difference in CPR when comparing 
tubal factor infertility patient cycles with non-tubal factor infertility patient cycles. Cycles with 
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patients presenting with tubal factor infertility had a CPR of 22.99% (n = 20) compared to 
cycles with patients that did not present with tubal factor infertility, 30.89% (n = 164). Thus, a 
lower CPR was observed in patients presenting with tubal factor, but this difference was not 
statistically significant (p = 0.138).  
 
At Site 1 the CPR in cycles where patients presented with tubal factor infertility was 29.73% 
(n = 11) compared to 36.36% (n = 144) in cycles where patients did not present with tubal 
factor infertility (p = 0.42). 
 
At Site 2 the CPR in cycles where patients presented with tubal factor infertility was 18.00% 
(n = 9) compared to 14.71% (n = 20) in cycles where patients did not present with tubal factor 
infertility (p = 0.58).  
 
d) BMI 
Figure 24 presents a non-parametric Lowess smooth graph of the association between CPR 
and BMI. The data used in this graph is pooled from Site and Site 2. The graph excludes one 
patient with a BMI < 16 from Site 1. The results indicated that there was a small decrease in 















Figure 24:  Lowess smooth graph showing the association between CPR and BMI 
for both Sites (pooled). 
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The Lowess smooth graph presented in Figure 25, illustrates the association between CPR 
and BMI for each Site separately. The number of participants with a BMI value > 40 was 
very small. The graph indicates that CPR decreases with an increased BMI at Site 1, with a 
rapid decline from a BMI value ≥ 30. At Site 2, CPR rapidly declines around a BMI value of 
20 and starts to increase from a BMI of 30, this could be due to an interaction of other 
factors. 
Figure 25:  Lowess smooth graph showing the association between CPR and BMI 
for Site 1 and Site 2 separately. 
 
Figure 26 illustrates the association between CPR and BMI at each Site, taking into account 
the effect of cycles presenting with and without endometriosis.  The results demonstrated that 
cycles presenting with endometriosis had a lower CPR but the association was the same with 
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Figure 26:  Lowess smooth graph showing the association between CPR and BMI 
and considering endometriosis at the two different Sites. 
 
e)  AMH 
The data presented in Figure 27 demonstrates the association between AMH and CPR for 
both Sites, pooled. The data was restricted to an AMH value <8. The results indicated that 
there was no association with regard to CPR for AMH up to a value of 4, but for AMH > 4 an 
increase in CPR was observed. The number of cycles with a patient AMH value of > 4 was 
very small, although this factor was initially one of the factors investigated, various amounts 
of was data missing in both Sites, thus analysis was limited.  
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Figure 27:  Lowess smooth graph showing the association between CPR and AMH 
for both Sites (pooled). 
 
Figure 28 demonstrates the association between AMH and CPR for the two Sites separately. 
The trend shown in Figure 28 is similar to that of the pooled data (Figure 27), but at different 
levels. As previously mentioned large numbers of AMH data were missing and this limited its 
use in the statistical models evaluating AMH effect on clinical pregnancy outcome. 
Figure 28:  Lowess smooth graph showing the association between CPR and AMH 
at the two different Sites.  
Stellenbosch University  https://scholar.sun.ac.za
76 
 
4.2.3.2 Further Statistical Analysis – Site 1 & 2 Combined 
 
a) Binomial Regression Model (Adjusted for Site & Age of Oocytes) 
 
A binomial regression model was performed for each of the determinant factors investigating 
their association with CPR. The model was adjusted for Site and the age of oocytes (female 
age). The data of both Sites were pooled to improve the accuracy of the outcomes. 
 
i) BMI 
Table 18 presents the outcome of the binomial regression model analyses applied to 
determine the association between BMI and CPR. As shown in the table, BMI is not associated 
with CPR in the basic adjusted model (p = 0.41). 
 
Table 18:  Association between BMI and CPR (adjusted for site & age of oocytes) 
for both Sites (pooled data). 
 
Risk Ratio (rr) 
Standard 
Error 
z - value P > ǀzǀ [95% Confidence Interval] 




The results from the adjusted binomial regression model presented in Table 19, demonstrates 
that AMH value is not associated with CPR (p = 0.17). AMH was not used in further models 
due to the significant numbers of missing data. More than 65% of the cycles had a missing 
AMH value and this could introduce severe bias in any result. 
 
Table 19:  Association between AMH and CPR (adjusted for site & age of oocytes) 
for both Sites (pooled data). 
 
Risk Ratio (rr) 
Standard 
Error 
z - value P > ǀzǀ [95% Confidence Interval] 








Endometriosis is not associated with CPR according to the adjusted binomial regression 
model results as indicated in Table 20 (p = 0.72). 
 
Table 20:  Association between endometriosis and CPR (adjusted for site & age of 
oocytes) for both Sites (pooled data). 
 
Risk Ratio (rr) 
Standard 
Error 
z - value P > ǀzǀ [95% Confidence Interval] 




Table 21 presents the results of an association between tubal factor infertility and CPR. The 
results of the adjusted binomial regression model indicated that the two variables are not 
associated (p = 0.72). 
 
Table 21:  Association between tubal factor diagnosis and CPR (adjusted for site & 
age of oocytes) for both Sites (pooled data). 
 
Risk Ratio (rr) 
Standard 
Error 
z - value P > ǀzǀ [95% Confidence Interval] 
0.93 0.18 - 0.35 0.72 0.62 1.38 
 
 
b) Combined Binomial Regression Model (Adjusted for Site & Age of Oocytes) 
 
A combined binomial regression model was then applied to the data and in this model BMI, 
endometriosis, tubal factor infertility, oocyte age and Site were all considered to determine the 
association of each factor with CPR. The results as presented in Table 22 indicated that BMI 
(p = 0.41), endometriosis (p = 0.99) and tubal factor infertility (p = 0.71) are not associated 
with CPR. 
 
The age of oocytes (female age), is significantly (negatively) associated with CPR with a p-
value of 0.02; rr = 0.98 (95%CI: 0.95 to 0.99). This result indicated that for every extra year 
added to the age of the oocytes (female partner), the probability of a clinical pregnancy is 2% 
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less than that of the base year (relative). Site is also significantly associated with CPR (p = 
0.00). Site 2 has a significant negative association (lower CPR) with CPR.   
 
Table 22:  Combined regression model showing the association between BMI, 
endometriosis, tubal factor infertility, oocyte age and Site and CPR 
(pooled data). 
 




z - value P > ǀzǀ 
[95% Confidence 
Interval] 
BMI 1.01 0.01 0.82 0.41 0.98 1.03 
Endometriosis 1.00 0.19 0.01 0.99 0.67 1.48 
Tubal Factor 0.92 0.19 - 0.37 0.71 0.60 1.40 
Oocyte Age 0.97 0.01 - 2.24 0.02 0.95 0.99 
Site 0.40 0.07 - 4.61 0.00 0.27 0.59 
 
 
c) Extended Combined Binomial Regression Model 
 
The previous models indicated a strong impact of Site on the results. The interaction between 
Site and each of the other determining factors was then investigated in an extended, combined 
binomial regression model. The results of this model indicated a significant interaction 
between Site and endometriosis. This term was therefore included in the final model (Table 
23).  
 
There were no other interactions by Site, for example oocyte age. Therefore, the parameters 
estimated for oocyte age is the pooled estimate from both Sites. 
 
The association between endometriosis and CPR were significantly different between the two 
Sites. The results from Site 1 indicated that endometriosis is not associated with CPR, rr = 
0.88 (95%CI: 1.01 to 6.57), p =0.569, but Site 2 showed a positive associated with CPR, rr = 
2.26 (95%CI: 0.99 to 5.18) p = 0.054. Both these estimates were adjusted for the other factors 
in the specific model. 
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The model also indicated that oocyte age (female age) is negatively associated with CPR. The 
results: rr = 0.98 (95%CI: 0.96 to 0.99), p = 0.021 indicate that the probability of having a 
clinical pregnancy decreases by a relative 2% with every added year in oocyte age. The 
association presented linear over age and non-linear effects are not significant, these tests 
are not included in the results.  
 
BMI showed no association with CPR (p = 0.40). The same effect was observed for both Sites 
indicating no association. 
 
Tubal factor infertility was also not associated with CPR (p = 0.796). No association was 
observed with Site and therefore this estimate of the risk ratio is a stable one across both 
Sites.  
 
Table 23: Extended combined binomial regression model showing the association 






z - value P > ǀzǀ 
[95% Confidence 
Interval] 
BMI 1.01 0.01 0.84 0.40 0.98 1.03 
Endometriosis 0.87 0.20 - 0.57 0.56 0.56 1.37 
Site & 
Endometriosis 
2.57 1.23 1,98 0.04 1.00 6.57 
Tubal Factor 0.94 0.20 - 0.26 0.79 0.62 1.43 
Oocyte Age 0.97 0.00 -2.31 0.02 0.95 0.99 
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d) Binomial Regression Models (with Odds Ratio to Quantify Risk) 
 
The previous relative risk models did not converge and therefore a binomial regression model 
with odds ratios was used to quantify the risk. 
 
Previous analysis showed no interaction with regard to Site, therefore the data of both Sites 
was pooled to provide a more accurate analysis of the risk factors.   
 
 
i) Binomial Regression Model with Odds Ratios with all Interactions  
 
In these models the number of MII oocytes aspirated was included since they were very 
different for the two Sites (See Tables 10 and 14 on page 55 and 63, respectively). 
 
The first model used in this analysis included all the interactions. The reason for this was to 
test if any association with CPR is different between the two different Sites. The results of this 
model, presented in Table 24, indicated that there were no factors that had any interaction 
with Site. 
  












Site & BMI 0.97 0.04 - 0.53 0.59 0.89 1.06 
Site & Endometriosis 3.29 2.39 1.64 0.10 0.79 13.69 
Site & Tubal Factor 2.20 1.49 1.16 0.24 0.58 8.31 
Site & Oocyte Age 0.96 0.05 - 0.62 0.53 0.86 1.07 
Site & Number of MII 
Oocytes 




ii) Binomial Regression Model with Odds Ratios with only certain Interactions  
 
Certain factors were then excluded from the odds ratio model to determine whether the result 
would differ from the above mentioned but, again, the results showed that none of the factors 
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had a significant interaction with Site (Table 25). The factors excluded were; BMI and number 
of MII oocytes.  
 














Site & Endometriosis 3.31 2.41 1.65 0.10 0.79 13.79 
Site & Tubal Factor 2.19 1.48 1.16 0.24 0.58 8.82 




iii) Binomial Regression Model with Odds Ratios with Diagnostic Factors 
Interactions. 
 
Only the diagnostic factors, BMI and tubal factor infertility, were included in this model to 
determine whether the result would differ from the above mentioned models. The results 
showed neither, BMI nor tubal factor infertility had a significant interaction with Site (Table 26). 
 














Site & Endometriosis 3.16 2.28 1.60 0.11 0.76 13.03 
Site & Tubal Factor 2.24 1.51 1.19 0.23 0.59 8.41 
 
 
e) Final Binomial Regression Model with Odds Ratios with all Interactions omitted 
(since they were not significant) 
 
Results are presented in Table 27. The model used in this analyses was the main effects 
model, where an adjustment was made for Site only. Pooled data was used to ensure an 
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increased stability of the estimates. The effect of Site, adjusts for the level of response in CPR, 
but does not adjust for the type of association.  
 
In this model, only Site (p = 0.001) and number of MII oocytes (p = 0.001) available are 
significant factors associated with CPR.   
 
Site 2 had a significantly lower CPR, or = 0.39 (95%CI: 0.22 to 0.66), p = 0.001, but the risk 
profile with respect to other factors was the same as for Site 1. The number of MII oocytes 
available is significantly associated with CPR, or = 1.08 (95%CI: 1.03 to 1.12) p = 0.001. This 
outcome (number of MII oocytes) is true for both Sites. The number of MII oocytes was used 
as a continuous variable and CPR increases by 8% for every additional mature oocyte 
available. 
 
Through the adjustment of the number of MII oocytes in the model, the interaction of 
endometriosis and Site ceases to exist. None of the other factors were significant except Site. 
Increasing the availability of the number of MII oocytes at Site 2 will offset the risk profile of 
the Site.   
 








z - value P > ǀzǀ 
[95% Confidence 
Interval] 
BMI 1.03 0.02 1.43 0.15 0.98 1.07 
Endometriosis 1.22 0.40 0.60 0.54 0.64 2.32 
Tubal Factor 0.95 0.31 - 0.15 0.87 0.49 1.82 
Oocyte Age 0.98 0.02 - 0.50 0.61 0.94 1.03 
Site 0.38 0.10 - 3.46 0.001 0.22 0.66 
Number MII 
Oocytes 
1.07 0.02 3.45 0.001 1.03 1.12 
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To reflect the association between CPR and number of MII oocytes, a Lowess smooth graph 
shows clearly that the linear association between the number of MII oocytes and CPR is visible 
at both Sites. (Figure 29).  At Site 2 the CPR is lower compared to Site 1 but a positive 
association is still visible. Thus, if the difference due to Site is taken into account, the 
association between the number of MII oocytes and CPR is the same across both Sites. 
 
 
Figure 29:  Lowess smooth graph showing the association between CPR and the 
number of MII Oocytes for each Site separately. 
 
 
4.2.3.3 Binomial Regression Models with for Site 1 & Site 2 Separately 
 
The results of the Site-specific models confirm the results obtained from the pooled analysis 
but due to the increase in the number of cycles when pooled, the precision and accuracy of 
the result are improved. 
 
a) Site 1 
The results from a Binomial Regression risk ratio model (determining which of the factors: 
BMI, endometriosis, tubal factor infertility and oocyte age are associated with CPR at Site 1), 
are presented in Table 28. Results indicated that oocyte age (female age) was the only factor 
that had a statistically significant negative association with CPR, rr = 0.97 (95%CI: 0.95 to 
0.99), p = 0.03. 
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z - value P > ǀzǀ 
[95% Confidence 
Interval] 
BMI 1.01 0.01 0.78 0.43 0.98 1.03 
Endometriosis 0.86 0.19 - 0.62 0.53 0.55 1.35 
Tubal Factor 0.82 0.21 - 0.72 0.47 0.49 1.38 
Oocyte Age 0.97 0.01 - 2.13 0.03 0.95 0.99 
 
 
Table 29 represents a binomial regression model with odds ratios used to quantify the risk for 
Site 1. Results indicated that when the number of MII oocytes are added to the model, the 
association between CPR and oocyte age is no longer statistically significant (p = 0.91) and 
only the number of MII oocytes has a significant association (positive) with CPR, rr = 1.08 
(95%CI: 1.03 to 1.14), p = 0.001. 
 
Table 29:   Binomial regression odds ratio model with number of MII oocytes 







z - value P > ǀzǀ 
[95% Confidence 
Interval] 
BMI 1.04 0.02 1.59 0.11 0.99 1.09 
Endometriosis 0.915 0.35 - 0.23 0.81 0.43 1.94 
Tubal Factor 0.67 0.31 - 0.84 0.39 0.26 1.69 
Oocyte Age 0.99 0.02 - 0.11 0.91 0.95 1.04 
Number MII 
Oocytes 
1.08 0.02 3.45 0.001 1.03 1.14 
 
 
b) Site 2 
 
Table 30 provides an overview of a binomial risk ratio regression model, determining which of 
the factors: BMI, endometriosis, tubal factor infertility and oocyte age are associated with CPR 
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at Site 2. The results of the model indicated that endometriosis was the only factor that had a 
statistically significant positive association with CPR, rr = 2.59 (95%CI: 1.08 to 6.25), p = 0.03. 
 
Table 30:   Binomial regression risk ratio model for Site 2. 




z - value P > ǀzǀ 
[95% Confidence 
Interval] 
BMI 1.01 0.03 0.33 0.74 0.95 1.07 
Endometriosis 2.59 1.16 2.13 0.03 1.08 6.25 
Tubal Factor 1.36 0.55 0.76 0.44 0.61 3.03 
Oocyte Age 0.96 0.03 - 0.82 0.41 0.89 1.05 
 
 
Table 31 represents a binomial regression model with odds ratios used to quantify the risk at 
Site 2. The results indicated that when the number of MII oocytes are added to the model, the 
association between CPR and endometriosis is no longer statistically significant (p = 0.07). 
None of the factors indicated a statistically significant association with CPR. 
 
Table 31:   Binomial regression odds ratio model with number of MII oocytes 







z - value P > ǀzǀ 
[95% Confidence 
Interval] 
BMI 1.01 0.03 o.48 0.63 0.94 1.09 
Endometriosis 3.01 1.85 1.79 0.07 0.89 10.10 
Tubal Factor 1.47 0.72 0.80 0.42 0.56 3.84 
Oocyte Age 0.96 0.04 - 0.74 0.46 0.87 1.06 
Number MII 
Oocytes 
1.02 0.05 0.47 0.63 0.91 1.15 
 
 
As mentioned before - the number of MII oocytes available is such a dominant factor that all 
other risk factors are surpassed and by increasing the availability of the number of MII oocytes 
at Site 2, the offset of the risk profile of the Site will occur.   
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CHAPTER 5 - DISCUSSION AND CONCLUSION  
Discussion 
By definition, infertility is, “a disease, defined by the failure to achieve a successful pregnancy 
after 12 months or more of appropriate, timed unprotected intercourse or therapeutic donor 
insemination” (Practice Committee of the American Society of Reproductive Medicine, 2013). 
Infertility treatment, more specifically ART, is accepted widely and globally, and most countries 
have a number of facilities that can readily provide fertility care, although in developing 
countries this is not always the case (Ombelet, 2014). ART, in most developing countries, is 
completely unavailable, scarcely available, or so expensive, that the majority of infertile 
couples simply cannot afford it (Murage et al., 2011). Multiple strategies should be considered 
in the process of making infertility treatment more accessible in developing countries. Some 
of these strategies include simplifying diagnostic procedures, ovarian stimulation protocols, 
assisted reproduction procedures and laboratory procedures and equipment to ultimately 
reduce the overall cost (Ombelet, 2007). 
The success of ART treatment can be influenced by many factors. These factors include; the 
equipment, laboratory techniques, patient profile and selection, quality control, skill and 
experience of clinicians and embryologists and funding available. 
Aim and Research Questions 
The current study was done at two fertility clinics, one in the public and one in the private 
sector and aimed to answer two research questions:  
a) How does the laboratory equipment, specifically the two types of CO₂ incubators 
used at the private laboratory, affect embryo quality and development and ultimately 
the CPR? 
b) Which patient factors (specifically female - diagnosis, number of oocytes, age, BMI 
and AMH) have a significant and independent impact on CPR at the public and private 
fertility clinics, respectively? 
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Laboratory Equipment – Comparison of Two CO₂ Incubators: A Retrospective Study  
 
The first research question was investigated through a retrospective analysis of data at a 
private fertility clinic during 2013 to 2014.  
 
Exclusion Criteria for the Retrospective Study 
To minimize the possible influence of confounding factors on the outcomes of the current 
retrospective study, a strict exclusion criteria was applied.  The use of a strict exclusion criteria 
resulted in a significant number of cycles being excluded from the study, but increased the 
reliability of the outcomes as significant factors, which have already been shown to influence 
success rates, for example advanced maternal age (Dew et al., 1998; Committee of American 
Society for Reproductive Medicine, 2006), were eliminated. The strict exclusion criteria also 
resulted in a skewed distribution of numbers between the two incubators. Various reasons 
contributed to the higher number of cycles cultured within the Forma Scientific CO₂ Incubator. 
Firstly, in 2013 and 2014 at the private clinic, there were more Forma Scientific CO₂ Incubators 
(n = 6) than MINC™ Benchtop Incubators (n = 2) in use. Secondly, the possibility existed that 
more cycles in the Forma could be accommodated compared to the MINC. Although these 
circumstances were not ideal for the purposes of the retrospective study, statistical analysis 
indicated that the results were of significant value. 
 
Importance of the CO₂ Incubator  
Not only does a CO₂ incubator contribute to the high cost of the overall ART service, but it is 
also the most important piece of equipment to be considered when it comes to the effective 
culturing of gametes and/or embryos (Higdon et al., 2008). Optimal culture conditions are 
essential for successful embryo development, implantation and ultimately, pregnancy 
outcome (Meseguer et al., 2012) and the choice and use of specific incubators can be directly 
proportional to the pregnancy outcome of a patient cycle. Multiple studies to date have 
recommended benchtop incubators, as these incubators have shown increased recovery 
rates of temperature and gas, which is beneficial for optimal embryo development (Cooke et 
al., 2004; Fujiwara et al., 2007; Hill et al., 2013). However, no study has been able to provide 
a distinctive answer to indicate which incubator has superior outcomes when comparing 
embryo development and ultimately, clinical pregnancy (Swain, 2014). Cooke et al., (2004) 
conducted a study comparing a K – MINC™ 1000 incubator and a Forma 3110 incubator. The 
results indicated that there was a significant difference in the percentage change at opening 
in the MINC™ compared to the Forma (temperature: 1.3% vs. 31%; humidity: 43% vs. 44%; 
CO₂: 33% vs. 58%; p < 0.01). The recovery time to 90% also showed a significant difference 
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in the MINC™ compared to the Forma (temperature: 1 min. vs. 180 min.; humidity: 12 min. 
vs. 180 min.; CO₂: 8 min. vs. 120 min.; p < 0.01). Similarly, Hill et al. (2013) concluded from a 
retrospective data analysis a higher internal environment recovery rate with Planer BT-37 
benchtop incubators compared to ThermoForma® large incubators. The results of the 
previously mentioned studies that found superior outcomes with the use of a benchtop culture 
incubator, contributed to our expectation and hypothesis that the MINC™ benchtop incubator 
would yield better quality embryos and result in a higher CPR compared to the conventional 
large Forma CO₂ incubator.  
 
Outcomes of the Current Study 
The results of the current study indicated clearly that the patient profiles in the two incubators, 
the Forma Scientific CO₂ Incubator (Forma – 20% O₂) and the MINC™ Benchtop Incubator 
(MINC – 5% O₂) were not significantly different.  Factors such as female diagnosis, male 
diagnosis, age of ova (female age), number of ova aspirated per cycle and  percentage normal 
sperm morphology showed no statistically significant difference between the two incubators 
and therefore indicated that patients were very well paired in the two incubator types. The 
above-mentioned factors can also have an effect on the outcomes (fertilization, embryo quality 
and pregnancy), but could be excluded since they were not significantly different in the two 
incubator types. 
 
The outcomes of interest for this study were; fertilization, embryo quality and clinical 
pregnancy. The results of the current retrospective analysis indicated that the two incubators 
investigated, the Forma and the MINC, had very similar outcomes in terms of fertilization rate, 
embryo quality and ultimately clinical pregnancy rate. Outcomes were almost identical or 
slightly better in the MINC compared to the Forma.  
 
Incubators and Fertilization Rate 
The results of the current study showed a non-significant difference in fertilization rate of 
oocytes in the two incubators (Forma; 79.41% vs MINC: 79.06%).  
Several studies have reported similar results to the current study when investigating the effect 
of different CO₂ incubators on fertilization rate. Steinkampf et al. (2014) reported no significant 
difference in fertilization rate when comparing a Forma Model 3110 (using 6% CO₂ and 20% 
O₂) and a Planer Model BT37GP benchtop incubator (with premixed 6% CO₂, 5% O₂ and 89% 
N₂), 68% vs. 67%. Kovačič et al. (2008) and Sobrinho et al. (2011) also concluded that the 
fertilization rate was not significantly different between oocytes cultured in low oxygen (5%) 
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compared to atmospheric oxygen (20%). A recent study by Nastri et al. (2016) reported the 
results of a systematic review and met-analysis including 21 published studies. The aim was 
to compare low oxygen to atmospheric oxygen tension for embryo culture. The results showed 
low quality evidence that there was no difference in the fertilization rate between the two 
groups (rr = 1.0; 95% CI 1.0 – 1.0).  
Higdon et al. (2008) reported interesting results from an extensive study where the authors 
determined the effect of incubator management on ART outcome. When looking specifically 
at the IVF fertilization rate, the results indicated that dual gas incubators (5% O₂; 95% in air - 
20% O₂) had an increased fertilization rate compared to triple gas incubators (7% CO₂; 5% O₂ 
and 88% N₂), IVF: 68% vs 62%; p = 0.05. For ICSI it was not significant: 74% vs 72%; p = 
0.4]. In contrast, Lee et al. (2010) also found a significant increase in fertilization rate in the K-
MINC 1000 incubator compared to the Forma 3110 incubator (72% vs 67%; p < 0.05).  
It seems therefore that at the level of fertilization, incubator type and O₂ concentration do not 
play a conclusive, significant role. The outcome of the current study did not support the stated 
hypothesis.  
 
Incubators and Embryo Quality  
The statistical evaluation of embryo quality (Veeck & Zaninovic, 2013) - determined on embryo 
culture days 2, 3 and 5 – indicated that there was no significant difference in the average 
number of good quality embryos cultured in the two incubators.  After re-modelling and 
analysing data as percentage of good quality embryos per number of oocytes aspirated, day 
3 GQE became significant. After being adjusted for the age of the oocytes (female age), use 
of donor oocytes and the number of MII oocytes available,  it was shown that the MINC had a 
15% (relative) higher probability of having good quality embryos on day 3 compared to the 
Forma. 
Few studies consider individual fertilization results for specific culture days when determining 
the effect of different incubators on embryo quality. The most frequent outcomes measured 
are fertilization rate, cleavage rate (culture day 2 – 4) and blastulation rate (culture day ≥ 5), 
but the results of the current study agree with several published reports. 
Several studies have reported no significant difference in embryo quality on various culturing 
days when comparing bench-top incubators and standard large-box incubators. Paternot et 
al. (2013), showed no overall impact on embryo quality after culturing the embryos in a bench-
top incubator or at lower O₂ concentration. Similarly, a study by Steinkampf et al. (2014) also 
reported no significant difference in the number of good quality embryos on culture day 3 when 
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comparing a Forma Model 3110 (using 6% CO₂/ 20% O₂) and a Planer model BT37GP 
benchtop incubator (with premixed 6% CO₂, 5% O₂ and 89% N₂). Lee et al. (2010) also found 
no significant difference with regard to embryo quality on culture day when comparing the K-
MINC 1000 incubator to the Forma 3110 incubator (72% vs 67%; p > 0.05). Podsiadly et al. 
(2016) similarly conducted a study comparing the Genea Embryo Review Incubator (GERI) 
time-lapse monitoring system to a standard bench top incubator and found that both systems 
provided similar outcomes in terms of embryo quality. 
Studies reporting significant differences in embryo quality with different incubators include that 
of Kovačič et al. (2008, 2010) and Guarneri et al. (2014). The 2008 study by Kovačič et a., 
focused on the specific effect of oxygen concentration on various culture days and  found that 
reduced oxygen, 5% versus 20%, resulted in a significantly higher proportion of good quality 
embryos, specifically on culture day 3 (whereas the other culture days showed no significant 
difference, not including blastulation rate). Another study by Kovačič et al. (2010) indicated 
that low oxygen resulted in a higher proportion of good quality embryos on culture day 2. 
Guarneri et al. (2014) conducted a similar study where the results indicated that the combined 
use of atmospheric and controlled oxygen or an exclusive use of low oxygen tension can result 
in good quality embryos. 
Our hypothesis was that embryo quality should be better in the MINC incubator where the 
internal environment, recovery period with regards to pH, temperature and gas concentrations 
was shown to be superior in previous reports (Cooke et al., 2002; Fujiwara et al., 2007; Lee 
et al., 2010).  
The outcome of a higher proportion of day 3 GQE in the MINC compared to the Forma, in the 
current study, is therefore in agreement with previous published results (Fujiwara et al., 2007). 
It must however be noted that this was only true after being adjusted for the age of the oocytes 
(female age), use of donor oocytes and the number of MII oocytes available. It was however 
unexpected that day 5 embryo quality did not show a significant difference between the two 
incubators since the O₂ concentration is thought to be most important at the blastocyst stage 
(Waldenstrom et al., 2009). Blastocyst evaluation is however very subjective and since five 
different embryologists are involved in embryo grading at the study laboratory, subjective 
evaluation could have had an effect on the outcome.  In general therefore, the study outcome 
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Incubators and Clinical Pregnancy  
For the purpose of this study, a clinical pregnancy is defined as the visibility of any product of 
conception seven weeks after an embryo transfer (World Health Organization, (2016). CPR is 
therefore expressed as foetal sac/embryo transfer at seven weeks gestation for this study. 
The results of the current study indicated no statistical significant difference in CPR between 
the MINC and the Forma patients (47.17% and 45.43%; respectively).   
The information available from published studies with regard to pregnancy outcome of 
embryos cultured in different incubators and different O₂ concentrations is diverse. Nanassy 
et al. (2010) indicated through retrospective analyses of two culture conditions (5% vs 20% 
O₂) that there was no statistical significant difference in CPR between the two culture systems 
(58.56% vs 64.36%). A study published by Swain (2014) also concluded that there is no 
statistical differences in terms of pregnancy outcome when comparing a conventional front-
load incubator and a small top-load incubator.   
A study conducted in Texas in 2009, indicated however that a reduction in O₂ concentration 
from 21% to 5%, when culturing embryos, resulted in an increased live birth rate (42.6% vs. 
54.4%; 95% CI 1.9 – 27.0; p = 0.04) (Meintjies et al., 2009). Another study that indicated 
similar results was a systematic review by Nastri et al. (2016). The authors reported that a 
lower oxygen concentration compared to standard atmospheric oxygen tension resulted in a 
± 5% improvement in live birth, ongoing pregnancy and clinical pregnancy. 
 
Introducing Time–lapse Incubators  
In other recent studies, bench - top incubators equipped with time-lapse monitoring technology 
have been compared to incubators without the time-lapse technology (Meseguer et al., 2012; 
Goldberg et al., 2015; Meseguer, 2016; Podsiadly et al., 2016).  Embryo evaluation, using 
time – lapse images, have been promoted as being superior to the classical embryo 
morphology evaluation methods. The results obtained in these studies have also been 
contradictory, with some studies claiming increased embryo quality and pregnancy outcomes 
and others not. One study comparing a time-lapse monitoring system (EmbryoScope™) and 
a Heracell™ 150 large-box incubator found an increase in blastocyst formation rate and 
ongoing pregnancy rate, but none of these findings were of statistical significance (Cruz et al., 
2011). In 2012, a large retrospective study was done by Meseguer et al. comparing results of 
the time-lapse monitoring system with standard large-box incubators. The results showed that 
the relative probability of clinical pregnancy was significantly increased when embryos were 
cultured in the time-lapse monitoring system compared to standard large-box incubators. 
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Rubio et al. (2014) found similar results when comparing a standard large–box incubator with 
the EmbryoScope™ time-lapse incubator and reported a significant increase in ongoing 
pregnancy and implantation rates. Similarly, Goldberg et al. (2015) found an increase in 
blastocyst formation and clinical pregnancy with embryos cultured in the time-lapse monitoring 
system, EmbryoScope™, compared to the standard incubator (Forma) lapse monitoring 
system with a standard incubator. Most of these studies have been criticized since they 
actually used two different kinds of incubators and better outcomes could probably be 
attributed to the improved culture conditions in the time-lapse (bench-top) incubators. 
Although the results of current study regarding CPR outcome did not show a significant 
increase in the MINC incubator group as was expected, and did therefore not support the 
hypothesis, it was similar in outcome to several of the other studies published. 
Regardless of the results of previous studies comparing incubator ART outcomes, the process 
of selecting an incubator for ART culture purposes should focus on the availability and 
utilization of low O₂ capability (Swain, 2014). This opinion has been widely published and is 
now accepted as one of the most important conditions of an ART incubator. Other factors such 
as cost, space and practicality must also be taken into consideration when selecting an ART 
culture incubator as they too play an extremely important role (Hill et al., 2013). Smaller 
incubators are more convenient and economical to use and deliver very good results, but they 
remain more expensive compared to the standard culture incubators (Hill et al., 2013). Most 
of the smaller incubators can also accommodate a smaller number of patients compared to 
the larger incubators. However, small bench-top incubators have an excellent internal 
environment recovery period, especially with regard to temperature (Walker et al., 2013), pH 
and gas concentrations (Swain et al., 2016). This characteristic has been widely published 
(Lee et al. 2010) and can influence embryo development and pregnancy.  
 
Limitations of the Study 
One of the biggest limiting factors of this retrospective study was its retrospective nature and 
the uneven distribution of patients between the two incubators. Uneven patient distribution 
could not be avoided since the time period chosen was the only period when both incubator 
types were used simultaneously. A prospective study will be ideal, but large box incubators 
are not being used as frequently as in the past, and a concurrent comparison will be difficult. 
 
Conclusive Remarks and Recommendations 
In conclusion, although the outcomes investigated (FR, percentage GQE and CPR), for the 
studied patient cohort, were increased in the MINC incubator compared to the Forma, none 
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were statistically significant. As the only statistically significant difference between the two 
incubators under investigation observed was the average number of good quality embryos on 
day 3 (p = 0.209), the hypothesis of the study is therefore rejected as no statistical significant 
difference was observed in the overall outcome in terms of CPR. 
However, since certain clinics still make use of Forma incubators for embryo culture, the 
outcome of the study gives some assurance that it can still be used effectively. Future studies 
could concentrate on incubator alternatives, especially in terms of cost analysis, for example 
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Effect of Female Patient Profile on Art Success – A Prospective Study 
The second research question was investigated by means of a prospective analysis of data at 
a private and public clinic during 2015 and 2016. 
 
Introduction 
The patient profile plays an extremely important role in the outcome of an ART cycle (Lintsen 
et al., 2007). In the current prospective study, data from two fertility clinics (2015 - 2016), one 
private and one public, were analysed to identify possible independent factors specifically 
influencing CPR. The two clinics are relatively similar with regard to standard operating 
procedures such as semen preparation, oocyte aspiration, embryo culture/evaluation and 
embryo transfer. The same embryo culture media is used at both laboratories. The public 
laboratory however, offers an affordable ART service with a different ovarian stimulation 
protocol and only made use of a conventional large Forma CO₂ incubator during the study 
period. Since data capturing is done regularly at both laboratories, for quality control purposes, 
it was evident that patient profiles differ within the two clinics. The most notable differences 
were; the average number of oocytes aspirated (the private clinic’s average aspirated 
number showed a two-fold increase compared to the public clinic), the average number of 
GQE available were higher at the private clinic, the day of transfer was predominantly day 3 
at the public clinic and day 5 at the private clinic, tubal factor diagnosis was approximately 
four times more prevalent in the public clinic, the public clinic had three times more patients 
with a high BMI (≥ 30) and donor cycles (10 times more patients made use of an oocyte 
donor at the private clinic).   
 
These pronounced differences were the foundation for the formulation of the research 
question as stated and the factors investigated with regard to their effect on CPR were; age 
of oocytes (female age), endometriosis, TFI, BMI, AMH and the number of MII oocytes 
available.  
 
In the majority of the prospective study’s statistical analysis, the data of the two clinics were 
pooled. Statistical analysis of pooled data presents more accurate results in terms of the effect 
of the factors investigated and their statistical significance on clinical pregnancy outcome, due 
to larger cycle numbers. The statistical analysis also revealed that the pooled results did not 
differ in terms of outcome compared to the results obtained from data that remained separate 
for the two clinics.  
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For the purpose of this study, a clinical pregnancy is defined as the visibility of any product of 
conception seven weeks after an embryo transfer (World Health Organization, 2016) and CPR 
is expressed as foetal heart/ET at seven weeks gestation. 
 
Different statistical models were considered to analyse the vast amount of data and to test the 
hypothesis.  
 
General and Final Statistical Outcome for the Private Clinic – Site 1 
The statistical results obtained for the private clinic data using the first binomial regression 
analyses model where BMI, endometriosis, tubal factor infertility and female age were 
considered, showed that only female age played a significant role in CPR outcome. As 
suspected, younger patients had a higher CPR. In a second binomial regression analyses 
model, where the number of MII oocytes available was also considered, the effect of female 
age disappeared and only the number of MII oocytes available was significant for CPR.  The 
female diagnoses, endometriosis and TFI had no significant influence on CPR.  AMH levels 
and BMI also showed no significant relation with CPR. 
 
General and Final Statistical Outcome for the Public Clinic – Site 2 
For the public clinic, various results were observed. In the first binomial regression analyses 
model where BMI, endometriosis, TFI and female age were considered, only endometriosis 
had a significant effect on CPR. Patients with endometriosis had an increased pregnancy rate. 
In the second binomial regression model where the number of MII oocytes was also taken into 
consideration, the significance of endometriosis disappeared and no other factor, including 
number of oocytes, had a significant effect on CPR. 
 
Oocyte Age and CPR 
Background 
Oocyte age (female age) at the time of an ART cycle, whether donor or own ova, plays a 
pivotal role in the overall pregnancy outcome (Wang et al., 2008). Oocyte quality depends on 
multiple biological processes and many of these processes can only be assessed at molecular 
level, but the fact remains that female age is primarily related to the biological capability to 
reproduce (Gioacchini et al., 2013). Various articles have been published indicating that 
women in their late thirties show a significant reduction in fecundity and an increased 
probability of infertility (Steiner & Jukic, 2016). The decline in fertility as a female patient’s age 
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increases is primarily the result of an age-related decrease in oocyte quality rather than 
changes in endometrial receptivity (Bentov & Casper, 2013). 
 
Statistical Results and Outcomes of Models Tested  
The prospective descriptive results of the current study indicated that the average oocyte age 
in both clinics was similar and that an increasing oocyte age results in a decrease in CPR, 
similar to what has been published widely in the literature. In both clinics the CPR of women 
> 35 years were 10% less than those ≤ 35 years. An extended combined binomial regression 
model (risk ratio) of the pooled data indicated a negative association between oocyte age and 
CPR and showed that the probability of having a clinical pregnancy decreased by 2% of every 
year added to oocyte age.  
 
When the two clinics’ data were separated and the first binomial regression model was used 
to analyse the data, only the private clinic had a statistically significant negative association 
between oocyte age and CPR. For the public clinic, the association between oocyte age and 
CPR was not significant. However, when number of MII oocytes was added in the second 
binomial regression model (with odds ratio to quantify risk), oocyte age had no significant 
association with CPR in the pooled data as well as for the two clinics separately. In a third 
binomial regression model (with odds ratio to quantify risk) and where all interactions with the 
site were omitted, oocyte age had no significant association with CPR for pooled data and for 
the two clinics separately. 
 
It is therefore clear that oocyte age has an effect on CPR, but when other confounding factors 
are also considered in the regression models, its significant association ceases to exist. 
 
Comparison of Results with the Relevant Literature 
The results obtained from the private clinic correlates with various published studies. A recent 
study by González-Foruria et al. (2016) indicated that among three female age groups 
analysed (≤ 35 years, 36 – 39 years and ≥ 40 years), pregnancy rates per cycle decreased  
significantly in the older patient cycles (11.4% vs. 11.6% vs. 5.9%). Gleicher et al. (2014) 
stated that the live birth rate for women aged 44 and 45 years (using their own oocytes) was 
1.4% and 2.7%, respectively. 
 
 A possible reason for the difference observed in the two clinics in the current study, in terms 
of the effect of oocyte age on CPR, could be the availability and use of donors. The high 
success rate of donor oocyte ART cycles, specifically for recipients with advanced maternal 
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age, indicate that this factor influences the overall pregnancy rates significantly. The public 
clinic rarely makes use of donor cycles, due to the high cost for patients. Therefore, in the 
public clinic, older patients use their own oocytes (with 42 years being the maximum age to 
start an ART cycle at the public clinic) and oocyte age distribution was less varied compared 
to that of the private clinic. In the private clinic, a larger proportion of patients use donor 
oocytes from very young donors.  This occurrence could therefore also contribute to the lower 
average oocyte age observed at the private clinic, even though the maximum patient 
(recipient) age at the private clinic was 54 years compared to 45 years at the public clinic. 
 
Conclusion/Remarks 
From the results of this study it can be concluded that age of ova (female age) is a predominant 
factor that influences CPR. When however, the number of MII oocytes is included in the 
analyses model, the outcome changes, and the number of MII oocytes remains as the only 
significant factor influencing CPR when all other factors are considered – and this was only 
observed in the private clinic. The number of mature ova aspirated therefore has a more 
significant effect on CPR than age of ova.  
 
For the public clinic, neither oocyte age nor number of MII oocytes was significantly associated 
with CPR when all the other factors were also considered.  This result is difficult to explain, 
but could be attributed to the relative low numbers of oocytes obtained in the program as well 
as the higher incidence of elevated BMI and tubal factor infertility. 
 
Since oocyte age plays a significant role in CPR, the statistical models were adjusted for 
oocyte age when determining the association between the factors such as BMI, AMH, 
endometriosis and tubal factor infertility and CPR.  
 
Endometriosis and CPR 
Background 
An estimated of 5 to 10% of the female population is affected by endometriosis, with a higher 
prevalence of ± 20 to 30% among women with infertility (Giudice, 2010; Prescott et al., 2016). 
Various articles and studies have been published identifying endometriosis with infertility but 
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Statistical Results and Outcomes of Models Tested  
The descriptive results from the prospective data obtained at the private clinic indicated that 
11% of patients presented with endometriosis. The public clinic showed a slightly lower 
prevalence of 9%. 
 
A descriptive pooled analysis of both clinics indicated no significant association between 
endometriosis and CPR. Analysis of data separated for each clinic indicated the same results. 
An interesting observation was the difference in CPR with patients not presenting with 
endometriosis between the two clinics. In the private clinic a CPR of 36.65% was reported and 
the public clinic a CPR of 14.20% for patients without endometriosis. This observation could 
indicate the difference in the patient population between the two clinics or it could just be due 
to the large difference in the number of patients observed in this specific category.  
 
Analyses with first binomial regression model and a second combined binomial regression 
model, with pooled data, confirmed no association between endometriosis and CPR. A third 
and extended combined binomial regression model showed that the association between 
endometriosis and CPR were significantly different between the two clinics. The private clinic 
data showed no association between endometriosis and CPR and this result remained the 
same in the model with the addition of the number of MII oocytes. The public clinic data 
analyses however, indicated a significant positive association between endometriosis and 
CPR, but when the number of MII oocytes was included in the model, the association between 
endometriosis and CPR were no longer of statistical significance. This observation has not 
been documented in previous studies, therefore it is possible that the other factors considered 
in the model contributed to the unexpected outcome. 
 
Comparison of Results with the Relevant Literature 
In 1998, a study by Bergendal et al. indicated that patients presenting with endometriosis had 
a significantly decreased fertilization rate but the pregnancy rates did not differ significantly 
from patients not presenting with endometriosis. Other studies have confirmed this 
observation with regard to the association between endometriosis and pregnancy rates 
(Matalliotakis et al., 2007; Singh et al., 2014). 
 
The data obtained from this study, and also the findings from other studies confirm that the 
effect of endometriosis on pregnancy outcome is still unsure. A study needs to be conducted 
with a large number of patients and where the influence of other factors that can potentially 
influence the results, are also considered.  The effect of endometriosis and tubal factor 
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infertility has been compared in a few studies (Omland et al., 2001; Omland et al., 2005; 
Mathieu d’Argent et al., 2010). To determine however, the overall effect of endometriosis on 
infertility, a study needs to be conducted that matches patients with endometriosis (and all 
other areas of diagnosis) with patients that do not present with endometriosis. This type of 
study might provide a clearer association between pregnancy outcome and endometriosis. 
 
Conclusion/Remarks 
In the current study the diagnosis of endometriosis was not independently associated with 
CPR when all the other contributing factors were also considered. This was true for both 
clinics. 
 
TFI and CPR 
Background 
Tubal pathology, contributing to 30 – 35% of infertility among women, has been identified as 
one of the most common causes of infertility (Kawwass et al., 2013). TFI can range from 
moderate to severe, pre- and postoperatively. Since such a wide range of severity exists within 
this diagnosis, it is difficult to conclude a distinctive association between TFI and pregnancy 
outcomes. A study by Zou et al. (2014) demonstrated that the pregnancy prognosis differed 
among the different classifications of TFI. The results of one classification system within this 
study indicated that patients with extreme and severe TFI had a 0% pregnancy rate compared 
to 42.9% pregnancy rate in patients with moderate TFI. These findings emphasize the difficulty 
in drawing inferences between TFI and pregnancy outcome. Various factors contribute to the 
TFI diagnosis and although patients may have the same diagnosis, the magnitude thereof 
may differ, thus resulting in different outcomes.  
 
Another important factor contributing to the prognosis of a patient with a TFI diagnosis is 
whether the hydrosalpinx has been removed or not. Numerous studies have shown that the 
presence of a hydrosalpinx is associated with an impaired ART outcome (Strandell & Lindhard, 
2002; Dreyer et al., 2016). A recent study by Dreyer et al. (2016) indicated a statistically 
significant increased ongoing pregnancy rate after hysteroscopic proximal occlusion removal 
compared to laparoscopic salpingectomy. This type of study provides more detailed 
information on the effect of treatment for hydrosalpinges on pregnancy outcome, but more in-
depth studies need to be done determining overall TFI to determine its association with CPR. 
Future studies should aim at dividing patients presenting with TFI according to the severity 
thereof and further subdivided according to whether or not they have had any form of treatment 
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for hydrosalpinges, including; drainage, neosalpingostomy, salpingectomy or proximal tubal 
occlusion (Dun & Nezhat, 2012). 
 
Statistical Results and Outcomes of Models Tested  
The patient profile regarding TFI was very different for the public compared to the private clinic, 
29% and 8% of the total number of patients, respectively. In the current study, the patient 
group with TFI always had a decreased CPR compared to the non-TFI group (for the pooled 
data as well the separate clinic data) but TFI was not associated with CPR in any of the models 
tested. 
 
Comparison of Results with the Relevant Literature 
TFI is often very prevalent in public clinic settings – in a Brazilian study published by Pantoja 
& Fernandez (2015), TFI was present in 73.3% of patients. In the current study, the number 
was much less (29%) but still significantly higher than that of the private clinic (8%). 
 
The pregnancy outcomes of patients presenting with TFI is difficult to  assess since it was 
shown by Zou et al. (2014) that outcomes differ in the mild, moderate and severe groups,  with 
pregnancies ranging from 44% - 19%.  The presence of a hydrosalpinx also influences 
outcomes (Strandell & Lindhard, 2002; Dreyer et al., 2016) and removal thereof has a 
significant positive effect on CPR (Dreyer et al., 2016).  In most of the cases at the public 
clinic, the hydrosalpinx was removed, but in some cases, it was unclear. In the private clinic, 
as part of the clinical protocol, all hydrosalpinges are removed before any ART treatment is 
considered. The presence of a hydrosalpinx was not a specific component of the investigation 
and all tubal factor patients were included to determine whether an association existed with 
CPR. TFI was not associated with CPR in any of the models tested in the current study, not 
for the public or private clinic. 
 
Conclusion/Remarks 
This result was unexpected especially for the public clinic, where almost a third of patients 
present with TFI and where the CPR in the TFI group is decreased compared to the non-TFI 
group. The difference in CPR was however not very big (4%) indicating that other confounding 
factors (female age, number of oocytes) also played a role in CPR outcome. Since the study 
also did not differentiate between the severity of the tubal factor and whether a hydrosalpinx 
was present or not, this could explain the unexpected result. The hypothesis for TFI on CPR 
is therefore rejected. 
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AMH and CPR 
Background 
Although AMH values in female patients are of significant importance for the recruitment and 
selection of follicle development (Cui et al., 2016), its function as a biochemical marker for 
predicting ovarian reserve has been highly debated over the past few years. A study by Tobler 
et al. (2015) demonstrated that 60% of the clinics (n = 796) that participated in the study, used 
AMH levels as a first line test for evaluating ovarian reserve. When comparing AMH and AFC 
as measures for ovarian reserve, it has been shown that both have a good predictive value 
but objectivity, convenience and potential standardization of AMH level throughout the 
menstrual cycle, increase the likelihood of AMH becoming the standardised test (La Marca et 
al., 2007; Fleming et al., 2015). 
 
A recent study that conducted a multivariate analysis of over 500 autologous cycles indicated 
that cycles with extremely low AMH levels compared with matched age-related normal AMH 
cycles, showed a twofold decrease in LBR per cycle (Seifer et al., 2016). Nelson et al. (2016) 
demonstrated through a validated prediction model that AMH, in combination with clinical 
characteristics, can serve as an accurate predictive tool indicating live birth likelihood. The 
same outcome was observed by Tal et al. (2014) indicating that increased AMH levels were 
associated with higher clinical pregnancy rates. Tal et al. (2015) later published another study 
that was contradictory to their previous study. This study indicated that AMH had a weak 
association with implantation and clinical pregnancy rates in ART. A recent study also showed 
that infertile patients had similar AMH levels compared to controls with no history of infertility 
(Hvidman et al., 2016). 
 
Statistical Results and Outcomes of Models Tested  
Although pooled and separate data for the two clinics indicated an increase in CPR with an 
increase in AMH value, the association was not statistically significant.  AMH was one of the 
main factors to be investigated in the prospective part of the study, but this category had a 
significant number of missing data, at both clinics. Due to the small number of AMH values 
available from the total patient population at clinics, further statistical analysis on AMH and 
CPR was not done and was also not included in any of the statistical regression models. 
 
Comparison of Results with the Relevant Literature 
In a study by Seifer et al. (2015) it was reported that patients with a low AMH (≤ 0.16 ng/mL) 
had a twofold lower live birth rate (9.5%/cycle) and a fivefold greater cancellation rate when 
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compared to age matched patients with normal AMH cycles. Fiçicioǧlu et al. (2006) however, 
reported no association between early follicular serum AMH and pregnancy success. In 
general the results of the current study agrees with these findings.  
 
Conclusion/Remarks 
AMH is not routinely done for all patients due to the fact that it is not yet considered a 
standardised test with regard to a fertility treatment work-up (Practice Committee of the 
American Society for Reproductive Medicine, 2015). AMH testing is also mainly done in older 
patients and less frequently done in younger patients.  One should also consider that AMH 
testing is relatively expensive, limiting its routine use in the public sector and AFC as an 
alternative marker should be considered. Future studies should aim at determining the 
association between AMH levels and specific pregnancy outcomes, specifically miscarriage 
rate since a recent study indicated that low AMH levels and subsequently diminished ovarian 
reserve might result in recurrent miscarriage (Atasever et al., 2016).  
 
Lifestyle Behaviour and CPR 
The effects of lifestyle behaviour on the success of ART treatment have been documented in 
many publications. In a prospective study by Domar et al, (2012), the researchers reported 
that infertility patients often continue with adverse lifestyle behaviour in spite of being advised 
against it.  Various lifestyle factors have been linked to decreased probability of successful 
ART outcomes including; obesity (Lintsen et al., 2005), smoking (Lintsen et al., 2005; 
Dechanet et al., 2011) and excessive alcohol consumption (Rossi et al., 2011). 
 
BMI and CPR 
Background 
Numerous studies have indicated the adverse effect of obesity (BMI ≥ 30kg/m²) on the female 
reproductive system. These effects include; anovulation, endocrine disorders and decreased 
oocyte quality (Wang et al., 2016), but have shown to be inconsistent, when determining to 
what extent BMI influences infertility. A possible additional mechanism explaining the 
association of CPR and BMI could be the reduction in endometrial quality (Bosdou et al., 2016; 
Rhee et al., 2016). In contrast, being underweight may also reduce fertility through a shortened 
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Comparison of Results with the Relevant Literature 
Although the majority of literature indicates a significant effect of BMI on CPR, some studies 
indicated contradictory results and outcomes.  
 
It was evident in the current study that CPR decreased with an increase in BMI. This was true 
for the pooled, as well as the separate clinic data, but the association of BMI with CPR was 
not statistically significant.  Additional data including the effect of BMI in patients with and 
without endometriosis in the two separate clinics revealed that endometriosis reduced CPR 
but did not change the association between BMI and CPR. Studies showing no effect of BMI 
on CPR have been published and agree with the findings of the current study.  A study by 
Matalliotakis et al. (2008) indicated no statistical significant association between BMI, CPR 
and overall ART outcome, although a lower stimulation response in women with an increased 
BMI was observed.  Another study conducted in 2015 indicated similar results, stating that 
there was no evidence found that weight status influenced infertility treatment outcome 
(Schliep et al., 2015). A large study by Provost et al. (2016) however, indicated that the 
success of ART cycles decreased, statistically significantly, with an increased BMI.  Various 
other studies have found similar results (Law et al., 2007; Luke et al., 2011; Pinborg et al., 
2011; Comstock et al., 2015). In a retrospective cohort study by Luke et al. (2009), reporting 
on 50172 cycles, it was found that obese women had a lower chance of pregnancy compared 
to females with a normal BMI.  
 
Conclusion/Remarks 
The non-significant result of the influence of BMI on CPR was unexpected especially for the 
public clinic where more than a third of patients were classified as obese. The CPR in the 
obese group was decreased and one would have expected a significant effect. The study 
hypothesis was however rejected for BMI and the unexpected result can possibly be explained 
by the fact that other determining factors contributed to the outcome.  
 
The results from the current study indicated a marked difference in the distribution of patients 
with a BMI ≥ 30 kg/m² compared to patients with a BMI <30 kg/m² in the two clinics. In the 
private clinic, it was 10% vs. 90% respectively and for the public clinic 32% vs. 68%. Patients 
with a high BMI was therefore significantly more prevalent in the public clinic and patient 
demographics differed between clinics. It can be argued that private clinic patients are more 
affluent and have different eating habits and also have better access to organized exercise 
compared to the public clinic patient. There could also be ethnic differences although this was 
not specifically addressed in the study.  This argument was underlined in an article by Bosdou 
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et al. (2016) showing that economic differences and sociocultural factors among different 
communities influence physical activity and dietary intake. The author recommended that 
future diagnosis, counselling and treatment of infertility should take region-specific risk factors 
into account. 
 
The BMI of many of the patients was not documented, due to incomplete patient medical 
records. This was therefore a limitation of the study and could have had an effect on the 
analytical outcome. Clinics, private and public should be informed to include information on 
BMI in patient medical records to ensure that future studies can make use of the information. 
Another limitation for this part of the study was that the BMI recorded was that of the patients 
undergoing the treatment, and not that of the surrogate or ova donor – this could have had an 
effect on outcome, specifically in the private clinic where many donor cycles are done. In the 
public clinic, very few donor cycles are done and the limitation is therefore not applicable there. 
In future studies on BMI effect on CPR, information of the BMI of the donor should be recorded 
to get an accurate analyses outcome. 
 
Ovarian Stimulation Protocols and CPR 
The effect of ovarian stimulation on CPR was not one of the aims of the study and was not 
specifically investigated, but since it differed in the two clinics, it is important to include in the 
discussion. 
 
Standard vs. Mild Ovarian Stimulation  
The success of ART is critically dependent on optimizing ovarian stimulation protocols that 
endeavour to provide good quality oocytes and embryos (Kligman & Rosenwaks, 2001). 
Although the topic of mild ovarian stimulation compared to standard ovarian stimulation in 
terms of ART success has been highly debated, the practicality of the type of ovarian 
stimulation used depends largely on the socio-economic background of the clinic and its 
patients. The use of standard ovarian stimulation has been shown to be very successful with 
regard to ART outcome, but its high cost (Heng, 2007) can make it impractical in clinics where 
funds are limited.  
 
A randomized controlled trial by Feliciani et al. (2009) showed that mild ovarian stimulation 
had similar ongoing pregnancy rates compared to long agonist ovarian stimulation. Another 
positive outcome of mild ovarian stimulation has been the possibility that the use thereof may 
increase the relative proportion of genetically normal oocytes and also the number of mature 
oocytes (Baart et al., 2007; Gianaroli et al., 2010; Blumenfeld, 2015), adding to the notion of 
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quality rather than quantity, but more studies are needed to support this claim. Standard, 
controlled ovarian stimulation has also been associated with a higher number of immature 
oocytes available from the total oocyte yield, but has not been associated with impaired 
pregnancy outcomes (Kok et al., 2006). In 2007, Heijnen et al. conducted a randomized, non-
inferiority effectiveness trial to determine whether mild IVF treatment had the same probability 
in resulting in a live birth pregnancy compared to standard IVF treatment. The results indicated 
that the cumulative live birth pregnancy rate for the mild treatment group was 43.4% compared 
to 44.7% for the standard treatment group. Standard treatment resulted in 1.3% more full term 
live births compared to mild treatment (95% CI: - 9.8%). These findings indicate mild IVF 
treatment can result in similar cumulative live birth outcome, compared to standard IVF 
treatment (Heijnen et al., 2007). 
 
On the other hand, Gleicher et al. (2012) indicated that low intensity IVF reduced pregnancy 
success without demonstrating relative cost advantages. Supporting this, a study by Groen et 
al. (2013), demonstrated that modified natural cycle IVF was not cost effective since controlled 
ovarian hyperstimulation IVF resulted in a higher cumulative live birth rate. A meta-analysis 
study published locally by Matsaseng et al. (2013) also found significantly in favour for 
conventional stimulation compared to mild stimulation in terms of live birth/ET outcome. 
Although acceptable results have been demonstrated with regard to mild ovarian stimulation 
protocols (Ubaldi et al., 2007; Datta 2016), the question remains whether the use of mild 
ovarian stimulation can be justified in terms of successful ART outcome?  
 
Ovarian Stimulation and Oocyte Number and Quality   
Follicular development and oocyte maturation are two closely related factors and controlled 
ovarian stimulation for ART affects the cells that are responsible for these two processes 
(Bosch et al., 2016). Various studies have shown that ART success is, to a large extent, 
dependant on the maturity and quality of the oocytes and multiple studies link the type of 
controlled ovarian stimulation used in a cycle, directly to this outcome (Sunkara et al., 2011; 
Ji et al., 2013). It was also shown in a study by Heng (2007) that the mature oocyte yield is 
directly proportional to the stimulation protocol followed during an ART cycle.  
 
Ovarian Stimulation, Oocyte Number and CPR 
Results from a study published by Sunkara et al. (2011) showed a non-linear association 
between the number of oocytes and live birth with 15 oocytes giving the highest live birth rate. 
The results of the current study also indicated that the number of MII oocytes available had a 
significant effect on CPR - more MII oocytes resulted in an increased CPR. The significant 
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association between the number of MII oocytes and CPR was demonstrated in the final 
binomial regression model, using odds ratios and including interactions of all other determinant 
factors. Final analysis of the pooled data indicated that only the clinic and the number of MII 
oocytes available had a statistically significant association with CPR, taking all other factors; 
BMI, TFI, endometriosis and oocyte age also into account. The analysis showed that CPR 
increases by 8% for every additional MII oocyte available. Although the association between 
the number of MII oocytes available and CPR remained consistent, the association was not 
statistically significant for the public clinic. It is possible to speculate that this result is because 
of the relative small oocyte yield in the public clinic, which is an indication of the effect of the 
mild ovarian stimulation protocol followed. This was not the case in the private clinic. A 
statistically significant association between the number of MII oocytes available and CPR was 
found. The private clinic uses standard ovarian stimulation protocols, a higher mature oocyte 
yield is possible, and higher number of MII oocytes resulted in an increased CPR. 
 
Stoop et al. (2012) made the interesting observation that the oocyte utilization rate between 
the ages of 23 to 37 years was more dependent on age than on ovarian response. For the ≥ 
38 year old group ovarian reserve was more important. Lemmen et al. (2016) reported similar 
results. In a possible follow-up study, it might therefore be important to separate data into two 
age groups to determine a more accurate association between the number of MII oocytes and 
CPR. 
 
Limitations of the Study 
Although it was not the aim of this study to compare the outcomes in public and private ART 
clinics, it is noteworthy that due to lack of funds, the public facility does differ from the private 
one in certain aspects. These differences were not investigated, but could have contributed to 
the significant difference in CPR.  
 The public ART laboratory is situated in the emergency obstetrics theatre complex of 
Tygerberg Hospital, and is not equipped with the suggested “clean room” 
specifications for ART laboratories. There is no HEPA air filter system and also no 
positive pressure applied in the laboratory. Inline HEPA/VOC filters are also not used. 
Therefore, air quality, shown to be an important factor in ART results (Heitman et al., 
2015) was not optimal during the study period.   
 Ovarian stimulation is also different, as mentioned before.  
 The oocyte aspiration procedure at the public clinic is performed with only local 
anaesthesia, and it’s uncertain whether this could have an effect on overall ART 
outcome.  
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 For the duration of the study, a conventional large CO₂ Forma incubator was used at 
the public clinic. Although the results of the retrospective study showed no significant 
effect on CPR for the different types of incubators, its role in CPR cannot be ignored. 
 A number of patients had to be excluded from the study – especially at the private 
clinic - since they did not receive consent forms. 
 A significant number of data was missing from patient files – and made statistical 
analyses of certain factors extremely difficult. 
 Due to the policy at the private clinic, students are not allowed to interact with patients 
directly – and the student conducting the research had to rely on the fertility sister, 
embryologists and clinicians for patient information.   
All other factors were the same in both laboratories: experience and skill of the embryologists 
and clinicians, culture medium and culture procedures, embryo evaluation and embryo 
transfer method. 
 
Conclusive Remarks  
It is clear from the results of the current study that ART outcome is multifactorial and that 
identifying one or two independent factors determining CPR at a specific fertility clinic, is 
difficult to achieve.  
 
It is also obvious from the data that the demographics and patient profiles in clinics differ and 
might have an influence on outcome. In the current study, it was especially true for TFI, BMI, 
oocyte donor availability, number of oocytes available and CPR. Social and cultural factors 
that exist within a social context, influence clinical practice by different healthcare services 
(Adisasmita et al., 2008). An example of differences between private and public clinics is that 
in most cases public clinics have an age restriction with regard to the patients they accept for 
ART treatment and in most cases an extensive waiting period exists. Private clinics however, 
have more “freedom” in managing and treating their patients (Castilla, 2009). Although these 
factors may not be directly associated with the outcomes observed in this study, they do 
provide a better understanding thereof.  
 
Similar trends - for the association of factors investigated with CPR - were found for the pooled 
data and the two clinics separately. Increased female age was associated with decreased 
CPR and so was TFI and increased BMI.  A higher number of MII oocytes resulted in an 
increased CPR.  The results of the final regression analysis of the current study indicated that 
for the private clinic, only the number of MII oocytes available, influenced CPR significantly – 
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more MII oocytes resulted in an increased CPR. In the public clinic, no significant association 
for any of the investigated factors was found.  
 
One can therefore speculate that if the number of MII oocytes available could be increased at 
the public clinic, CPR might also increase. To achieve this, the stimulation protocol will most 
probably have to be adapted. The implication for such a strategy is of course, increased cost. 
In reality, all the factors (success and cost) have to be considered to the best benefit to the 
patient. Economic challenges to infertility treatment access was not a factor investigated in 
the current study, but the issue must be considered as it influences most of the factors that 
could have a relation to pregnancy outcome. Infertility has still not been widely accepted as a 
disease and therefore the treatment, including ovarian stimulation and laboratory output, is 
costly (Davis & Sokol, 2016).  
 
The complexity of fertility treatments also contribute to their inaccessibility in many countries. 
Paulson et al. (2016) reviewed four methods to determine whether they would be effective in 
making infertility treatment access more available. The methods were; mild ovarian stimulation 
protocols, in vitro maturation, modified natural cycles and intravaginal culturing of embryos. 
Although unconventional, all these methods have demonstrated live birth outcomes and need 
further investigation (Davis & Sokol 2016; Paulson et al., 2016). Future studies should aim at 




Finally, after reviewing the outcomes of the study, certain recommendations can be made: 
For the Public Clinic: 
 Acquisition of a benchtop CO₂ incubator with 5% O₂ is recommended. 
 Fortunately, funds became available recently and the public clinic started using a 
Miri® (ESCO Medical, South Africa) benchtop incubator since May 2016. The effect 
of this new incubator on outcomes will be monitored and possibly be part of a new 
study.  
 Modified stimulation protocols should be considered to achieve a higher number of MII 
oocytes without compromising oocyte quality and an increase cycle cost.  
 Currently, a modified stimulation protocol (Segawa et al., 2007; Okimura et al., 
2008) has been implemented since April 2016 aiming at improving both quality and 
number of oocytes aspirated and is part of future studies aiming to maximize 
success but minimize cost for public clinic patients. 
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 Implementation of at least inline filters for the CO₂ incubators should be encouraged. 
 The recently introduced Miri® incubator is equipped with filters and UV sterilization 
of the gas and should result in better results.  
For the Private Clinic: 
 For future research studies, a better coordination between the students and personnel 
should be implemented. 
 Protocols and all possible limiting factors should be thoroughly discussed and agreed upon 
before the study starts. 
 Patient medical records must be complete for all patients – Information such as BMI, for 
example, should be available for all patients and fertility sisters and doctors that mostly 
correspond with patients, should ensure that the patient provides all the information 












Appendix I – Semen Preparation  
(Adapted from the WHO laboratory manual for the examination and processing of human 
semen, 5th edition, 2010) 
(Tygerberg Fertility Clinic SOP 5 and Aevitas Fertility Clinic SOP) 
Swim-Up Method 
● Mix semen sample well (ensure sample has liquefied) 
● Dilute sample in a 1:2 ratio (semen: sperm washing medium [SAGE® Advantage 
HEPES buffered sperm preparation medium - SpermPrep®]) in a test tube 
● Vortex sample, centrifuge at 450 x g for 10 minutes 
● Remove supernatant, leave pellet undisturbed 
● Resuspend pellet in 2 mL SpermPrep® 
● Centrifuge at 450 g for 10 minutes 
● After second centrifugation, remove supernatant and carefully overlay pellet with 0.5 
mL SpermPrep®  
● Leave to stand at 45° angle in an 37°C incubator for one hour 
● Aspirate the top layer of the sample, leaving pellet undisturbed. 
 
Density Gradient Centrifugation 
● This technique makes use of 3 different density gradient stock solutions (stock solution 
used is SilSelect® FertiPro); 
o 90% : 0.90mL of stock solution plus 1.0mL SpermPrep® 
o 70% : 0.70mL of stock solution plus 0.3mL SpermPrep® 
o 45% : 0.45mL of stock solution plus 0.55mL SpermPrep® 
● The solutions are carefully layered on top of each other, starting with the 90% solution 
at the bottom of a conical tube and allowed to equilibrate at 37°C 
● Mix semen sample well (ensure sample has liquefied) 
● Dilute sample in a 1:2 ratio (semen: sperm washing medium [SAGE® Advantage 
HEPES buffered sperm preparation medium - SpermPrep®]) in a test tube 
● Centrifuge at 350 to 450 x g for 10 minutes 
● Resuspend pellet in 1 mL SpermPrep® and carefully overlay on gradient 
● Centrifuge sample at 35 x g between 15 – 18 minutes 
● Remove top gradient layers, leaving only the pellet 
● Resuspend pellet in 0.3 – 0.5 mL medium and aspirate into a clean conical tube 
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● The resuspended sperm sample is diluted with 2mL medium and centrifuged at 300 – 
450 x g for 10 minutes 
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Appendix II – Standard Ovarian Stimulation Protocol 
(The Practice Committee of the American Society for Reproductive Medicine, 2013) 
(Aevitas Fertility Clinic SOP) 
The standard antagonist stimulation protocol consists of daily gonadotropins (225 IU FSH in 
a step down fashion to 150 IU) for 5 days beginning on day 3 of the menstrual cycle. 
  
Adjustments to the gonadotropin dosage is determined by ultrasound monitoring; 0.25 mg of 
Cetrorelix® (GnRH antagonist) is added as a subcutaneous injection when the leading 
follicle measures 14 mm or more. 10,000 IU hCG is given SC or IM when the lead follicle 
was ≥ 18 mm and at least two other follicles were ≥ 16 mm in size.   
  
Oocyte retrieval is performed within 36 hours after hCG administration. 
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Appendix III - Oocyte Retrieval Method – Public Clinic 
(Matsaseng & Kruger, 2014) 
Approximately, 15 to 30 minutes before an oocyte retrieval procedure is performed the patient 
is consciously sedated using only local Pethidene® (100mg) intramuscularly and a cervical 
block with 1% Lignocaine®. The clinician inserts a needle (guided by means of a transvaginal 
ultrasound) through the vaginal wall and into an ovarian follicle. The other end of the needle 
is attached to a suction device that expels follicular fluid into a laboratory tube.  
 
Once the follicle is entered, suction is gently applied to aspirate follicular fluid and with it, 
hopefully, cellular material including the oocyte. The follicular fluid is handed to an 
embryologist in the IVF laboratory to identify and quantify the ova. Next, other follicles are 
aspirated. Once the ovarian follicles have been aspirated on one ovary, the needle is 
withdrawn, and the procedure repeated on the other ovary. In the mild stimulation programme 
more than 10 oocytes is seldom recovered. After completion, the needle is withdrawn, and 
haemostasis is achieved.  
 
The procedure lasts between 5 to 10 minutes after which the patient recovers for 
approximately 30 minutes and once they are fully awake and in the company of a family 
member, they are discharged.   
 
  
Stellenbosch University  https://scholar.sun.ac.za
114 
 
Appendix IV - Oocyte Retrieval Method – Private Clinic  
 
(Aevitas Fertility Clinic SOP) 
 
The oocyte retrieval procedure is performed under conscious sedation (Dormicum® IV) and 
using transvaginal ultrasound guidance. The clinician inserts a needle through the vaginal wall 
and into an ovarian follicle, taking care not to injure organs located between the vaginal wall 
and the ovary. The other end of the needle is attached to a suction device that expels follicular 
fluid.  
 
Once the follicle is entered, suction is gently applied to aspirate follicular fluid and with they, 
hopefully, cellular material including the oocyte. The follicular fluid is handed to an 
embryologist in the IVF laboratory to identify and quantify the ova. Next, other follicles are 
aspirated. Once the ovarian follicles have been aspirated on one ovary, the needle is 
withdrawn, and the procedure repeated on the other ovary. It is not unusual to recover 20 
oocytes as women are generally hyper-stimulated in advance of this procedure. After 
completion, the needle is withdrawn, and haemostasis is achieved.  
 
The procedure usually approximately lasts 15 to 30 minutes. 
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Appendix V - In Vitro Fertilization 
(Tygerberg Fertility Clinic SOP 9 and Aevitas Fertility Clinic SOP) 
Make sure that all forms and documents are prepared 
Check patient’s file and record to eliminate all possible uncertainties/queries    
 
Aspiration 
Medium preparation – previous day 
See section on medium preparation 
 
Ovum Pick up 
● Check suction pump (100-120 mmHg) 
● Prepare glass polished pipettes for pick up 
● Place pick-up tubes in heated block 
● Hand theatre medium tube to sister when needed 
● Place aspirated follicular fluids in heated block and examine for oocyte-cumulus 
complexes using a large Petri dish on a heated stage (37-40ºC) of a dissection 
microscope 
● Determine maturity [see appendix at end of section] 
o GV, MI, MII 
o Spread complexes to visualize the first polar body (if possible) 
o Note maturity and all other features on the ova form 
● Put the complexes (with as little as possible blood and medium) in the pick-up tubes 
(MI and MII separate) 
● When finished, rinse all complexes in small Petri dish with gassed fertilization medium 
– check number obtained 
● Transfer to 4 well NUNC dish – maturities separate and not more than 5 complexes 
per well 
● Incubate in the CO2 incubator until insemination 
● Complete all forms 
 
Insemination 
● Inseminate complexes with the correct number/volume of prepared sperm 
o Morphology  ≤ 4 % - up to 2 x 106 sperm/ovum            
o Morphology  4, ≤ 14 % – 500 000 sperm/ovum                       
o Morphology   14 %  – 100 000 sperm/ovum                
▪ (work out the correct volume) 
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● Do insemination ± 40 hours post HCG administration if at all possible 
● Incubate overnight at  37 ºC, 6% CO2 
 
Embryo evaluation 
Dish preparation for embryo culture 
● Prepare a culture dish with cleavage medium drops (Quinns – Cooper Surgical) for the 
following day 
● Prepare culture drops under oil (Quinns – Cooper Surgical)  
o Work as fast as possible to prevent evaporation 
o Work on a cold surface  
o Make drops equal to the number of oocytes (but add one extra for rinsing) 










Day 1   (2 PN) 
● Clean oocytes with denuding pipettes ( Cook Australia)  
o If oocytes are not clearly visible – dislodge first with two sterile, hypodermic 
needles   
● Rinse well in clean 4 well NUNC dish  
● Check for pronuclei (PN)  and polar body (PB) number on the inverted microscope 
with heated stage 
o Note any abnormal number of PN [ > or < than 2], or any other anomalies  
● Transfer to preincubated  cleavage medium drops covered with mineral oil in a small 
Petri dish 










Embryo quality/morphology check 
 
 
Day 2 (2- 4 cell) 
● Check for cell stage and embryo morphology on the inverted microscope with heated 
stage 
o See section on embryo morphology evaluation 
● Select embryos for transfer if a day 2 transfer 
o See section on embryo transfer  
Day 3 (6-8 cell) 
● Check for cell stage and embryo morphology on the inverted microscope with heated 
stage 
o See section on embryo morphology evaluation 
● Transfer embryos to preincubated  blastocyst medium drops covered with mineral oil  
● Select embryos for transfer if a day 3 transfer 
o   See section on embryo transfer  
 
Day 5/6 (Blastocyst transfer) 
● Check for cell stage/blastocyst morphology on the inverted microscope with heated 
stage 
o See section on blastocyst morphology evaluation 
● Transfer embryos/blastocysts  to preincubated  blastocyst medium drops covered 
with mineral oil  
● Select embryos/blastocysts for transfer if a day 5 transfer 
o   See section on embryo transfer  
 
Cryopreservation 
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Appendix VI - Intra-cytoplasmic Sperm Injection  
(Tygerberg Fertility Clinic SOP 10 and Aevitas Fertility Clinic SOP) 
Make sure that all forms and documents are prepared 
Check patient’s file and record to eliminate all possible uncertainties/queries    
 
Aspiration 
Medium preparation – previous day 
  
Ovum Pick up 
● Check suction pump (100-120 mmHg) 
● Prepare glass polished pipettes for pick up 
● Place pick-up tubes in heated block 
● Hand theatre medium tube to sister when needed 
● Place aspirated follicular fluids in heated block and examine for oocyte-cumulus 
complexes using a large Petri dish on a heated stage (37-40ºC) of a dissection 
microscope 
o Note obvious abnormal features and maturities 
● Put the complexes (with as little as possible blood and medium) in the pick-up tube 
● When finished, rinse all complexes in small Petri dish with gassed fertilization 
medium – check number obtained 
● Leave in fertilization medium in CO2 incubator until time for denuding of oocytes 
o Try to do denuding ±38 hours post HCG injection 
 
Denuding of oocytes 
● Prepare pipettes for the process: fire polished glass Pasteur pipettes, hand drawn 
glass pipettes and the Cook stripper (Marcus Medical) pipette   
● Prepare a 4 well NUNC dish for denuding: [USE ONE DISH FOR EVERY 8 
OOCYTES] 
o In well 2, 3 and 4 place ± 0.8 – 0.9 ml warmed HEPES buffered flushing 
medium (Quinns, Cooper Surgical)  
o In well 1 place 0.6 ml HEPES buffered flushing medium and add 0.3 ml 
hyaluronidase [80 UI/ml] (Quinns, Cooper Surgical) 
o Place in the incubator [without CO2] at 37ºC for ± 10 minutes to reach 37ºC 
● Place a predetermined number of oocyte/cumulus complexes in well 1, wait for ± 30 
seconds 
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● Gently flush the complexes with a standard fire polished pipette until all cumulus cells 
are digested (oocytes with corona cells and small number of cumulus cells form 
“fluffy balls”) 
o If complexes stay intact use two hypodermic needles to “tease” oocytes from 
the complexes 
● Use the same fire polished pipette and transfer the oocytes with as little as possible 
hyaluronidase solution to well 2  
● Now flush oocytes individually with a big [170-200um] pulled glass pipette to remove 
some of the loose cumulus cells and transfer to well 3 
● In well 3 start the stripping using the plastic Cook denuding pipette [130um] (Marcus 
Medical) – try to remove all corona cells to 
allow for evaluation of oocyte maturity 
o Make sure that the pipette works 
correctly before oocytes are 
aspirated 
o If oocytes seem stuck in pipette – 
blow out into one of the wells using a syringe and adapter 
● Place the denuded oocytes into a pre-prepared holding or “rugby ball” dish, into the 
elliptical fertilization wash medium drop. 
● [this dish is prepared the previous day and cultured at 6% CO2/37ºC – drops are 
covered with oil – Quinns - Cooper Surgical)  
      Cleavage medium 
 
 
      Fertilization medium 
 
● Determine the maturity of the oocytes and transfer to the clean fertilization drops – all 
MII oocytes to the left drop and all MI and GV to the right drop  
● Culture until injection 
● Complete all forms  





























● Incubate for ±30 minutes at 37ºC [no CO2] 
 
Sperm Immobilization 
● Add sperm cells to the sperm preparation medium 
● Select motile, morphological normal spermatozoa form the drop with the ICSI 
injection pipette and immobilize the sperm cell 
o Collect enough sperm cells for the injection procedure. 
 
Sperm injection 
● Place MII oocytes to be injected in the oocyte drops ( 2 per drop)  
● Select an immobilized sperm cell and carefully inject oocyte  
● Continue until all oocytes are injected 
● Transfer back into the elliptical drop (fertilization) to wash and then to the cleavage 
drops for overnight culture (6% CO2/37ºC   
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Dish preparation for embryo culture 
● Prepare a culture dish with cleavage medium drops (Quinns – Cooper Surgical) for 
the next day 
● Make drops under oil (Quinns – Cooper Surgical)  
o Work as fast as possible to prevent evaporation 
o Work on a cold surface  
o Make drops equal to the number of oocytes (but add one extra for rinsing) 




Day 1 (2 PN) 
 
● Check for pro nuclei (PN)  and polar body (PB) number on the inverted microscope 
with heated stage 
o Note any abnormal number of PN [ > or < than 2], or any other anomalies  
● Transfer to preincubated  cleavage medium drops covered with mineral oil in a small 
Petri dish 
● Incubate overnight at  37 ºC, 6% CO2 
 
Embryo quality/morphology check 
 
Day 2 (2- 4 cell) 
● Check for cell stage and embryo morphology on the inverted microscope with 
heated stage 
o See section on embryo morphology evaluation 
● Select embryos for transfer if a day 2 transfer 






Stellenbosch University  https://scholar.sun.ac.za
122 
 
Day 3 (6-8 cell) 
● Check for cell stage and embryo morphology on the inverted microscope with 
heated stage 
o See section on embryo morphology evaluation 
● Transfer embryos to preincubated  blastocyst medium drops covered with mineral oil  
● Select embryos for transfer if a day 3 transfer 
o See section on embryo transfer  
 
Day 5/6 (Blastocyst transfer) 
● Check for cell stage/blastocyst morphology on the inverted microscope with heated 
stage 
o See section on blastocyst morphology evaluation 
● Transfer embryos/blastocysts  to preincubated  blastocyst medium drops covered 
with mineral oil  
● Select embryos/blastocysts for transfer if a day 5 transfer 




Select blastocysts for vitrification after transfers – See Appendix XIII. 
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Appendix VII – Physiological Intra-Cytoplasmic Sperm Injection  
(Adapted Origio PICSI® Protocol) 
(Tygerberg Fertility Clinic SOP 11 and Aevitas Fertility Clinic SOP) 
Preparation for use: 
 
Hydrate the hyaluronan microdots by placing single 10-µL droplets of Human Tubal Fluid 
(HTF) containing at least 5 mg/mL serum protein, or other suitable sperm diluent, at the end 
of each locating line covering the area where the microdot is situated (Figure 1). 
Alternatively, the sperm suspension can be added directly to the dry microdot. Drops of 
polyvinylpyrrolidone (PVP) or other fluids useful for manipulating sperm may also be placed 
elsewhere on the dish at this time.  
 
Carefully flood the dish with tissue culture oil to prepare it for use. Hydrating the microdot 
before applying the sperm gives the hyaluronan time to swell.  
 
Swelling and sperm binding begin normally in 5 minutes or less. However some microdots 
may require 30 minutes or more to reach full binding capability.  
 
Therefore, whenever marginal sperm binding is observed, pre-hydrate for 30minutes or 
more, or allow sperm to incubate on the dot for 30 minutes or more before selecting sperm. 
 




 Add the sperm to the pre-hydrated microdot in a volume equal to or greater than that 
used to pre-hydrate the dot (approximately 10 µL).  
 Touch the tip of the micropipette containing the sperm to the edge of the hydrating 
drop at the bottom of the dish under the oil and expel the sperm.  
o By delivering the sperm in a volume equal to the hydrating fluid, immediate 
mixing and delivery of sperm to the vicinity of the microdot is assured.  
o If the sperm are delivered in a smaller volume at the edge of the drop, greater 
than 30 minutes may be required for them to swim through the hydrating fluid 
to the microdot.  
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 Once bound, hyaluronan bound sperm are easily identified: they exhibit no 
progressive migration despite vigorous tail beating.  
 Factors governing sperm binding: To rapidly populate the microdot with bound 
sperm, place approximately 100,000hyaluronan-binding sperm per mL 
(approximately 1,000-2,000 total sperm in10-20 µL volume) over the microdot.  
 
Sperm Location Selection:  
 
 The wall of the hyaluronan microdot is a physical barrier to which many sperm will 
bind since this is usually the first point of contact.  
 It is sometimes difficult to distinguish whether the sperm are bound or they are simply 
swimming against the edge of the microdot. You may be sure of selecting bound 
sperm by selecting them from the interior of the microdot. 
 Obtaining a good density of bound sperm: If the density of bound sperm is too high or 
too low for good sperm selection, dilute or concentrate the prepared sperm sample 
and use the adjusted sperm sample to seed the next microdot.  
 Three microdots are provided on each PICSI® Sperm Selection Device to give a 
sufficient opportunity.  
 
Sperm collection:  
 
 To collect a bound sperm, position the tip of the ICSI micropipette next to the sperm 
and gently suck fluid into the pipette, drawing in the sperm.  
 Continue collecting until 20-50sperm are captured.  
 Expel the captured sperm into a PVP drop to process them for ICSI (inactivating the 
tail, re-evaluating motility and morphology.)  
 From the PVP droplet, select and load single, processed sperm for injection into the 




 Sperm bind best to hyaluronan hydrogel at temperatures below 30°C.  
 At temperatures above30°C, sperm swimming vigour increases and the swimming 
force may overcome the binding force.  
 The result is that about one-third of sperm bound at room temperature will show 
some progressive migration at 37°C and may be deemed not bound, immature.  
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 PICSI® Sperm Selection Device dishes placed on a 37°C heated stage will come to 
about 33°C and then remain at that temperature. At 33°C or even at 37°C, many 
bound sperm will remain available for selection. 
 
Instructions for Use 
 
Technique considerations:  
 
 Microdot shape: The PICSI® Sperm Selection Device hyaluronan microdot is crater-
shaped. The edge of the microdot is a raised wall of hydrogel surrounding a low, flat 
interior layer. The wall is flexible and may be irregular in shape due to uneven 
hydration of the hydrogel. The hydrogel wall can be pierced and torn by an ICSI 
micropipette driven directly in to it. It is best to position the elevated micropipette tip 
over the microdot interior and lower it to the microdot surface for recovery of sperm.  
 
 Microdot caves: During manufacture, uneven hydration may cause segments of the 
microdot wall to create small “caves” that open toward the inside edge of the wall. 
Sperm that swim into a cave are trapped, not bound. Trapped sperm usually all face 
away from the centre of the microdot and show vigorously beating tails, often in 
clusters. The heads of trapped sperm can move laterally and sometimes back and 
forth within the walls of the cave. Trapped sperm should not be selected since their 
binding status is unclear. 
 
 Microdot stability: If a part of the wall separates from the polystyrene, the same 
forces that create caves can cause the microdot wall to progressively detach from the 
dish and coil up like a spring. When this occurs, some or all of the wall will separate 
from the microdot. However, the microdot interior hyaluronan layer will remain intact. 
The interior hyaluronan layer is stable for hours, it collects and houses bound sperm 
that may be used for ICSI. Sperm bound to the curled up wall remnant should not be 
used for sperm selection and isolation.  
  
Stellenbosch University  https://scholar.sun.ac.za
126 
 
Appendix VIII – Intracytoplasmic Morphological Sperm Injection  
(Tygerberg Fertility Clinic SOP 12 and Aevitas Fertility Clinic SOP) 
Make sure that all forms and documents are prepared 
Check patient’s file and record to eliminate all possible uncertainties/queries    
 
Aspiration 
Medium preparation – previous day 
  
Ovum Pick up 
● Check suction pump (100-120 mmHg) 
● Prepare glass polished pipettes for pick up 
● Place pick-up tubes in heated block 
● Hand theatre medium tube to sister when needed 
● Place aspirated follicular fluids in heated block and examine for oocyte-cumulus 
complexes using a large Petri dish on a heated stage (37-40ºC) of a dissection 
microscope 
o Note obvious abnormal features and maturities 
● Put the complexes (with as little as possible blood and medium) in the pick-up tube 
● When finished, rinse all complexes in small Petri dish with gassed fertilization 
medium – check number obtained 
● Leave in fertilization medium in CO2 incubator until time for denuding of oocytes 
o Try to do denuding ±38 hours post HCG injection 
 
Denuding of oocytes 
● Prepare pipettes for the process: fire polished glass Pasteur pipettes, hand drawn 
glass pipettes and the Cook stripper (Marcus Medical) pipette   
● Prepare a 4 well NUNC dish for denuding: [USE ONE DISH FOR EVERY 8 
OOCYTES] 
o In well 2, 3 and 4 place ± 0.8 – 0.9 ml warmed HEPES buffered flushing 
medium (Quinns, Cooper Surgical)  
o In well 1 place 0.6 ml HEPES buffered flushing medium and add 0.3 ml 
hyaluronidase [80 UI/ml] (Quinns, Cooper Surgical) 
o Place in the incubator [without CO2] at 37ºC for ± 10 minutes to reach 37ºC 
● Place a predetermined number of oocyte/cumulus complexes in well 1, wait for ± 30 
seconds 
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● Gently flush the complexes with a standard fire polished pipette until all cumulus cells 
are digested (oocytes with corona cells and small number of cumulus cells form 
“fluffy balls”) 
o If complexes stay intact use two hypodermic needles to “tease” oocytes from 
the complexes 
● Use the same fire polished pipette and transfer the oocytes with as little as possible 
hyaluronidase solution to well 2  
● Now flush oocytes individually with a big [170-200um] pulled glass pipette to remove 
some of the loose cumulus cells and transfer to well 3 
● In well 3 start the stripping using the plastic Cook denuding pipette [130um] (Marcus 
Medical) – try to remove all corona cells to 
allow for evaluation of oocyte maturity 
o Make sure that the pipette works 
correctly before oocytes are 
aspirated 
o If oocytes seem stuck in pipette – 
blow out into one of the wells using a syringe and adapter 
● Place the denuded oocytes into a pre-prepared holding or “rugby ball” dish, into the 
elliptical fertilization wash medium drop. 
● [this dish is prepared the previous day and cultured at 6% CO2/37ºC – drops are 
covered with oil – Quinns- Cooper Surgical)  
      Cleavage medium 
 
 
      Fertilization medium 
 
● Determine the maturity of the oocytes and transfer to the clean fertilization drops – all 
MII oocytes to the left drop and all MI and GV to the right drop  
● Culture until injection 
● Complete all forms  











● For IMSI with ejaculated semen, prepared the following injection dish (glass bottom 
dish): 
 







● Incubate for ±30 minutes at 37ºC (no CO2) 
 
Sperm selection and immobilization 
● Add sperm cells to the sperm preparation medium 
● Select motile, morphological normal spermatozoa form the drop with the ICSI 
injection pipette using the 20x objective 
● Place the selected sperm into the left SP drop and focus on the edge of the drop.  
● Change the heated stage to the setting where the dish overlaps with the opening on 
the stage, the dish needs to come in contact with the objective. 
● Put the 100x objective in place and suspend a small drop of oil onto the objective 
● Place the glass bottom dish containing your sperm onto the oil covered objective. 
The left SP drop should be in the centre of the objective.  
● Using the more robust magnification to focus on your SP edge. Bring your needle 
down and make an indentation in the edge. The sperm will swim into the indentation. 
● Select the morphologically normal sperm without any vacuoles and move them to the 
SP drop to the right.  
● After selecting enough sperm change your heated stage again and proceed with 
normal ICSI protocol.  
● immobilize the sperm cell 
o Collect enough sperm cells for the injection procedure. 
 
Sperm injection 
● Place MII oocytes to be injected in the oocyte drops (2 per drop)  
● Select an immobilized sperm cell and carefully inject oocyte  
● Continue until all oocytes are injected 
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● Transfer back into the elliptical drop (fertilization) to wash and then to the cleavage 
drops for overnight culture (6% CO2 / 37ºC) 
● Do injection ± 40 hours post HCG administration if at all possible 
 




Dish preparation for embryo culture 
● Prepare a culture dish with cleavage medium drops (Quinns – Cooper Surgical) for 
the next day 
● Make drops under oil (Quinns – Cooper Surgical)  
o Work as fast as possible to prevent evaporation 
o Work on a cold surface  
o Make drops equal to the number of oocytes (but add one extra for rinsing) 




Day 1 (2 PN) 
 
● Check for pro nuclei (PN)  and polar body (PB) number on the inverted microscope 
with heated stage 
o Note any abnormal number of PN [ > or < than 2], or any other anomalies  
● Transfer to preincubated  cleavage medium drops covered with mineral oil in a small 
Petri dish 
● Incubate overnight at  37 ºC, 6% CO2 
 
Embryo quality/morphology check 
 
Day 2 (2- 4 cell) 
● Check for cell stage and embryo morphology on the inverted microscope with 
heated stage 
o See section on embryo morphology evaluation 
● Select embryos for transfer if a day 2 transfer 
o See section on embryo transfer  
 




Day 3 (6-8 cell) 
● Check for cell stage and embryo morphology on the inverted microscope with 
heated stage 
o See section on embryo morphology evaluation 
● Transfer embryos to preincubated  blastocyst medium drops covered with mineral oil  
● Select embryos for transfer if a day 3 transfer 
o See section on embryo transfer  
 
Day 5/6 (Blastocyst transfer) 
● Check for cell stage/blastocyst morphology on the inverted microscope with heated 
stage 
o See section on blastocyst morphology evaluation 
● Transfer embryos/blastocysts  to preincubated  blastocyst medium drops covered 
with mineral oil  
● Select embryos/blastocysts for transfer if a day 5 transfer 




Select blastocysts for vitrification after transfers – See Appendix XIII. 
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Appendix IX - Embryo Grading Day 2 and Day 3  
(Modified from Veeck, 2003) 
(Tygerberg Fertility Clinic SOP 17 and Aevitas Fertility Clinic SOP) 
 
Grade 1: Embryo with few blastomeres of any size, severe or complete 
fragmentation. 
 
Grade 2: Embryo with blastomeres of equal and unequal size, significant 
cytoplasmic fragmentation. 
 
Grade 3: Embryo with blastomeres of distinctly unequal size, few or no 
cytoplasmic fragments. 
 
Grade 4: Embryo with blastomeres of equal size; minor cytoplasmic fragments. 
 
Grade 5: Embryo, with blastomeres of equal size; no cytoplasmic fragments. 
  




Appendix X - Grading Criteria for Good Quality Embryos  














































2 4 (- / +)
Day 2 3 5 (- / +)
4
> 4 
6 4 (- / +)
Day 3 7 5 (- / +)
8
> 8
10 cel l 4 (- / +)
Day 4 Early Compact (EC / VK) 5 (- / +)
Compact (C / K)
> Compact (C / K)
Day 5 Early Blastocyst (EB / VB)
1A; 1B NO C Grading
> 1A; 1B
Day 6 > 3AA; 3AB; 3BA; 3BB NO C Grading
> 3AA; 3AB; 3BA; 3BB
Day 7 3AA; 3AB; 3BA; 3BB NO C Grading
> 3AA; 3AB; 3BA; 3BB
EMBRYO GRADING (GQED 2 - 7; PQED 2 - 7)
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Appendix XI - Grading Criteria for Human Blastocysts  
(Veeck, 2003) 
(Tygerberg Fertility Clinic SOP 17 and Aevitas Fertility Clinic SOP) 
See Figure 30 
 
Degree of expansion and hatching status: 
1. Early blastocyst; the blastocoel filling more than half the volume of the conceptus, but 
no expansion in overall size as compared to earlier stages. 
2. Blastocyst; the blastocoel filling more than half of the volume of the conceptus, with 
slight expansion in overall size and notable thinning of the zona pellucida. 
3. Full blastocyst; a blastocoel more than 50% of the conceptus volume and overall size 
fully enlarged with a very thin zona pellucida. 
4. Hatching blastocyst; (non-preimplantation genetic diagnosis). The trophectoderm has 
started to herniate through the zona. 
5. Fully hatched blastocyst; (non-preimplantation genetic diagnosis). Free blastocyst fully 
removed from zona pellucida. 
6. Hatching or hatched blastocyst; (preimplantation genetic diagnosis). 
 
Inner Cell Mass (ICM) grading: 
A. Tightly packed, compacted cells 
B. Larger, loose cells 
C. No ICM distinguishable 
D. Cells of ICM appear degenerative 
 
Trophectoderm grading: 
A. Many healthy cells forming a cohesive epithelium 
B. Few, but healthy cells, large in size 
C. Poor, very large, or unevenly distributed cells; may appear as few cells squeezed to 
the side 
D. Cells of the trophectoderm appear degenerative. 
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Figure 30. Grading criteria for human blastocysts (Veeck, 2003) 
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Appendix XII - Cryopreservation and Thawing of Oocytes 
(Kitazato® BioPharma Protocol) 
Oocyte - Vitrification 
Vitrification Kit 
 
The Kitazato vitrification kit consists of: 
Equilibration medium  
  Vitrification medium  
 





1. 1x centre-well organ culture dish (Falcon 35 3037) 
2.  Attenuated glass pipettes/or Stripper pipette with stripper tips 
3.  Liquid nitrogen in large polystyrene holder 
4.  Labelled Cryotop (patient’s name, identity number & date of freezing) 
- If more than one Cryotop is to be used you can either use different coloured 
Cryotop for each oocyte set, or simply label each Cryotop on the very top with 
a number corresponding to the set of oocytes that are placed onto it. 
5.  Gassed fertilization medium for the first drop of the equilibration process.  
6.  1ml of the equilibration medium (Solution 1) and 1ml of the vitrification medium 
(Solution 2) into Eppendorf tubes and bring to ROOM TEMPERATURE 





1. Equilibration (ROOM TEMPERATURE) 
 
• In the lid of the 1ml centre-well organ culture dish make the drops. 
  • Place oocytes into fertilization medium drop for 1minute (a). 
• After 1 minute drag fertilization drop into the first equilibration drop. Keep in 
the first drop for 3 minutes.  
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- During the first minute keep oocytes in the ‘tunnel’ between the 
drops (b). In the second and third minutes gradually move the 
oocytes further into the equilibration drop (c & d). 
• After 3 minutes drag the first equilibration drop into the second equilibration 
drop. Keep oocytes in the second drop for 3 minutes. (Method as above). 
• After 3 minutes transfer the oocytes from the second equilibration drop to the 
last, large equilibration drop. Keep in this drop for at least 9 minutes. (DO 
NOT drag the other drops into the last drop). (Oocytes may be held in this last 
droplet for longer than 9 minutes if necessary). 
- If you have a number of oocytes to vitrify, make a few parallel rows 
of media and take the oocytes through the equilibration steps to 
the last equilibration drop. Once in the last drop, you can leave the 
other oocytes in the last drop while you take the first set of oocytes 
into the vitrification and loading stages. 
 
2. Vitrification (ROOM TEMPERATURE) 
 
• Place the 1ml of vitrification medium (solution 2) into the centre-well organ culture 
dish. 
• After the 9 minutes in the last equilibration drop, transfer the oocytes into the 1ml 
vitrification medium (put on the bottom of the dish) for no more than 1 minute (this 
includes the time for loading onto the Cryotop). 
• The oocytes will float and move around. Keep catching them and transferring them to 
the bottom of the dish. 
 
3. Loading Cryotop 
 
NB! The most important thing during the vitrification procedure is to load as little medium 
onto the Cryotop as possible. Load the oocytes in as little medium and then suck off excess 
medium around the oocytes, being careful not to suck the oocytes up again. 
 
• Load a MAXIMUM of 4 oocytes per Cryotop, preferably less. 
• Place the top of the Cryotop into the liquid nitrogen. 
• Using an attenuated glass pipette (by hand or by mouth) or a stripper-tip pipette, 
transfer all oocytes onto the tip of the Cryotop (ensure that the Cryotop is turned so 
that the writing on the Cryotop is facing up – this ensures that the scientist that is 
thawing the oocytes knows which side the oocytes are on). 
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• Suck off as much excess medium as possible. Work quickly. 
• Plunge the tip of the Cryotop directly in the liquid nitrogen. 
• Insert the tip into the top of the Cryotop. 
 
• When transferring the Cryotops to the tank, remove the tube from the goblet and 
transfer into the polystyrene holder that the Cryotops are in. Transfer all the Cryotops 
into the tube under liquid nitrogen and then transfer the tube back to the goblet. This 
ensures that the Cryotops are never exposed to air. Only put the cotton wool into the 
tube once the tube has been transferred back to the tank. This will prevent air 





The Kitazato thawing kit consists of: 
 
 Thawing medium – 1.0 Mol Sucrose 
 Diluent medium – 0.5 Mol Sucrose 
 Washing medium 1 – No sucrose. Just a culture medium 




1. 1x centre-well organ culture dish (Falcon 35 3037) (warmed in incubator to 37ºC). 
2. Attenuated glass pipettes/ or Stripper pipette with stripper tips. 
3. Liquid nitrogen in large polystyrene holder. 
4. 1ml of Thawing medium (solution 1) in Eppendorf tube and bring to 37ºC. 
5. 0.4ml Diluent medium (solution 2) into Eppendorf tube and bring to ROOM 
TEMPERATURE. 
6. Combine 0.2ml Diluent medium and 0.2ml Washing Medium (we’ll call it solution 2b - 
0.25M sucrose) together in Eppendorf and bring to ROOM TEMPERATURE. 
7. 0.5ml Washing medium 1 or 2 (solution 3) into Eppendorf and bring to ROOM 
TEMPERATURE. 
8. 0.5ml gassed fertilization / cleavage medium (37ºC) for the final drops of the thawing 
process. (The fertilization / cleavage medium is not essential as the washing medium 
will suffice, but if you are going to transfer the oocytes to fertilization / cleavage 
medium it will be good to wash the oocytes in cleavage medium). 







• Place liquid nitrogen into a large polystyrene holder. 
• Transfer the entire tube holding the patient’s Cryotops from the tank into the 
polystyrene holder. 
• Remove the required Cryotops from the tube and replace the tube into the 
tank leaving the Cryotops for thawing in the polystyrene holder. 
 
2. Solution 1 (37ºC) 
 
• Work on a room temperature stage. 
• Place the 1ml of solution 1 (37ºC) into the warmed centre-well organ culture 
dish. 
• Work quickly so as not to reduce the temperature of the 37ºC medium too 
much. 
• Ensure that the microscope is adjusted prior to removing the Cryotop as 
speed is important. 
• Under liquid nitrogen remove the top of the Cryotop. 
• Working very quickly, place the tip of the Cryotop into solution 1. Under 
microscopic vision gently wave the tip until the oocytes dislodge. (If 
necessary, use a pipette to blow / remove the oocytes from the Cryotop). 
Remove the Cryotop as quickly as possible so as not to reduce the 
temperature of the medium too much. 
• Leave oocytes in solution 1 for 1 minute. 
 
3. Solution 2 & 2b (ROOM TEMPERATURE) 
 
• In the lid of the 1ml centre-well organ culture dish make the drops. 
  • Transfer oocytes from the centre-well dish into Solution 2 for 3 minutes. 
• Transfer the oocytes into Solution 2b for 3 minutes. 
• Transfer the oocytes into the first washing drop and move them through the 
washing droplets to the last drop of washing medium. 
• Drag the last washing drop into the first drop of fertilization / cleavage medium 
(so as not to shock the oocytes). Do the same into the second drop. 
Stellenbosch University  https://scholar.sun.ac.za
139 
 
• Pick up the oocytes and transfer them into the last fertilization / cleavage 
drop. 
• Transfer the oocytes to the gassed fertilization / cleavage medium and place 
into the incubator for 1 or 2 hours prior to ICSI.  
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Appendix XIII - Cryopreservation and Thawing of Embryos/Blastocysts 
(VitriFreeze™ and VitriThaw™ FertiPro Protocol) 




In a 4-well dish fill the first well with 300 μl of Pre-incubation medium, the second with 
VitriFreeze 1 and the third with VitriFreeze 2 solution. Next open as many packs of HSV 
devices as will be required for the vitrification step, taking into account that 1 HSV device 
can hold up to 2 embryos. 
Conveniently place the separate parts of the HSV device on the workbench for easy access 




Transfer the embryos from the blastocyst cell culture medium in to each of the VitriFreeze 




Vitri Freeze 1 Vitri Freeze 2 Temperature 
Early Blastocyst / 
Morulae 
2’ 2’ 30’’ Room temperature 
Blastocyst – expanded 
blastocyst 
2’ 3’ 30’’ 37°C 
Blastocyst – expanded 
blastocyst + artificial 
shrinkage* 




* Before starting the vitrification procedure, in order to reduce the negative effect of the 
blastocoel, expanded blastocysts should be collapsed by reducing artificially with a glass 










1.  Using an attenuated pipette or an equally suitable device, deposit maximum 2 
blastocysts in a volume of approximately 0.3μl of VitriFreeze 2, in the gutter of the tip 
of the vitrification straw. 
2. Place the vitrification straw in the outer sheath and seal it as indicated in the 
instructions for use of the HSV device. 
3.  Plunge the sealed device into the liquid nitrogen. 
 
Thawing 
1.  Remove the vitrification straw from the outer sheath as indicated in the instructions 
for use of the HSV device. 
2.  Immediately plunge the vitrification straw into pre-heated VitriThaw Thawing medium 
1 (37°C) and leave in thawing 1 for 3 minutes. 
3.  Transfer into VitriThaw Thawing medium 2 (37°C) and leave in this medium for 2 
minutes. 
4.  Transfer into VitriThaw Thawing medium 3 (37°C) and leave in this medium for 2 
minutes. 
5.  Finally transfer into VitriThaw Thawing medium 4 (37°C) and wash for at least 1 
minute. 
6.  Transfer into blastocyst culture medium for continued cell culture.  
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Appendix XIV - Embryo Transfer Method  
(Matsaseng & Kruger, 2014) 
(Tygerberg Fertility Clinic SOP 18 and Aevitas Fertility Clinic SOP) 
Routinely, an embryo transfer occurs 2 to 5 days after the oocyte retrieval. The procedure 
starts by placing a speculum in the vagina to visualize the cervix, which is cleaned with gauze 
wetted with HEPES buffered (flushing) culture medium. It is important that the patient’s bladder 
is full before the transfer occurs as this ensures that the endometrial cavity can be accessed 
easily and atraumatically and embryos transferred easily and exactly at the right place.  
 
A soft transfer catheter, which contains the embryos to be transferred, is inserted through the 
cervical canal and advanced to the uterine cavity. After insertion of the catheter, the media 
containing the embryos are deposited into the uterine cavity. It is important that, after the 
deposit of the embryos, the embryologist checks the catheter immediately to ensure that the 
embryos don’t remain inside it.  
 
The transfer is guided with an ultrasound (abdominal ultrasound) to ensure correct placement 
in the uterine cavity. Anaesthesia is not required when performing an embryo transfer. 
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Appendix XV - Consent Form – Prospective Study 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
TITLE OF THE RESEARCH PROJECT: 
“Investigation into Possible Factors Influencing Clinical Pregnancy 
Rate in a public and private sector ART Clinic” 
 
REFERENCE NUMBER: S15/03/050A (Health Research Ethical Committee Approval Number) 
PRINCIPAL INVESTIGATOR: Nicole Ashley Nel 
ADDRESS: Aevitas Fertility Clinic, Vincent Pallotti Hospital, Pinelands 
Tygerberg Hospital, Tygerberg, Cape Town 
CONTACT NUMBER: +27 82 799 9444 
 
You are being invited to take part in a research project. Please take some time to read the 
information presented here, which will explain the details of this project. Please ask the study staff 
or doctor any questions about any part of this project that you do not fully understand. It is very 
important that you are fully satisfied that you clearly understand what this research entails and how 
you will be involved. Also, your participation is entirely voluntary and you are free to decline to 
participate. If you say no, this will not affect you negatively in any way whatsoever. You are also free 
to withdraw from the study at any point, even if you do agree to take part. This study has been 
approved by the Health Research Ethics Committee at Stellenbosch University and will be 
conducted according to the ethical guidelines and principles of the international Declaration of 
Helsinki, South African Guidelines for Good Clinical Practice and the Medical Research Council (MRC) 
Ethical Guidelines for Research. 
 
What is this research study all about? 
Many people have difficulty to fall pregnant and have a baby of their own. There are many 
solutions for this problem – one being the use of Assisted Reproductive Techniques (ART’s). 
There are many factors and reasons why a couple may have difficulty to fall pregnant. When 
Fertility doctors need to find out what these reasons are they do a thorough workup/investigation of 
the couple. The investigations include both the male and female partner’s medical history, certain 
lifestyle habits (smoking, alcohol use, Body Mass Index) and medical tests so that contributing 
factors to the couple’s infertility can be identified. The contributing factors could be from the male 
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partner, female partner or both. The success of ART treatment may also be influenced by many 
factors such as female age, the number of eggs and the quality of the embryos. The aim of this study 
will be to investigate which factors may have a significant effect on a successful clinical pregnancy [a 
positive fetal heartbeat at 7 weeks] outcome at two different ART laboratories – one a private [Drs 
Aevitas Clinic at Vincent Pallotti Hospital] and the other a public sector [Tygerberg Fertility Clinic, 
Tygerberg Hospital] Fertility Clinic.  
 
To do this study we need to use the routine data collected in each clinic from your files. The 
data and information will be collected in an anonymous manner and you will not be identified and 
none of your personal information will be used. 
 
Why have you been invited to participate? 
You have been identified as a suitable candidate for the study since you agreed to undergo 
either IVF or ICSI treatment at the respective Fertility Clinics and fall into the group of patients who 
falls within the inclusion criteria of the study. 
 
What will your responsibilities be? 
All we ask is that you read through the information and sign the form provided to give consent for 
the use of your medical records – you will stay anonymous. 
 
Will you benefit from taking part in this research? 
You may benefit because your consent to take part in the study and the results of the study 
may help to improve the outcome of successful pregnancy, also for other sub-fertile couples. 
 
Are there in risks involved in your taking part in this research? 
There are no risks. 
 
Who will have access to your medical records? 
Your identity and any additional information about your treatment will be confidential and 
protected. If the research is used in any kind of publication, your identity will remain 
anonymous. Your information will be available only to the principle and co-investigators 
involved in the research project. 
 
What will happen in the unlikely event of some form injury occurring as a direct result of your 
taking part in this research study? 
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There will not be any form of injury as a direct or indirect result of you giving consent to use the 
information needed for the study. 
 
Will you be paid to take part in this study and are there any costs involved? 
No, you will not be paid and there are no costs involved. 
Is there anything else that you should know or do? 
-You can contact myself, the researcher, or the supervisor of the project Dr. Marie-Lena de Beer (+27 
83 708 8964) if you have any further queries or encounter any problems. 
-You can contact the Health Research Ethics Committee at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your study doctor. 
-You will receive a copy of this information and consent form for your own records. 
 
 
Declaration by participants 
By signing below, we (Initials & Surname) …………………………………..……..…………………. and 
……………………………………………………………………….. agree to take part in a research study entitled: “Investigation into Possible 
Factors Influencing Clinical Pregnancy Rate in a public and private sector ART Clinic” 
We declare that: 
We have read or had read to us this information and consent form and it is written in a language 
with which we are fluent and comfortable. 
We have had a chance to ask questions and all our questions have been adequately answered. 
We understand that taking part in this study is voluntary and we have not been pressurised to take 
part. 
We may choose to leave the study at any time and will not be penalised or prejudiced in any way. 
We may be asked to leave the study before it has finished, if the study doctor or researcher feels it is 
in our best interests, or if we do not follow the study plan, as agreed to. 
Signed at (place) ......................…........…………….. on (date) …………....…………………………………………. 
................................................................................... ................................................................................ 
Signature of participant [partner one] Signature of witness 
……………………………………………………………….. 
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Declaration by investigator 
I (Initials & Surname) ……………………………………………………………………….……..……… declare that: 
I explained the information in this document to …………………………………………………………….. 
and ……………………………………………………..……… 
I encouraged them to ask questions and took adequate time to answer them 
I am satisfied that they adequately understands all aspects of the research, as discussed above 
I did/did not use an interpreter. (If an interpreter is used then the interpreter must sign the 
declaration below 
Signed at (place) ......................…........…………….. on (date) …………....…………………………………………. 
................................................................................... ................................................................................ 
Signature of investigator Signature of witness 
 
Declaration by interpreter 
I (name) ……………………………………………..……… declare that: 
I assisted the investigator (name) ………………………………………………………..….to explain the information 
in this document to (name of participants) ……………..……………………………………………………. 
and …………………………………..…………………..………using the language medium of Afrikaans/Xhosa. 
We encouraged them to ask questions and took adequate time to answer them. 
I conveyed a factually correct version of what was related to me. 
I am satisfied that the participants fully understand the content of this informed consent document 
and has had all their questions satisfactorily answered. 
Signed at (place) ......................…........…………….. on (date) …………....…………………………………………. 
................................................................................... ................................................................................ 
Signature of interpreter Signature of witness 
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Appendix XVI - Retrospective Data Results 
1. Distribution of patients between different incubators  
 
. gen inc2=inc 
 
. tab inc , missing 
 
        INC |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          1 |         69       17.78       17.78 
          2 |         72       18.56       36.34 
          3 |         45       11.60       47.94 
          4 |         64       16.49       64.43 
          5 |         77       19.85       84.28 
          8 |         14        3.61       87.89 
          9 |         14        3.61       91.49 
         10 |         17        4.38       95.88 
         11 |         13        3.35       99.23 
         12 |          1        0.26       99.48 
         14 |          1        0.26       99.74 
         16 |          1        0.26      100.00 
------------+----------------------------------- 
      Total |        388      100.00 
 
 
2. Distribution of patients grouped between two incubators under investigation 
 
. recode inc2 (1/5=1) (8/11=2) (12/16=.) 
(inc2: 319 changes made) 
 
. tab inc2 , missing 
 
       inc2 |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          1 |        327       84.28       84.28 
          2 |         58       14.95       99.23 
          . |          3        0.77      100.00  not considered for analysis 
------------+----------------------------------- 
      Total |        388      100.00 
 
 
3. Age of Ova distribution between incubators 
 
. tab ageova inc2, col 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
 
           |         inc2 
    AgeOva |         1          2 |     Total 
-----------+----------------------+---------- 
        19 |         2          0 |         2  
           |      0.61       0.00 |      0.52  
-----------+----------------------+---------- 
        20 |         2          1 |         3  
           |      0.61       1.72 |      0.78  
-----------+----------------------+---------- 
        21 |         7          0 |         7  
           |      2.14       0.00 |      1.82  
-----------+----------------------+---------- 
        22 |        18          1 |        19  
           |      5.50       1.72 |      4.94  
-----------+----------------------+---------- 
        23 |        10          3 |        13  
           |      3.06       5.17 |      3.38  
-----------+----------------------+---------- 
        24 |        12          3 |        15  
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           |      3.67       5.17 |      3.90  
-----------+----------------------+---------- 
        25 |        17          1 |        18  
           |      5.20       1.72 |      4.68  
-----------+----------------------+---------- 
        26 |        19          1 |        20  
           |      5.81       1.72 |      5.19  
-----------+----------------------+---------- 
        27 |        14          5 |        19  
           |      4.28       8.62 |      4.94  
-----------+----------------------+---------- 
        28 |        14          2 |        16  
           |      4.28       3.45 |      4.16  
-----------+----------------------+---------- 
        29 |        17          5 |        22  
           |      5.20       8.62 |      5.71  
-----------+----------------------+---------- 
        30 |        26          1 |        27  
           |      7.95       1.72 |      7.01  
-----------+----------------------+---------- 
        31 |        18          6 |        24  
           |      5.50      10.34 |      6.23  
-----------+----------------------+---------- 
        32 |        26          3 |        29  
           |      7.95       5.17 |      7.53  
-----------+----------------------+---------- 
        33 |        24          5 |        29  
           |      7.34       8.62 |      7.53  
-----------+----------------------+---------- 
        34 |        22          3 |        25  
           |      6.73       5.17 |      6.49  
-----------+----------------------+---------- 
        35 |        15          8 |        23  
           |      4.59      13.79 |      5.97  
-----------+----------------------+---------- 
        36 |        33          3 |        36  
           |     10.09       5.17 |      9.35  
-----------+----------------------+---------- 
        37 |        31          7 |        38  
           |      9.48      12.07 |      9.87  
-----------+----------------------+---------- 
     Total |       327         58 |       385  
           |    100.00     100.00 |    100.00  
 
 
. ttest ageova, by(inc2) 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   Forma |     327    30.24771    .2698549    4.879824    29.71683    30.77858 
   Mincs |      58    30.96552    .6089499    4.637625    29.74612    32.18492 
---------+-------------------------------------------------------------------- 
combined |     385    30.35584    .2469271     4.84506    29.87035    30.84134 
---------+-------------------------------------------------------------------- 
    diff |           -.7178108    .6902328               -2.074931    .6393091 
------------------------------------------------------------------------------ 
    diff = mean(Forma) - mean(Mincs)                              t =  -1.0400 
Ho: diff = 0                                     degrees of freedom =      383 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 





4. Male diagnoses (coded) between incubators  
 
. tabulate mdiag inc2, exact 
 
           |         inc2 
     Mdiag |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         1 |       126         20 |       146  
         2 |        18          2 |        20  
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         3 |         8          1 |         9  
         4 |         4          0 |         4  
         5 |        14          3 |        17  
         6 |         2          2 |         4  
         8 |        25          5 |        30  
         9 |        46         13 |        59  
        10 |         3          0 |         3  
        11 |         8          0 |         8  
        12 |        20          3 |        23  
        13 |         1          0 |         1  
        15 |        20          4 |        24  
        16 |         1          0 |         1  
        20 |         0          1 |         1  
-----------+----------------------+---------- 
     Total |       296         54 |       350  
 
           Fisher's exact =                 0.519 
 
No difference in mdiag profile  
. tab mdiag inc2 ,col 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
 
           |         inc2 
     Mdiag |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         1 |       126         20 |       146  
           |     42.57      37.04 |     41.71  
-----------+----------------------+---------- 
         2 |        18          2 |        20  
           |      6.08       3.70 |      5.71  
-----------+----------------------+---------- 
         3 |         8          1 |         9  
           |      2.70       1.85 |      2.57  
-----------+----------------------+---------- 
         4 |         4          0 |         4  
           |      1.35       0.00 |      1.14  
-----------+----------------------+---------- 
         5 |        14          3 |        17  
           |      4.73       5.56 |      4.86  
-----------+----------------------+---------- 
         6 |         2          2 |         4  
           |      0.68       3.70 |      1.14  
-----------+----------------------+---------- 
         8 |        25          5 |        30  
           |      8.45       9.26 |      8.57  
-----------+----------------------+---------- 
         9 |        46         13 |        59  
           |     15.54      24.07 |     16.86  
-----------+----------------------+---------- 
        10 |         3          0 |         3  
           |      1.01       0.00 |      0.86  
-----------+----------------------+---------- 
        11 |         8          0 |         8  
           |      2.70       0.00 |      2.29  
-----------+----------------------+---------- 
        12 |        20          3 |        23  
           |      6.76       5.56 |      6.57  
-----------+----------------------+---------- 
        13 |         1          0 |         1  
           |      0.34       0.00 |      0.29  
-----------+----------------------+---------- 
        15 |        20          4 |        24  
           |      6.76       7.41 |      6.86  
-----------+----------------------+---------- 
        16 |         1          0 |         1  
           |      0.34       0.00 |      0.29  
-----------+----------------------+---------- 
        20 |         0          1 |         1  
           |      0.00       1.85 |      0.29  
-----------+----------------------+---------- 
     Total |       296         54 |       350  
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           |    100.00     100.00 |    100.00 
 
 
5. Female diagnoses (coded) between incubators  
 
. tabulate fdiag inc2, exact 
 
           |         inc2 
     Fdiag |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         1 |       187         32 |       219  
         2 |        18          2 |        20  
        13 |         3          1 |         4  
        14 |        21          1 |        22  
        15 |        22          9 |        31  
        16 |        41         11 |        52  
        17 |         8          0 |         8  
        18 |         1          0 |         1  
        19 |         2          0 |         2  
        28 |         1          0 |         1  
-----------+----------------------+---------- 
     Total |       304         56 |       360  
 




tab fdiag inc2 ,col 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
 
           |         inc2 
     Fdiag |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         1 |       187         32 |       219  
           |     61.51      57.14 |     60.83  
-----------+----------------------+---------- 
         2 |        18          2 |        20  
           |      5.92       3.57 |      5.56  
-----------+----------------------+---------- 
        13 |         3          1 |         4  
           |      0.99       1.79 |      1.11  
-----------+----------------------+---------- 
        14 |        21          1 |        22  
           |      6.91       1.79 |      6.11  
-----------+----------------------+---------- 
        15 |        22          9 |        31  
           |      7.24      16.07 |      8.61  
-----------+----------------------+---------- 
        16 |        41         11 |        52  
           |     13.49      19.64 |     14.44  
-----------+----------------------+---------- 
        17 |         8          0 |         8  
           |      2.63       0.00 |      2.22  
-----------+----------------------+---------- 
        18 |         1          0 |         1  
           |      0.33       0.00 |      0.28  
-----------+----------------------+---------- 
        19 |         2          0 |         2  
           |      0.66       0.00 |      0.56  
-----------+----------------------+---------- 
        28 |         1          0 |         1  
           |      0.33       0.00 |      0.28  
-----------+----------------------+---------- 
     Total |       304         56 |       360  
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6. Procedures (coded) between incubators  
 
. . tab proc inc2 ,col 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
 
           |         inc2 
      Proc |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         1 |        34          6 |        40  
           |     10.40      10.34 |     10.39  
-----------+----------------------+---------- 
         2 |       116         13 |       129  
           |     35.47      22.41 |     33.51  
-----------+----------------------+---------- 
         3 |        24          5 |        29  
           |      7.34       8.62 |      7.53  
-----------+----------------------+---------- 
         4 |        45          7 |        52  
           |     13.76      12.07 |     13.51  
-----------+----------------------+---------- 
         5 |        11          3 |        14  
           |      3.36       5.17 |      3.64  
-----------+----------------------+---------- 
         6 |        94         24 |       118  
           |     28.75      41.38 |     30.65  
-----------+----------------------+---------- 
         8 |         2          0 |         2  
           |      0.61       0.00 |      0.52  
-----------+----------------------+---------- 
        12 |         1          0 |         1  
           |      0.31       0.00 |      0.26  
-----------+----------------------+---------- 
     Total |       327         58 |       385  
           |    100.00     100.00 |    100.00  
 
 
. tabulate proc inc2, exact 
 
           |         inc2 
      Proc |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         1 |        34          6 |        40  
         2 |       116         13 |       129  
         3 |        24          5 |        29  
         4 |        45          7 |        52  
         5 |        11          3 |        14  
         6 |        94         24 |       118  
         8 |         2          0 |         2  
        12 |         1          0 |         1  
-----------+----------------------+---------- 
     Total |       327         58 |       385  
 
           Fisher's exact =                 0.435 
 
 
7. Sperm morphology frequency  
 
. tab morph inc2 ,col 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
 
           |         inc2 
     Morph |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
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         1 |         9          2 |        11  
           |      3.88       4.88 |      4.03  
-----------+----------------------+---------- 
         2 |        13          1 |        14  
           |      5.60       2.44 |      5.13  
-----------+----------------------+---------- 
         3 |        16          3 |        19  
           |      6.90       7.32 |      6.96  
-----------+----------------------+---------- 
         4 |        14          2 |        16  
           |      6.03       4.88 |      5.86  
-----------+----------------------+---------- 
         5 |        10          2 |        12  
           |      4.31       4.88 |      4.40  
-----------+----------------------+---------- 
         6 |        20          3 |        23  
           |      8.62       7.32 |      8.42  
-----------+----------------------+---------- 
         7 |        23          2 |        25  
           |      9.91       4.88 |      9.16  
-----------+----------------------+---------- 
         8 |        23          2 |        25  
           |      9.91       4.88 |      9.16  
-----------+----------------------+---------- 
         9 |        19          4 |        23  
           |      8.19       9.76 |      8.42  
-----------+----------------------+---------- 
        10 |         9          5 |        14  
           |      3.88      12.20 |      5.13  
-----------+----------------------+---------- 
        11 |        23          3 |        26  
           |      9.91       7.32 |      9.52  
-----------+----------------------+---------- 
        12 |        16          2 |        18  
           |      6.90       4.88 |      6.59  
-----------+----------------------+---------- 
        13 |         8          3 |        11  
           |      3.45       7.32 |      4.03  
-----------+----------------------+---------- 
        14 |         7          3 |        10  
           |      3.02       7.32 |      3.66  
-----------+----------------------+---------- 
        15 |         4          1 |         5  
           |      1.72       2.44 |      1.83  
-----------+----------------------+---------- 
        16 |         6          0 |         6  
           |      2.59       0.00 |      2.20  
-----------+----------------------+---------- 
        17 |         3          0 |         3  
           |      1.29       0.00 |      1.10  
-----------+----------------------+---------- 
        18 |         2          1 |         3  
           |      0.86       2.44 |      1.10  
-----------+----------------------+---------- 
        19 |         2          1 |         3  
           |      0.86       2.44 |      1.10  
-----------+----------------------+---------- 
        20 |         2          1 |         3  
           |      0.86       2.44 |      1.10  
-----------+----------------------+---------- 
        22 |         2          0 |         2  
           |      0.86       0.00 |      0.73  
-----------+----------------------+---------- 
        25 |         1          0 |         1  
           |      0.43       0.00 |      0.37  
-----------+----------------------+---------- 
     Total |       232         41 |       273  




end of do-file 
 
 
. ttest morph, by(inc2) 
 
Two-sample t test with equal variances 




   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   Forma |     232    8.413793    .3020763     4.60109    7.818616     9.00897 
   Mincs |      41    9.146341    .7404357    4.741102    7.649865    10.64282 
---------+-------------------------------------------------------------------- 
combined |     273     8.52381    .2796734    4.620962     7.97321    9.074409 
---------+-------------------------------------------------------------------- 
    diff |           -.7325484    .7830283                -2.27414    .8090435 
------------------------------------------------------------------------------ 
    diff = mean(Forma) - mean(Mincs)                              t =  -0.9355 
Ho: diff = 0                                     degrees of freedom =      271 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 




8. Frequency of donor ova   
 
. . tabulate donova inc2, exact col 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
 
           |         inc2 
    DonOva |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         0 |       228         46 |       274  
           |     69.94      79.31 |     71.35  
-----------+----------------------+---------- 
         1 |        98         12 |       110  
           |     30.06      20.69 |     28.65  
-----------+----------------------+---------- 
     Total |       326         58 |       384  
           |    100.00     100.00 |    100.00  
 
           Fisher's exact =                 0.159 
   1-sided Fisher's exact =                 0.095 
 




9. Number of ova distribution  
 
. tab NrOva inc2 ,col 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
 
           |         inc2 
     NrOva |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         3 |         8          1 |         9  
           |      2.45       1.72 |      2.34  
-----------+----------------------+---------- 
         4 |         6          4 |        10  
           |      1.84       6.90 |      2.60  
-----------+----------------------+---------- 
         5 |        16          4 |        20  
           |      4.91       6.90 |      5.21  
-----------+----------------------+---------- 
         6 |        22          4 |        26  
           |      6.75       6.90 |      6.77  
-----------+----------------------+---------- 
         7 |        29          4 |        33  
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           |      8.90       6.90 |      8.59  
-----------+----------------------+---------- 
         8 |        19          2 |        21  
           |      5.83       3.45 |      5.47  
-----------+----------------------+---------- 
         9 |        17          3 |        20  
           |      5.21       5.17 |      5.21  
-----------+----------------------+---------- 
        10 |        18          6 |        24  
           |      5.52      10.34 |      6.25  
-----------+----------------------+---------- 
        11 |        20          8 |        28  
           |      6.13      13.79 |      7.29  
-----------+----------------------+---------- 
        12 |        17          2 |        19  
           |      5.21       3.45 |      4.95  
-----------+----------------------+---------- 
        13 |        25          2 |        27  
           |      7.67       3.45 |      7.03  
-----------+----------------------+---------- 
        14 |        17          1 |        18  
           |      5.21       1.72 |      4.69  
-----------+----------------------+---------- 
        15 |        14          1 |        15  
           |      4.29       1.72 |      3.91  
-----------+----------------------+---------- 
        16 |        13          1 |        14  
           |      3.99       1.72 |      3.65  
-----------+----------------------+---------- 
        17 |        13          2 |        15  
           |      3.99       3.45 |      3.91  
-----------+----------------------+---------- 
        18 |        12          1 |        13  
           |      3.68       1.72 |      3.39  
-----------+----------------------+---------- 
        19 |         4          0 |         4  
           |      1.23       0.00 |      1.04  
-----------+----------------------+---------- 
        20 |        11          1 |        12  
           |      3.37       1.72 |      3.13  
-----------+----------------------+---------- 
        21 |         3          4 |         7  
           |      0.92       6.90 |      1.82  
-----------+----------------------+---------- 
        22 |         5          1 |         6  
           |      1.53       1.72 |      1.56  
-----------+----------------------+---------- 
        23 |         9          0 |         9  
           |      2.76       0.00 |      2.34  
-----------+----------------------+---------- 
        24 |         3          2 |         5  
           |      0.92       3.45 |      1.30  
-----------+----------------------+---------- 
        25 |         3          1 |         4  
           |      0.92       1.72 |      1.04  
-----------+----------------------+---------- 
        26 |         2          0 |         2  
           |      0.61       0.00 |      0.52  
-----------+----------------------+---------- 
        28 |         6          0 |         6  
           |      1.84       0.00 |      1.56  
-----------+----------------------+---------- 
        29 |         2          1 |         3  
           |      0.61       1.72 |      0.78  
-----------+----------------------+---------- 
        30 |         2          0 |         2  
           |      0.61       0.00 |      0.52  
-----------+----------------------+---------- 
        31 |         2          0 |         2  
           |      0.61       0.00 |      0.52  
-----------+----------------------+---------- 
        32 |         2          1 |         3  
           |      0.61       1.72 |      0.78  
-----------+----------------------+---------- 
        34 |         2          0 |         2  
           |      0.61       0.00 |      0.52  
-----------+----------------------+---------- 
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        38 |         1          0 |         1  
           |      0.31       0.00 |      0.26  
-----------+----------------------+---------- 
        40 |         1          0 |         1  
           |      0.31       0.00 |      0.26  
-----------+----------------------+---------- 
        41 |         0          1 |         1  
           |      0.00       1.72 |      0.26  
-----------+----------------------+---------- 
        50 |         1          0 |         1  
           |      0.31       0.00 |      0.26  
-----------+----------------------+---------- 
        56 |         1          0 |         1  
           |      0.31       0.00 |      0.26  
-----------+----------------------+---------- 
     Total |       326         58 |       384  
           |    100.00     100.00 |    100.00  
 
 
. ttest NrOva , by(inc2) 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   Forma |     326    13.27914    .4199777    7.582895    12.45292    14.10536 
   Mincs |      58    12.58621    1.020075    7.768661    10.54354    14.62887 
---------+-------------------------------------------------------------------- 
combined |     384    13.17448     .388092    7.605019    12.41142    13.93754 
---------+-------------------------------------------------------------------- 
    diff |            .6929342    1.084623               -1.439645    2.825514 
------------------------------------------------------------------------------ 
    diff = mean(Forma) - mean(Mincs)                              t =   0.6389 
Ho: diff = 0                                     degrees of freedom =      382 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 




10. Frequency of MI oocytes  
 
. tab mi inc2 ,col 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
 
           |         inc2 
        MI |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         0 |       103         18 |       121  
           |     31.50      31.03 |     31.43  
-----------+----------------------+---------- 
         1 |        65         10 |        75  
           |     19.88      17.24 |     19.48  
-----------+----------------------+---------- 
         2 |        63         11 |        74  
           |     19.27      18.97 |     19.22  
-----------+----------------------+---------- 
         3 |        27          9 |        36  
           |      8.26      15.52 |      9.35  
-----------+----------------------+---------- 
         4 |        19          5 |        24  
           |      5.81       8.62 |      6.23  
-----------+----------------------+---------- 
         5 |        23          1 |        24  
           |      7.03       1.72 |      6.23  
-----------+----------------------+---------- 
         6 |         8          2 |        10  
           |      2.45       3.45 |      2.60  
-----------+----------------------+---------- 
         7 |         8          2 |        10  
Stellenbosch University  https://scholar.sun.ac.za
156 
 
           |      2.45       3.45 |      2.60  
-----------+----------------------+---------- 
         8 |         4          0 |         4  
           |      1.22       0.00 |      1.04  
-----------+----------------------+---------- 
         9 |         2          0 |         2  
           |      0.61       0.00 |      0.52  
-----------+----------------------+---------- 
        10 |         2          0 |         2  
           |      0.61       0.00 |      0.52  
-----------+----------------------+---------- 
        13 |         2          0 |         2  
           |      0.61       0.00 |      0.52  
-----------+----------------------+---------- 
        17 |         1          0 |         1  
           |      0.31       0.00 |      0.26  
-----------+----------------------+---------- 
     Total |       327         58 |       385  
           |    100.00     100.00 |    100.00  
 
 
. tabulate mi inc2, exact 
 
 
           |         inc2 
        MI |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         0 |       103         18 |       121  
         1 |        65         10 |        75  
         2 |        63         11 |        74  
         3 |        27          9 |        36  
         4 |        19          5 |        24  
         5 |        23          1 |        24  
         6 |         8          2 |        10  
         7 |         8          2 |        10  
         8 |         4          0 |         4  
         9 |         2          0 |         2  
        10 |         2          0 |         2  
        13 |         2          0 |         2  
        17 |         1          0 |         1  
-----------+----------------------+---------- 
     Total |       327         58 |       385  
 
           Fisher's exact =                 0.760 
 
 
11. Frequency MII oocytes  
 
. tab mii inc2 ,col 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
 
           |         inc2 
       MII |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         2 |         3          1 |         4  
           |      0.92       1.72 |      1.04  
-----------+----------------------+---------- 
         3 |         9          3 |        12  
           |      2.75       5.17 |      3.12  
-----------+----------------------+---------- 
         4 |        21          3 |        24  
           |      6.42       5.17 |      6.23  
-----------+----------------------+---------- 
         5 |        23          4 |        27  
           |      7.03       6.90 |      7.01  
-----------+----------------------+---------- 
         6 |        36          8 |        44  
           |     11.01      13.79 |     11.43  
-----------+----------------------+---------- 
         7 |        22          8 |        30  
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           |      6.73      13.79 |      7.79  
-----------+----------------------+---------- 
         8 |        19          3 |        22  
           |      5.81       5.17 |      5.71  
-----------+----------------------+---------- 
         9 |        24          2 |        26  
           |      7.34       3.45 |      6.75  
-----------+----------------------+---------- 
        10 |        22          6 |        28  
           |      6.73      10.34 |      7.27  
-----------+----------------------+---------- 
        11 |        21          2 |        23  
           |      6.42       3.45 |      5.97  
-----------+----------------------+---------- 
        12 |        20          3 |        23  
           |      6.12       5.17 |      5.97  
-----------+----------------------+---------- 
        13 |        16          2 |        18  
           |      4.89       3.45 |      4.68  
-----------+----------------------+---------- 
        14 |        16          2 |        18  
           |      4.89       3.45 |      4.68  
-----------+----------------------+---------- 
        15 |        11          2 |        13  
           |      3.36       3.45 |      3.38  
-----------+----------------------+---------- 
        16 |         6          1 |         7  
           |      1.83       1.72 |      1.82  
-----------+----------------------+---------- 
        17 |         9          0 |         9  
           |      2.75       0.00 |      2.34  
-----------+----------------------+---------- 
        18 |        14          2 |        16  
           |      4.28       3.45 |      4.16  
-----------+----------------------+---------- 
        19 |         5          0 |         5  
           |      1.53       0.00 |      1.30  
-----------+----------------------+---------- 
        20 |         5          2 |         7  
           |      1.53       3.45 |      1.82  
-----------+----------------------+---------- 
        21 |         3          0 |         3  
           |      0.92       0.00 |      0.78  
-----------+----------------------+---------- 
        22 |         4          0 |         4  
           |      1.22       0.00 |      1.04  
-----------+----------------------+---------- 
        23 |         4          0 |         4  
           |      1.22       0.00 |      1.04  
-----------+----------------------+---------- 
        24 |         2          1 |         3  
           |      0.61       1.72 |      0.78  
-----------+----------------------+---------- 
        25 |         3          0 |         3  
           |      0.92       0.00 |      0.78  
-----------+----------------------+---------- 
        26 |         3          0 |         3  
           |      0.92       0.00 |      0.78  
-----------+----------------------+---------- 
        27 |         0          1 |         1  
           |      0.00       1.72 |      0.26  
-----------+----------------------+---------- 
        29 |         2          1 |         3  
           |      0.61       1.72 |      0.78  
-----------+----------------------+---------- 
        32 |         1          0 |         1  
           |      0.31       0.00 |      0.26  
-----------+----------------------+---------- 
        33 |         1          0 |         1  
           |      0.31       0.00 |      0.26  
-----------+----------------------+---------- 
        37 |         1          0 |         1  
           |      0.31       0.00 |      0.26  
-----------+----------------------+---------- 
        38 |         0          1 |         1  
           |      0.00       1.72 |      0.26  
-----------+----------------------+---------- 
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        45 |         1          0 |         1  
           |      0.31       0.00 |      0.26  
-----------+----------------------+---------- 
     Total |       327         58 |       385  
           |    100.00     100.00 |    100.00  
 
 
12. Proportion fertilized MI & MII 
 
. ttest fertmii , by(inc2) 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   Forma |     327    8.611621     .272772    4.932575    8.075005    9.148236 
   Mincs |      58    8.258621    .7678351    5.847658    6.721057    9.796184 
---------+-------------------------------------------------------------------- 
combined |     385    8.558442    .2586038    5.074173    8.049985    9.066898 
---------+-------------------------------------------------------------------- 
    diff |            .3530001    .7236675               -1.069858    1.775859 
------------------------------------------------------------------------------ 
    diff = mean(Forma) - mean(Mincs)                              t =   0.4878 
Ho: diff = 0                                     degrees of freedom =      383 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.6870         Pr(|T| > |t|) = 0.6260          Pr(T > t) = 0.3130 
 
.  
end of do-file 
 
.  
. . ttest fertmi , by(inc2) 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   Forma |     327    .0183486    .0074331    .1344143    .0037257    .0329716 
   Mincs |      58    .0172414    .0172414    .1313064   -.0172839    .0517666 
---------+-------------------------------------------------------------------- 
combined |     385    .0181818    .0068182    .1337824    .0047762    .0315875 
---------+-------------------------------------------------------------------- 
    diff |            .0011072    .0190856               -.0364184    .0386329 
------------------------------------------------------------------------------ 
    diff = mean(Forma) - mean(Mincs)                              t =   0.0580 
Ho: diff = 0                                     degrees of freedom =      383 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.5231         Pr(|T| > |t|) = 0.9538          Pr(T > t) = 0.4769 
 
end of do-file 
 
 
There were 17 pt where fertmii>mii. This cannot be. Thus assumed fertmii =mi and proportion 
fertilised=100% 
 
. . ttest p_fertmi , by(inc2) 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   Forma |     224    .0113095    .0047403    .0709468    .0019679    .0206511 
   Mincs |      40       .0125       .0125    .0790569   -.0127836    .0377836 
---------+-------------------------------------------------------------------- 
combined |     264    .0114899    .0044359    .0720756    .0027554    .0202244 
---------+-------------------------------------------------------------------- 
    diff |           -.0011905    .0123953               -.0255975    .0232166 
------------------------------------------------------------------------------ 
    diff = mean(Forma) - mean(Mincs)                              t =  -0.0960 
Ho: diff = 0                                     degrees of freedom =      262 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.4618         Pr(|T| > |t|) = 0.9236          Pr(T > t) = 0.5382 





Very few pt with any fertilisation of mi 
 
 
. . ttest p_fertmii , by(inc2) 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   Forma |     327    .7941573    .0099234    .1794457    .7746354    .8136792 
   Mincs |      58    .7906504    .0220263    .1677476    .7465434    .8347574 
---------+-------------------------------------------------------------------- 
combined |     385     .793629    .0090476    .1775264      .77584     .811418 
---------+-------------------------------------------------------------------- 
    diff |            .0035069    .0253257               -.0462878    .0533016 
------------------------------------------------------------------------------ 
    diff = mean(Forma) - mean(Mincs)                              t =   0.1385 
Ho: diff = 0                                     degrees of freedom =      383 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.5550         Pr(|T| > |t|) = 0.8899          Pr(T > t) = 0.4450 
 
No difference in mii fertilisation rate 79% in both incubators 
 
 
13. Frequency of good quality embryos on cycle day 2   
 
tab GQDAY2 inc2 ,col 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
 
           |         inc2 
    GQDAY2 |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         3 |        48         14 |        62  
           |     15.05      24.56 |     16.49  
-----------+----------------------+---------- 
         4 |        51         11 |        62  
           |     15.99      19.30 |     16.49  
-----------+----------------------+---------- 
         5 |        49          5 |        54  
           |     15.36       8.77 |     14.36  
-----------+----------------------+---------- 
         6 |        33          3 |        36  
           |     10.34       5.26 |      9.57  
-----------+----------------------+---------- 
         7 |        30          3 |        33  
           |      9.40       5.26 |      8.78  
-----------+----------------------+---------- 
         8 |        22          4 |        26  
           |      6.90       7.02 |      6.91  
-----------+----------------------+---------- 
         9 |        19          4 |        23  
           |      5.96       7.02 |      6.12  
-----------+----------------------+---------- 
        10 |        22          5 |        27  
           |      6.90       8.77 |      7.18  
-----------+----------------------+---------- 
        11 |         9          3 |        12  
           |      2.82       5.26 |      3.19  
-----------+----------------------+---------- 
        12 |        12          0 |        12  
           |      3.76       0.00 |      3.19  
-----------+----------------------+---------- 
        13 |         5          0 |         5  
           |      1.57       0.00 |      1.33  
-----------+----------------------+---------- 
        14 |         3          2 |         5  
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           |      0.94       3.51 |      1.33  
-----------+----------------------+---------- 
        15 |         4          0 |         4  
           |      1.25       0.00 |      1.06  
-----------+----------------------+---------- 
        16 |         1          1 |         2  
           |      0.31       1.75 |      0.53  
-----------+----------------------+---------- 
        17 |         1          1 |         2  
           |      0.31       1.75 |      0.53  
-----------+----------------------+---------- 
        18 |         4          1 |         5  
           |      1.25       1.75 |      1.33  
-----------+----------------------+---------- 
        19 |         1          0 |         1  
           |      0.31       0.00 |      0.27  
-----------+----------------------+---------- 
        20 |         1          0 |         1  
           |      0.31       0.00 |      0.27  
-----------+----------------------+---------- 
        21 |         2          0 |         2  
           |      0.63       0.00 |      0.53  
-----------+----------------------+---------- 
        24 |         1          0 |         1  
           |      0.31       0.00 |      0.27  
-----------+----------------------+---------- 
        26 |         1          0 |         1  
           |      0.31       0.00 |      0.27  
-----------+----------------------+---------- 
     Total |       319         57 |       376  
           |    100.00     100.00 |    100.00  
 
 
. ttest GQDAY2 , by(inc2) 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   Forma |     319    6.940439     .217478    3.884281    6.512561    7.368316 
   Mincs |      57    6.666667    .5168425    3.902075    5.631307    7.702027 
---------+-------------------------------------------------------------------- 
combined |     376    6.898936    .2002509    3.883009    6.505181    7.292692 
---------+-------------------------------------------------------------------- 
    diff |            .2737722    .5589464               -.8252992    1.372844 
------------------------------------------------------------------------------ 
    diff = mean(Forma) - mean(Mincs)                              t =   0.4898 
Ho: diff = 0                                     degrees of freedom =      374 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.6877         Pr(|T| > |t|) = 0.6246          Pr(T > t) = 0.3123 
 
Number of good quality embryo on day2 the same 
 
 
14. Frequency of good quality embryos on cycle day 3   
 
. tab GQDAY3 inc2 ,col 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
 
           |         inc2 
    GQDAY3 |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         0 |         9          0 |         9  
           |      2.83       0.00 |      2.41  
-----------+----------------------+---------- 
         1 |        18          4 |        22  
           |      5.66       7.14 |      5.88  
-----------+----------------------+---------- 
         2 |        39          6 |        45  
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           |     12.26      10.71 |     12.03  
-----------+----------------------+---------- 
         3 |        67         10 |        77  
           |     21.07      17.86 |     20.59  
-----------+----------------------+---------- 
         4 |        41         10 |        51  
           |     12.89      17.86 |     13.64  
-----------+----------------------+---------- 
         5 |        44          8 |        52  
           |     13.84      14.29 |     13.90  
-----------+----------------------+---------- 
         6 |        29          4 |        33  
           |      9.12       7.14 |      8.82  
-----------+----------------------+---------- 
         7 |        20          2 |        22  
           |      6.29       3.57 |      5.88  
-----------+----------------------+---------- 
         8 |        19          1 |        20  
           |      5.97       1.79 |      5.35  
-----------+----------------------+---------- 
         9 |        11          4 |        15  
           |      3.46       7.14 |      4.01  
-----------+----------------------+---------- 
        10 |         6          2 |         8  
           |      1.89       3.57 |      2.14  
-----------+----------------------+---------- 
        11 |         4          1 |         5  
           |      1.26       1.79 |      1.34  
-----------+----------------------+---------- 
        12 |         2          0 |         2  
           |      0.63       0.00 |      0.53  
-----------+----------------------+---------- 
        13 |         1          0 |         1  
           |      0.31       0.00 |      0.27  
-----------+----------------------+---------- 
        14 |         3          3 |         6  
           |      0.94       5.36 |      1.60  
-----------+----------------------+---------- 
        15 |         1          1 |         2  
           |      0.31       1.79 |      0.53  
-----------+----------------------+---------- 
        17 |         1          0 |         1  
           |      0.31       0.00 |      0.27  
-----------+----------------------+---------- 
        19 |         2          0 |         2  
           |      0.63       0.00 |      0.53  
-----------+----------------------+---------- 
        23 |         1          0 |         1  
           |      0.31       0.00 |      0.27  
-----------+----------------------+---------- 
     Total |       318         56 |       374  




. ttest GQDAY3 , by(inc2) 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   Forma |     318    4.786164    .1802023    3.213467     4.43162    5.140707 
   Mincs |      56    5.285714    .4689822    3.509542    4.345853    6.225576 
---------+-------------------------------------------------------------------- 
combined |     374    4.860963    .1685424    3.259455     4.52955    5.192375 
---------+-------------------------------------------------------------------- 
    diff |           -.4995508    .4722849               -1.428234    .4291322 
------------------------------------------------------------------------------ 
    diff = mean(Forma) - mean(Mincs)                              t =  -1.0577 
Ho: diff = 0                                     degrees of freedom =      372 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.1454         Pr(|T| > |t|) = 0.2909          Pr(T > t) = 0.8546 
 
. graph box GQDAY3 , over(inc2) 
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15. Frequency of good quality embryos on cycle day 5   
 
. tab GQDAY5 inc2 ,col 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
 
           |         inc2 
    GQDAY5 |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         0 |        30          6 |        36  
           |     12.35      15.00 |     12.72  
-----------+----------------------+---------- 
         1 |        40         10 |        50  
           |     16.46      25.00 |     17.67  
-----------+----------------------+---------- 
         2 |        41          6 |        47  
           |     16.87      15.00 |     16.61  
-----------+----------------------+---------- 
         3 |        37          3 |        40  
           |     15.23       7.50 |     14.13  
-----------+----------------------+---------- 
         4 |        38          4 |        42  
           |     15.64      10.00 |     14.84  
-----------+----------------------+---------- 
         5 |        19          1 |        20  
           |      7.82       2.50 |      7.07  
-----------+----------------------+---------- 
         6 |        16          2 |        18  
           |      6.58       5.00 |      6.36  
-----------+----------------------+---------- 
         7 |         8          6 |        14  
           |      3.29      15.00 |      4.95  
-----------+----------------------+---------- 
         8 |         7          1 |         8  
           |      2.88       2.50 |      2.83  
-----------+----------------------+---------- 
         9 |         3          0 |         3  
           |      1.23       0.00 |      1.06  
-----------+----------------------+---------- 
        11 |         1          0 |         1  
           |      0.41       0.00 |      0.35  
-----------+----------------------+---------- 
        12 |         1          0 |         1  
           |      0.41       0.00 |      0.35  
-----------+----------------------+---------- 
        13 |         2          0 |         2  
           |      0.82       0.00 |      0.71  
-----------+----------------------+---------- 
        15 |         0          1 |         1  
           |      0.00       2.50 |      0.35  
-----------+----------------------+---------- 
     Total |       243         40 |       283  
           |    100.00     100.00 |    100.00  
 
 




. ttest GQDAY5 , by(inc2) 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   Forma |     243    3.144033    .1586405     2.47296    2.831541    3.456525 
   Mincs |      40       3.225    .4993425    3.158119    2.214984    4.235016 
---------+-------------------------------------------------------------------- 
combined |     283    3.155477    .1530401    2.574534    2.854231    3.456723 
---------+-------------------------------------------------------------------- 
    diff |           -.0809671    .4400519               -.9471837    .7852496 




    diff = mean(Forma) - mean(Mincs)                              t =  -0.1840 
Ho: diff = 0                                     degrees of freedom =      281 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.4271         Pr(|T| > |t|) = 0.8542          Pr(T > t) = 0.5729 
 
 
16. Frequency of good quality embryos on cycle days 2, 3 & 5 – Distribution between two 
incubators   
 
Modeling the probability of having a good embryo quality on days 2,2 and 5 for the two 
incubators where the denominator is the total number of ova. The model is adjusted for the age 
of the ova, where seom donor ova was involved and the number of mii ova available. 




. generate pergd2= GQDAY2/ NrOva 
(10 missing values generated) 
 
. generate pergd3= GQDAY3/ NrOva 
(12 missing values generated) 
 
. generate pergd5= GQDAY5/ NrOva 
(104 missing values generated) 
 
. tabstat pergd2 pergd3 pergd5, statistics( mean count sd ) by(inc2) varwidth(14) columns 
> (statistics) 
 
inc2         variable |      mean         N        sd 
----------------------+------------------------------ 
Forma          pergd2 |  .5589354       318  .1869036 
               pergd3 |  .3931441       317  .2063107 
               pergd5 |  .2360079       243  .1735365 
----------------------+------------------------------ 
Mincs          pergd2 |   .574494        57  .2032567 
               pergd3 |  .4458132        56  .2201563 
               pergd5 |  .2176929        40  .1705393 
----------------------+------------------------------ 
Total          pergd2 |  .5613003       375  .1892781 
               pergd3 |  .4010516       373  .2089919 
               pergd5 |  .2334192       283  .1729345 
----------------------------------------------------- 
 
. xi: binreg GQDAY2 i.inc2 ageova i.donova mii, rr n(NrOva) vce(cluster ptnr) 
i.inc2            _Iinc2_1-2          (naturally coded; _Iinc2_1 omitted) 
i.donova          _Idonova_1-2        (_Idonova_1 for donova==0 omitted) 
 
Generalized linear models                         No. of obs      =        374 
Optimization     : MQL Fisher scoring             Residual df     =        369 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  652.4588348                   (1/df) Deviance =   1.768181 
Pearson          =  592.2582469                   (1/df) Pearson  =   1.605036 
 
Variance function: V(u) = u*(1-u/NrOva)           [Binomial] 
Link function    : g(u) = ln(u/NrOva)             [Log] 
 
                                                  BIC             =  -1533.592 
 
                                 (Std. Err. adjusted for 374 clusters in ptnr) 
------------------------------------------------------------------------------ 
             |             Semirobust 
      GQDAY2 | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    _Iinc2_2 |   1.015209   .0504566     0.30   0.761     .9209797    1.119079 
      ageova |   1.002432   .0053321     0.46   0.648     .9920358    1.012938 
  _Idonova_2 |   .9830849   .0562256    -0.30   0.765     .8788368    1.099699 
         mii |    .990021   .0026132    -3.80   0.000     .9849125     .995156 
       _cons |   .5595437   .0989846    -3.28   0.001     .3955983     .791432 
------------------------------------------------------------------------------ 
No difference in good probability at day 2 p=.761 
 
. xi: binreg GQDAY3 i.inc2 ageova i.donova mii, rr n(NrOva) vce(cluster ptnr) 
i.inc2            _Iinc2_1-2          (naturally coded; _Iinc2_1 omitted) 
i.donova          _Idonova_1-2        (_Idonova_1 for donova==0 omitted) 





Generalized linear models                         No. of obs      =        372 
Optimization     : MQL Fisher scoring             Residual df     =        367 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  804.3363556                   (1/df) Deviance =   2.191652 
Pearson          =  740.8271866                   (1/df) Pearson  =   2.018603 
 
Variance function: V(u) = u*(1-u/NrOva)           [Binomial] 
Link function    : g(u) = ln(u/NrOva)             [Log] 
 
                                                  BIC             =  -1367.898 
 
                                 (Std. Err. adjusted for 372 clusters in ptnr) 
------------------------------------------------------------------------------ 
             |             Semirobust 
      GQDAY3 | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    _Iinc2_2 |   1.154268   .0790091     2.10   0.036     1.009351    1.319991 
      ageova |   .9961983   .0079541    -0.48   0.633     .9807299    1.011911 
  _Idonova_2 |   .9581891   .0841636    -0.49   0.627     .8066498    1.138197 
         mii |   .9855162   .0041316    -3.48   0.001     .9774515    .9936474 
       _cons |    .497486   .1320792    -2.63   0.009       .29566    .8370842 
------------------------------------------------------------------------------ 
Significant difference in good probability on day 3. rr=1.15 (95%CI 1.01 to 1.32), p=.036. 
Thus the Minc incubator has a 15% (relative) probability of having good embryos on day 3 
compared to the Forma type. From the descriptive statistics we see that the mean proportion 
good embryos on day 3 is .393 in the Forma incubators versus .445 in the Minc incubator. The 
crude ratio is 1.13 which is close to the adjusted ratio from the model. 
 
 
. xi: binreg GQDAY5 i.inc2 ageova i.donova mii, rr n(NrOva) vce(cluster ptnr) 
i.inc2            _Iinc2_1-2          (naturally coded; _Iinc2_1 omitted) 
i.donova          _Idonova_1-2        (_Idonova_1 for donova==0 omitted) 
 
 
Generalized linear models                         No. of obs      =        282 
Optimization     : MQL Fisher scoring             Residual df     =        277 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  684.6339911                   (1/df) Deviance =   2.471603 
Pearson          =   612.658972                   (1/df) Pearson  =   2.211765 
 
Variance function: V(u) = u*(1-u/NrOva)           [Binomial] 
Link function    : g(u) = ln(u/NrOva)             [Log] 
 
                                                  BIC             =  -878.1743 
 
                                 (Std. Err. adjusted for 282 clusters in ptnr) 
------------------------------------------------------------------------------ 
             |             Semirobust 
      GQDAY5 | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    _Iinc2_2 |   1.016109   .1397514     0.12   0.908     .7760137    1.330488 
      ageova |   .9966452   .0126569    -0.26   0.791     .9721443    1.021764 
  _Idonova_2 |   .9181337   .1211473    -0.65   0.517     .7089087    1.189109 
         mii |   .9785701   .0079925    -2.65   0.008     .9630298    .9943611 




One days 2 and 5 there is no effect whereas on day 5 there is some effect. Not sure why one do 
not see a consistent effect. Drop of in number at day 5 n=282. 
 
 
17. Pregnancy Rate   
 
. . tabulate PR inc2, exact col 
 
 
           |         inc2 
        PR |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         0 |       129         20 |       149  
           |     40.69      37.74 |     40.27  
-----------+----------------------+---------- 
         1 |        24          5 |        29  
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           |      7.57       9.43 |      7.84  
-----------+----------------------+---------- 
         2 |         1          0 |         1  
           |      0.32       0.00 |      0.27  
-----------+----------------------+---------- 
         3 |         1          0 |         1  
           |      0.32       0.00 |      0.27  
-----------+----------------------+---------- 
         4 |         3          0 |         3  
           |      0.95       0.00 |      0.81  
-----------+----------------------+---------- 
         5 |        15          4 |        19  
           |      4.73       7.55 |      5.14  
-----------+----------------------+---------- 
         6 |       111         16 |       127  
           |     35.02      30.19 |     34.32  
-----------+----------------------+---------- 
         7 |         6          2 |         8  
           |      1.89       3.77 |      2.16  
-----------+----------------------+---------- 
         8 |        12          1 |        13  
           |      3.79       1.89 |      3.51  
-----------+----------------------+---------- 
         9 |         3          0 |         3  
           |      0.95       0.00 |      0.81  
-----------+----------------------+---------- 
        31 |         4          2 |         6  
           |      1.26       3.77 |      1.62  
-----------+----------------------+---------- 
        32 |         5          3 |         8  
           |      1.58       5.66 |      2.16  
-----------+----------------------+---------- 
        33 |         3          0 |         3  
           |      0.95       0.00 |      0.81  
-----------+----------------------+---------- 
     Total |       317         53 |       370  
           |    100.00     100.00 |    100.00  
 
           Fisher's exact =                 0.575 
 
No difference – all the categories are close 
 
 
17.1 Foetal Heart 
 
. tabulate FH inc2, exact col 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
 
           |         inc2 
        FH |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         0 |       136         22 |       158  
           |     49.45      46.81 |     49.07  
-----------+----------------------+---------- 
         1 |        89         20 |       109  
           |     32.36      42.55 |     33.85  
-----------+----------------------+---------- 
         2 |        47          5 |        52  
           |     17.09      10.64 |     16.15  
-----------+----------------------+---------- 
         3 |         3          0 |         3  
           |      1.09       0.00 |      0.93  
-----------+----------------------+---------- 
     Total |       275         47 |       322  
           |    100.00     100.00 |    100.00  
 
           Fisher's exact =                 0.484 
 
 
Stellenbosch University  https://scholar.sun.ac.za
166 
 
. tabulate FH inc2, exact col 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
 
           |         inc2 
        FH |     Forma      Mincs |     Total 
-----------+----------------------+---------- 
         0 |       136         22 |       158  
           |     49.45      46.81 |     49.07  
-----------+----------------------+---------- 
         1 |        89         20 |       109  
           |     32.36      42.55 |     33.85  
-----------+----------------------+---------- 
         2 |        47          5 |        52  
           |     17.09      10.64 |     16.15  
-----------+----------------------+---------- 
         3 |         3          0 |         3  
           |      1.09       0.00 |      0.93  
-----------+----------------------+---------- 
     Total |       275         47 |       322  
           |    100.00     100.00 |    100.00  
 





18. Clinical Pregnancy Rate 
 
. tabulate inc2 clin_pr, chi2 row 
  
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
   
           |        clin_pr 
      inc2 |         0          1 |     Total 
-----------+----------------------+---------- 
     Forma |       173        144 |       317 
           |     54.57      45.43 |    100.00 
-----------+----------------------+---------- 
     Mincs |        28         25 |        53 
           |     52.83      47.17 |    100.00 
-----------+----------------------+---------- 
     Total |       201        169 |       370 
           |     54.32      45.68 |    100.00 
  
          Pearson chi2(1) =   0.0557   Pr = 0.813 
  
No difference 
Some more modelling of risk difference (rd). Adjusted for age of ova, procedure used 
(IVF,PICSI ,ICSI),donor ova used,surrogate used and number of mii. 
  
. xi: binreg clin_pr i.inc2 ageova i.proc3 i.donova i.surr mii, rd 
i.inc2            _Iinc2_1-2          (naturally coded; _Iinc2_1 omitted) 
i.proc3           _Iproc3_0-2         (naturally coded; _Iproc3_0 omitted) 
i.donova          _Idonova_1-2        (_Idonova_1 for donova==0 omitted) 
i.surr            _Isurr_0-1          (naturally coded; _Isurr_0 omitted) 
  
Generalized linear models                         No. of obs      =        369 
Optimization     : MQL Fisher scoring             Residual df     =        361 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  494.2326504                   (1/df) Deviance =   1.369066 
Pearson          =  369.0002449                   (1/df) Pearson  =   1.022161 
  
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = u                       [Identity] 
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                                                  BIC             =  -1639.565 
  
------------------------------------------------------------------------------ 
             |                 EIM 
     clin_pr | Risk Diff.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    _Iinc2_2 |   .0482779   .0733129     0.66   0.510    -.0954128    .1919686 
      ageova |   .0085928   .0077341     1.11   0.267    -.0065657    .0237514 
   _Iproc3_1 |   -.152674   .0871449    -1.75   0.080    -.3234748    .0181268 
   _Iproc3_2 |  -.0766151   .0860183    -0.89   0.373    -.2452078    .0919777 
  _Idonova_2 |   .1953642   .0808181     2.42   0.016     .0369636    .3537648 
    _Isurr_1 |  -.0306542   .1606965    -0.19   0.849    -.3456136    .2843051 
         mii |   .0077962   .0042126     1.85   0.064    -.0004604    .0160528 




Estimated difference in pregnancy rate between minca and Forma incubators is 4.8% (95%CI: -9.5 
to 19.2%) 
,p=.51.  This adjusted difference is larger than the crude difference (47.2 versus 45.4%) and 
is due to the differences in adjusted factors. Confidence interval is wide reflecting the 
uncertainty of the sample size and estimate. No evidence based on the current study to say 
that the incubators have different performance. 
Intesting to note that there is a huge difference in clinical pregnancy rate between donated 
and orginal ova. 19.5% difference , p=.016. Suppose this is well known. 
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Appendix XVII - Prospective Data Results 
Clinical Pregnancy [Positive Foetal Sac] 
1. Endometriosis 
 
. tabulate fd_2 clin_pr, chi2 row 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
   FDiag== |        clin_pr 
    2.0000 |         0          1 |     Total 
-----------+----------------------+---------- 
         0 |       387        164 |       551  
           |     70.24      29.76 |    100.00  
-----------+----------------------+---------- 
         1 |        48         20 |        68  
           |     70.59      29.41 |    100.00  
-----------+----------------------+---------- 
     Total |       435        184 |       619  
           |     70.27      29.73 |    100.00  
 
          Pearson chi2(1) =   0.0036   Pr = 0.952 
 
 
Endometriosis and cpr by site ( already done previously with comments – see above) 
. by site, sort : tabulate fd_2 clin_pr, chi2 row 
 
------------------------------------------------------------------------------------------ 
-> site = aev 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
   FDiag== |        clin_pr 
    2.0000 |         0          1 |     Total 
-----------+----------------------+---------- 
         0 |       242        140 |       382  
           |     63.35      36.65 |    100.00  
-----------+----------------------+---------- 
         1 |        36         15 |        51  
           |     70.59      29.41 |    100.00  
-----------+----------------------+---------- 
     Total |       278        155 |       433  
           |     64.20      35.80 |    100.00  
 
          Pearson chi2(1) =   1.0255   Pr = 0.311 
 
------------------------------------------------------------------------------------------ 
-> site = tbh 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
   FDiag== |        clin_pr 
    2.0000 |         0          1 |     Total 
-----------+----------------------+---------- 
         0 |       145         24 |       169  
           |     85.80      14.20 |    100.00  
-----------+----------------------+---------- 
         1 |        12          5 |        17  
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           |     70.59      29.41 |    100.00  
-----------+----------------------+---------- 
     Total |       157         29 |       186  
           |     84.41      15.59 |    100.00  
 




2. Tubal Factor 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
   FDiag== |        clin_pr 
   14.0000 |         0          1 |     Total 
-----------+----------------------+---------- 
         0 |       368        164 |       532  
           |     69.17      30.83 |    100.00  
-----------+----------------------+---------- 
         1 |        67         20 |        87  
           |     77.01      22.99 |    100.00  
-----------+----------------------+---------- 
     Total |       435        184 |       619  
           |     70.27      29.73 |    100.00  
 
          Pearson chi2(1) =   2.1993   Pr = 0.138 
 
Tubal factor . by site, sort : tabulate fd_6 clin_pr, chi2 row 
 
------------------------------------------------------------------------------------------ 
-> site = aev 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
   FDiag== |        clin_pr 
   14.0000 |         0          1 |     Total 
-----------+----------------------+---------- 
         0 |       252        144 |       396  
           |     63.64      36.36 |    100.00  
-----------+----------------------+---------- 
         1 |        26         11 |        37  
           |     70.27      29.73 |    100.00  
-----------+----------------------+---------- 
     Total |       278        155 |       433  
           |     64.20      35.80 |    100.00  
 
          Pearson chi2(1) =   0.6480   Pr = 0.421 
 
------------------------------------------------------------------------------------------ 
-> site = tbh 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
   FDiag== |        clin_pr 
   14.0000 |         0          1 |     Total 
-----------+----------------------+---------- 
         0 |       116         20 |       136  
           |     85.29      14.71 |    100.00  
-----------+----------------------+---------- 
         1 |        41          9 |        50  
           |     82.00      18.00 |    100.00  
-----------+----------------------+---------- 
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     Total |       157         29 |       186  
           |     84.41      15.59 |    100.00  
 









. tabstat PatientAge DonorAge OocyteAge BMI count1 count2 mot1 mot2 NROocytes NrMII NrFer 
> t GQED2 GQED3 GQED4 GQED5 GQED6 GQED7 DayET NrET GQEET NrET, statistics( count min p25  
> p50 p75 max ) by(site) varwidth(8) columns(statistics) 
 
site     variable |         N       min       p25       p50       p75       max 
------------------+------------------------------------------------------------ 
1        Patien~e |       572        23        34        37        40        54 
         DonorAge |       108        19        23        24        28        44 
         Oocyte~e |       572        19        30        35        39        46 
              BMI |       468     15.12    20.855     23.31      26.5     45.36 
           count1 |       430         0        15        40        70       150 
           count2 |       429         0         3        12        30       101 
             mot1 |       430         0        30        50        55        80 
             mot2 |       429         0        50        90        95        99 
         NROocy~s |       463         0         4         8        13        66 
            NrMII |       460         0         3         6        11        46 
           NrFert |       427         0         3         5         9        39 
            GQED2 |       415         0         2         4         7        28 
            GQED3 |       366         0         2         4         7        22 
            GQED4 |        44         0         0       1.5         3        10 
            GQED5 |       247         0         1         3         5        17 
            GQED6 |        28         0         0         0       1.5         6 
            GQED7 |         8         0         0         0         0         1 
            DayET |       479         2         3         5         5         7 
             NrET |       533         0         1         2         2         8 
            GQEET |       478         0         1         2         2         5 
             NrET |       533         0         1         2         2         8 
------------------+------------------------------------------------------------ 
2        Patien~e |       248        25        32        35        38        45 
         DonorAge |         6        20        22      24.5        35        35 
         Oocyte~e |       248        20        31        35        38        45 
              BMI |       232      17.8     23.59     26.97    31.075     47.78 
           count1 |       224         0       4.5        40        65       300 
           count2 |       225       .01        .5        10        20       101 
             mot1 |       218         0        30        50        50        90 
             mot2 |       219         0        40        90        95        99 
         NROocy~s |       241         0         2         3         5        30 
            NrMII |       224         0         2         3         4        30 
           NrFert |       225         0         1         2         3        28 
            GQED2 |       198         0         1         2         3        14 
            GQED3 |       173         0         1         1         2        10 
            GQED4 |        40         0         0         1         2         4 
            GQED5 |        19         0         0         1         3         9 
            GQED6 |         1         0         0         0         0         0 
            GQED7 |         0         .         .         .         .         . 
            DayET |       185         1         3         3         3         6 
             NrET |       248         0         0         2         2         4 
            GQEET |       185         0         1         2         2         4 
             NrET |       248         0         0         2         2         4 
------------------+------------------------------------------------------------ 
Total    Patien~e |       820        23        33        36        40        54 
         DonorAge |       114        19        23        24        28        44 
         Oocyte~e |       820        19        31        35        38        46 
              BMI |       700     15.12    21.625     24.71     28.13     47.78 
           count1 |       654         0        10        40        70       300 
           count2 |       654         0         2        10        30       101 
             mot1 |       648         0        30        50        55        90 
             mot2 |       648         0        50        90        95        99 
         NROocy~s |       704         0         3         5        11        66 
            NrMII |       684         0         3         5         9        46 
           NrFert |       652         0         2         4         7        39 
            GQED2 |       613         0         2         3         6        28 
            GQED3 |       539         0         1         3         5        22 
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            GQED4 |        84         0         0         1         3        10 
            GQED5 |       266         0         1         3         5        17 
            GQED6 |        29         0         0         0         1         6 
            GQED7 |         8         0         0         0         0         1 
            DayET |       664         1         3         4         5         7 
             NrET |       781         0         1         2         2         8 
            GQEET |       663         0         1         2         2         5 
             NrET |       781         0         1         2         2         8 
------------------------------------------------------------------------------- 
 
. tabstat AMH BMI OocyteAge  NROocytes NrMII DayET NrET GQEET, statistics( count min p25 p 
> 50 p75 max ) by(site) varwidth(8) columns(statistics) 
 
site     variable |         N       min       p25       p50       p75       max 
------------------+------------------------------------------------------------ 
1  aevitas    AMH |       195       .08       .38       1.2      2.53     12.25 
              BMI |       468     15.12    20.855     23.31      26.5     45.36 
         Oocyte~e |       572        19        30        35        39        46 
         NROocy~s |       463         0         4         8        13        66 
            NrMII |       460         0         3         6        11        46 
            DayET |       479         2         3         5         5         7 
             NrET |       533         0         1         2         2         8 
            GQEET |       478         0         1         2         2         5 
------------------+------------------------------------------------------------ 
2  TBH        AMH |        85       .16       .72      1.38      3.48     18.88 
              BMI |       232      17.8     23.59     26.97    31.075     47.78 
         Oocyte~e |       248        20        31        35        38        45 
         NROocy~s |       241         0         2         3         5        30 
            NrMII |       224         0         2         3         4        30 
            DayET |       185         1         3         3         3         6 
             NrET |       248         0         0         2         2         4 
            GQEET |       185         0         1         2         2         4 
------------------+------------------------------------------------------------ 
Total         AMH |       280       .08      .505       1.3      2.78     18.88 
              BMI |       700     15.12    21.625     24.71     28.13     47.78 
         Oocyte~e |       820        19        31        35        38        46 
         NROocy~s |       704         0         3         5        11        66 
            NrMII |       684         0         3         5         9        46 
            DayET |       664         1         3         4         5         7 
             NrET |       781         0         1         2         2         8 
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Small decrease in cpr over increase in bmi. Data sparse above BMI>40. 
 
Number of participants over BMI=40 is small 
BMI and cpr by site and endometriosis. Endo has lower cpr but association the same across BMI. 
3.3 AMH 
 
Restricted to AMH <8 
No association up to AMH=4 then an increase – number above 4 small 
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Restricted to <10 
Trend is the same by at different levels. Lots of missing data which limits it use in the 
models. 
3.4 Age of Oocyte 
Very few young patients in tbh. Overall trends are the same confirming results from pooled 
analysis. No interaction between oocyteage and site with respect to the outcome clinical 
pregnancy. 
 
4. Regression models for CPR using the above factors as determinants in the model.  
 
Doing a binomial regression model with each of the determinants with CPR adjusted for site and 




. xi: binreg clin_pr BMI OocyteAge i.site , rr 
i.site            _Isite_1-2          (naturally coded; _Isite_1 omitted) 
 
 
Generalized linear models                         No. of obs      =        538 
Optimization     : MQL Fisher scoring             Residual df     =        534 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  626.5595503                   (1/df) Deviance =   1.173332 
Pearson          =  537.6985313                   (1/df) Pearson  =   1.006926 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  BIC             =  -2731.157 
 
------------------------------------------------------------------------------ 
             |                 EIM 
     clin_pr | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         BMI |   1.010109   .0124765     0.81   0.415     .9859497    1.034861 
   OocyteAge |   .9771112   .0100395    -2.25   0.024     .9576311    .9969877 
    _Isite_2 |   .3976129   .0773101    -4.74   0.000     .2716168    .5820555 
       _cons |   .6415825      .2856    -1.00   0.319     .2681271    1.535198 
------------------------------------------------------------------------------ 




. xi: binreg clin_pr AMH OocyteAge i.site , rr 
i.site            _Isite_1-2          (naturally coded; _Isite_1 omitted) 
Generalized linear models                         No. of obs      =        215 
Optimization     : MQL Fisher scoring             Residual df     =        211 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  256.7494394                   (1/df) Deviance =   1.216822 
Pearson          =  215.4731523                   (1/df) Pearson  =     1.0212 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  BIC             =  -876.4552 
 
------------------------------------------------------------------------------ 
             |                 EIM 
     clin_pr | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         AMH |   1.044782   .0333424     1.37   0.170     .9814338    1.112219 
   OocyteAge |   .9785973       .014    -1.51   0.130      .951539    1.006425 
    _Isite_2 |   .5059629   .1417104    -2.43   0.015     .2922225    .8760395 
       _cons |   .7039241    .339798    -0.73   0.467     .2732965    1.813083 
------------------------------------------------------------------------------ 
AMH not associated in this basic adjusted model. AMH not further used due to the extensive 
missing values in the data >65%!. This level of missingness can introduce severe bias in any 
result. 
 





. xi: binreg clin_pr fd_2 OocyteAge i.site , rr 
i.site            _Isite_1-2          (naturally coded; _Isite_1 omitted) 
 
 
Generalized linear models                         No. of obs      =        619 
Optimization     : MQL Fisher scoring             Residual df     =        615 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  717.3802174                   (1/df) Deviance =   1.166472 
Pearson          =  617.9320284                   (1/df) Pearson  =   1.004768 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  BIC             =  -3235.905 
 
------------------------------------------------------------------------------ 
             |                 EIM 
     clin_pr | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        fd_2 |   .9321431   .1841266    -0.36   0.722     .6329136    1.372843 
   OocyteAge |   .9726291   .0094621    -2.85   0.004     .9542594    .9913524 
    _Isite_2 |   .4482482   .0819427    -4.39   0.000     .3132661    .6413922 





4.4 Tubal Factor 
 
. xi: binreg clin_pr fd_6 OocyteAge i.site , rr 
i.site            _Isite_1-2          (naturally coded; _Isite_1 omitted) 
 
 
Generalized linear models                         No. of obs      =        619 
Optimization     : MQL Fisher scoring             Residual df     =        615 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  717.3898132                   (1/df) Deviance =   1.166488 
Pearson          =  617.3270852                   (1/df) Pearson  =   1.003784 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  BIC             =  -3235.895 
 
------------------------------------------------------------------------------ 
             |                 EIM 
     clin_pr | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        fd_6 |   .9311696   .1893196    -0.35   0.726     .6251263    1.387043 
   OocyteAge |   .9726314   .0094657    -2.85   0.004     .9542548    .9913618 
    _Isite_2 |   .4555812   .0849225    -4.22   0.000     .3161534    .6564985 





5. Combined binomial regression model 
 
. xi: binreg clin_pr BMI fd_2 fd_6 OocyteAge i.site  , rr 
i.site            _Isite_1-2          (naturally coded; _Isite_1 omitted) 
 
Generalized linear models                         No. of obs      =        538 
Optimization     : MQL Fisher scoring             Residual df     =        532 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  626.4162669                   (1/df) Deviance =   1.177474 
Pearson          =  537.9328769                   (1/df) Pearson  =   1.011152 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  BIC             =  -2718.724 
 




             |                 EIM 
     clin_pr | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         BMI |   1.010287   .0125675     0.82   0.411     .9859533    1.035222 
        fd_2 |   1.002177   .1997848     0.01   0.991     .6780419    1.481263 
        fd_6 |   .9246829   .1969432    -0.37   0.713      .609116    1.403737 
   OocyteAge |   .9772056   .0100608    -2.24   0.025     .9576844    .9971247 
    _Isite_2 |   .4025823   .0794859    -4.61   0.000     .2733967    .5928107 
       _cons |   .6408761   .2864065    -1.00   0.319     .2669153    1.538773 
------------------------------------------------------------------------------ 
 BMI, endo, tubal not associated with cpr 
 Age of oocytes is significantly associated rr=.98 (95%CI: .96 to .99), p=.025. Thus 
for every extra year the probability is 2% less than of the base year (relative). 
 Site TBH: negatively associated with cpr. Site is a proxy for the patient populations 
seen. 
 
6. Extended model 
 
Due to the strong impact of site the interaction of site with each of the determinants were 
investigated. There was a significant interaction between site and endometriosis. This term 
was therefore included in the final model. There were no other interactions: no interactions 
between oocyteage and site for example. Therefore the parameters estimated for oocyte age for 
example is the pooled estimate from both sites. 
 
 
. xi: binreg clin_pr BMI i.site*fd_2 fd_6 OocyteAge i.site  , rr 
i.site            _Isite_1-2          (naturally coded; _Isite_1 omitted) 
i.site*fd_2       _IsitXfd_2_#        (coded as above) 
note: _Isite_2 omitted because of collinearity 
 
 
Generalized linear models                         No. of obs      =        538 
Optimization     : MQL Fisher scoring             Residual df     =        531 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  623.2882881                   (1/df) Deviance =   1.173801 
Pearson          =  537.9222429                   (1/df) Pearson  =   1.013036 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  BIC             =  -2715.565 
 
------------------------------------------------------------------------------ 
             |                 EIM 
     clin_pr | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         BMI |   1.010459   .0125411     0.84   0.402     .9861754     1.03534 
    _Isite_2 |   .3552575   .0774896    -4.74   0.000     .2316739    .5447653 
        fd_2 |   .8778275   .2006671    -0.57   0.569     .5608267    1.374009 
_IsitXfd_2_2 |   2.573437   1.230724     1.98   0.048     1.007938    6.570425 
        fd_6 |   .9467217   .2006154    -0.26   0.796     .6249542    1.434156 
   OocyteAge |   .9766213   .0099948    -2.31   0.021     .9572271    .9964085 
    _Isite_2 |          1  (omitted) 
       _cons |   .6584946    .292872    -0.94   0.348      .275405    1.574463 
------------------------------------------------------------------------------. 
 lincom fd_2+ _IsitXfd_2_2 , eform 
 
 ( 1)  fd_2 + _IsitXfd_2_2 = 0 
------------------------------------------------------------------------------ 
     clin_pr |     exp(b)   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         (1) |   2.259034   .9565067     1.92   0.054     .9851722    5.180044 
 
 Impact endo on cpr significantly different between the two sites. 
For the Aviates site endo is not associated with cpr rr=.88 (95%CI: 1.01 to 6.57), 
p=.569. For TBH endometriosis diagnosis is positively associated with cpr, rr=2.26 
(95%CI: .99 to 5.18) p=.054. Both these estimates are adjusted for the other factors 
in the model. 
 Oocyte age is negatively associated with cpr. The rr=.98 (95%ci: .96 to .99) , p=.021 
indicates that the probability of having a clinical pregnancy decreases by  a relative 
2% for every year. The association is linear over age – non-linear effects not 
significant ( tests not shown) 
 BMI not associated with cpr. Again the same effect over both sites. 
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 Tubal factor not a determinant for cpr, p=.796. Again there was no association with 




7. CPR tabulated by ENDOMETRIOSiS by site to understand results from the model. 
 
. by site, sort : tabulate fd_2 clin_pr, chi2 row (endo) 
 
------------------------------------------------------------------------------------------ 
 site = 1 Private Clinic 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
   FDiag== |        clin_pr 
    2.0000 |         0          1 |     Total 
-----------+----------------------+---------- 
         0 |       242        140 |       382  
           |     63.35      36.65 |    100.00  
-----------+----------------------+---------- 
         1 |        36         15 |        51  
           |     70.59      29.41 |    100.00  
-----------+----------------------+---------- 
     Total |       278        155 |       433  
           |     64.20      35.80 |    100.00  
 




site = 2 – Public Clinc 
 
+----------------+ 
| Key            | 
|----------------| 
|   frequency    | 
| row percentage | 
+----------------+ 
 
   FDiag== |        clin_pr 
    2.0000 |         0          1 |     Total 
-----------+----------------------+---------- 
         0 |       145         24 |       169  
           |     85.80      14.20 |    100.00  
-----------+----------------------+---------- 
         1 |        12          5 |        17  
           |     70.59      29.41 |    100.00  
-----------+----------------------+---------- 
     Total |       157         29 |       186  
           |     84.41      15.59 |    100.00  
 
          Pearson chi2(1) =   2.7155   Pr = 0.099 
 
 
7.1 Aevitas model 
 
. xi: binreg clin_pr BMI fd_2 fd_6 OocyteAge if site==1 , rr 
 
Generalized linear models                         No. of obs      =        362 
Optimization     : MQL Fisher scoring             Residual df     =        357 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  475.0962933                   (1/df) Deviance =   1.330802 
Pearson          =  361.2208737                   (1/df) Pearson  =   1.011823 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  BIC             =  -1628.221 





             |                 EIM 
     clin_pr | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         BMI |   1.010718   .0137547     0.78   0.433     .9841155    1.038039 
 endo   fd_2 |   .8672684   .1983603    -0.62   0.534     .5539467     1.35781 
 tubal  fd_6 |   .8274202   .2187221    -0.72   0.474     .4928532    1.389104 
   OocyteAge |   .9776321    .010385    -2.13   0.033     .9574883    .9981997 





7.2 TBH model 
 
. xi: binreg clin_pr BMI fd_2 fd_6 OocyteAge if site==2 , rr 
 
Generalized linear models                         No. of obs      =        176 
Optimization     : MQL Fisher scoring             Residual df     =        171 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  147.0799297                   (1/df) Deviance =   .8601165 
Pearson          =  176.9143285                   (1/df) Pearson  =   1.034587 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  BIC             =  -737.0728 
 
------------------------------------------------------------------------------ 
             |                 EIM 
     clin_pr | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         BMI |    1.01028   .0315699     0.33   0.743     .9502609     1.07409 
        fd_2 |   2.599755   1.164539     2.13   0.033     1.080547    6.254912 
        fd_6 |   1.363064   .5574569     0.76   0.449     .6115013    3.038331 
   OocyteAge |   .9688466    .037524    -0.82   0.414     .8980231    1.045256 
       _cons |   .2733733   .4179925    -0.85   0.396     .0136538    5.473411 
 
 
8. Models with MII Oocytes 
 
 
8.1 Model with all interactions 
 
For formal analysis of the risk factors see models above. 
Also table with descriptive stats above by site done previously. 
Models with NR MII returned 
The relative risk models did not converge and I therefore used a binomial regression model 
with odds ratios to quantify the risk. 
Started with a model that had all the intereactions. This is to test if any association with 
cpr is different between sites. 
The first model shows that there is no factor with an interaction with site. Took out some of 
the interactions but in the end none were significant. The final model is therefore a main 
effects model where there is an adjustment for site only. The site effect adjusts for the 
level of response in cpr but not in the type of association. In the final model only site and 
number of MII oocytes available were significant factors. This is true across both sites One 
get a very stable estimate by doing a pooled analysis. With adjusting for Nr MII also in the 
model the interaction of endometriosis and site disappear. None of the other factors are 
significant. Nr MII is therefore such a dominant factor that it swamps all other risk factors 
Model with all interactions(yellow) 
 
.  xi: binreg clin_pr i.site*BMI i.site*fd_2 i.site*fd_6 i.site*OocyteAge i.site  i.site*N 
> rMII , or 
i.site            _Isite_1-2          (naturally coded; _Isite_1 omitted) 
i.site*BMI        _IsitXBMI_#         (coded as above) 
i.site*fd_2       _IsitXfd_2_#        (coded as above) 
Stellenbosch University  https://scholar.sun.ac.za
178 
 
i.site*fd_6       _IsitXfd_6_#        (coded as above) 
i.site*Oocyte~e   _IsitXOocyt_#       (coded as above) 
i.site*NrMII      _IsitXNrMII_#       (coded as above) 
 
Generalized linear models                         No. of obs      =        457 
Optimization     : MQL Fisher scoring             Residual df     =        445 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  507.3379559                   (1/df) Deviance =   1.140085 
Pearson          =  455.0601087                   (1/df) Pearson  =   1.022607 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u/(1-u))             [Logit] 
 
                                                  BIC             =  -2218.146 
 
------------------------------------------------------------------------------- 
              |                 EIM 
      clin_pr | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
     _Isite_2 |   2.242697   4.992907     0.36   0.717     .0285591    176.1153 
          BMI |   1.042624   .0274358     1.59   0.113     .9902142    1.097808 
  _IsitXBMI_2 |   .9763252   .0443222    -0.53   0.598     .8932079    1.067177 
     _Isite_2 |          1  (omitted) 
         fd_2 |   .9152843   .3522441    -0.23   0.818     .4305009    1.945979 
 _IsitXfd_2_2 |   3.293774   2.394945     1.64   0.101     .7920898    13.69662 
     _Isite_2 |          1  (omitted) 
         fd_6 |   .6717523    .316736    -0.84   0.399     .2666008     1.69261 
 _IsitXfd_6_2 |   2.201427   1.492286     1.16   0.244     .5830404    8.312084 
     _Isite_2 |          1  (omitted) 
    OocyteAge |   .9974493   .0241534    -0.11   0.916     .9512154     1.04593 
_IsitXOocyt_2 |   .9670134   .0527008    -0.62   0.538     .8690471    1.076023 
     _Isite_2 |          1  (omitted) 
     _Isite_2 |          1  (omitted) 
        NrMII |   1.089135   .0269443     3.45   0.001     1.037585    1.143246 
_IsitXNrMII_2 |   .9437219   .0593856    -0.92   0.357     .8342198    1.067598 




8.2 Model with only certain interactions 
 
.  xi: binreg clin_pr BMI i.site*fd_2 i.site*fd_6 i.site*OocyteAge i.site  NrMII , or 
i.site            _Isite_1-2          (naturally coded; _Isite_1 omitted) 
i.site*fd_2       _IsitXfd_2_#        (coded as above) 
i.site*fd_6       _IsitXfd_6_#        (coded as above) 
i.site*Oocyte~e   _IsitXOocyt_#       (coded as above) 
Generalized linear models                         No. of obs      =        457 
Optimization     : MQL Fisher scoring             Residual df     =        447 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  508.4742871                   (1/df) Deviance =   1.137526 
Pearson          =  458.2456187                   (1/df) Pearson  =   1.025158 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u/(1-u))             [Logit] 
 
                                                  BIC             =  -2229.259 
 
------------------------------------------------------------------------------- 
              |                 EIM 
      clin_pr | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
          BMI |   1.034378   .0220338     1.59   0.113     .9920812    1.078477 
     _Isite_2 |   .8078238   1.534963    -0.11   0.911     .0194954    33.47357 
         fd_2 |   .9125414   .3491958    -0.24   0.811     .4310516    1.931861 
 _IsitXfd_2_2 |   3.314479   2.411893     1.65   0.100      .796177    13.79815 
     _Isite_2 |          1  (omitted) 
         fd_6 |   .6847531   .3188442    -0.81   0.416      .274907     1.70562 
 _IsitXfd_6_2 |   2.198688   1.488462     1.16   0.245      .583337      8.2872 
     _Isite_2 |          1  (omitted) 
    OocyteAge |   .9935871   .0234946    -0.27   0.786     .9485892    1.040719 
_IsitXOocyt_2 |   .9693866     .05291    -0.57   0.569     .8710391    1.078838 
     _Isite_2 |          1  (omitted) 
        NrMII |   1.078187   .0236195     3.44   0.001     1.032873    1.125488 
        _cons |   .1862943   .1943539    -1.61   0.107     .0241086     1.43955 
------------------------------------------------------------------------------- 





8.3 Model with interactions with diagnostic factors 
 
.  xi: binreg clin_pr BMI i.site*fd_2 i.site*fd_6 OocyteAge i.site  NrMII , or 
i.site            _Isite_1-2          (naturally coded; _Isite_1 omitted) 
i.site*fd_2       _IsitXfd_2_#        (coded as above) 
i.site*fd_6       _IsitXfd_6_#        (coded as above) 
note: _Isite_2 omitted because of collinearity 
note: _Isite_2 omitted because of collinearity 
 
Generalized linear models                         No. of obs      =        457 
Optimization     : MQL Fisher scoring             Residual df     =        448 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  508.7987489                   (1/df) Deviance =   1.135711 
Pearson          =  456.5784715                   (1/df) Pearson  =   1.019148 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u/(1-u))             [Logit] 
 
                                                  BIC             =  -2235.059 
 
------------------------------------------------------------------------------ 
             |                 EIM 
     clin_pr | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         BMI |   1.033769   .0219799     1.56   0.118     .9915743    1.077759 
    _Isite_2 |    .277525   .0958186    -3.71   0.000     .1410637    .5459952 
        fd_2 |   .9130412   .3495845    -0.24   0.812     .4311049    1.933739 
_IsitXfd_2_2 |   3.166845   2.286743     1.60   0.110     .7691018    13.03977 
    _Isite_2 |          1  (omitted) 
        fd_6 |   .6835159   .3181832    -0.82   0.414     .2744771    1.702123 
_IsitXfd_6_2 |    2.24028   1.513321     1.19   0.232     .5960891    8.419641 
   OocyteAge |   .9879087   .0211498    -0.57   0.570     .9473136    1.030243 
    _Isite_2 |          1  (omitted) 
       NrMII |   1.075949   .0232241     3.39   0.001      1.03138    1.122444 
       _cons |   .2338454   .2251485    -1.51   0.131     .0354311    1.543382 
------------------------------------------------------------------------------ 
 
8.4 Final model with all interaction omitted since they were not significant 
 
.  xi: binreg clin_pr BMI fd_2 fd_6 OocyteAge i.site  NrMII , or 
i.site            _Isite_1-2          (naturally coded; _Isite_1 omitted) 
 
Generalized linear models                         No. of obs      =        457 
Optimization     : MQL Fisher scoring             Residual df     =        450 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  512.0612712                   (1/df) Deviance =   1.137914 
Pearson          =    456.50605                   (1/df) Pearson  =   1.014458 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u/(1-u))             [Logit] 
 
                                                  BIC             =  -2244.046 
 
------------------------------------------------------------------------------ 
             |                 EIM 
     clin_pr | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         BMI |   1.030499   .0216113     1.43   0.152     .9890006    1.073739 
        fd_2 |    1.22024   .4015392     0.60   0.545     .6402421    2.325662 
        fd_6 |   .9506806   .3169077    -0.15   0.879     .4946386    1.827179 
   OocyteAge |   .9894298   .0211367    -0.50   0.619      .948858    1.031736 
    _Isite_2 |   .3855531   .1062295    -3.46   0.001     .2246761    .6616244 
       NrMII |   1.077137   .0231901     3.45   0.001     1.032631    1.123561 
       _cons |   .2229341   .2132613    -1.57   0.117     .0341907    1.453602 
------------------------------------------------------------------------------ 
 
 Tbh site has significantly lower cpr or=.39 (95%CI:.22 to .66), p=.001 
 The number of MII oocytes available are significantly associated with cpr or=1.08 
(95%CI: 1.03 to 1.12) p=.001. Nr MII used a a continuos variables and or increases by 
8% for every additional mature occyte available. From the scatter plot and smooth the 
strong association is clear, linear and the same across both sites 
 By testing for interactions and founding none we can pool the data and do a better 
analysis of the risk factors. The patient population at tbh has a lower cpr profile 
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but the risk profile with respect to other factors is the same as for AEV. By having 
more MI oocytes in tbh will offset the risk profile of tbh.  Site is a proxy for many 
elements. 
To reflect the association with Nr MII a lowess smooth and categorised table are presented. In 
the tbh table the cpr is lower but you still have the positive association. Thus taking the 
difference due to site into account the association of nR Mii is the same across both sites. 
generate nummii= NrMII 
(239 missing values generated) 
 
. recode nummii (1/10=1) (11/20=2) (21/30=3) (30/max=4) 
(nummii: 608 changes made) 
 
9. Separate models for sites 
9. 1 Site 1 
xi: binreg clin_pr BMI fd_2 fd_6 OocyteAge  NrMII if site==1, or 
 
 
Generalized linear models                         No. of obs      =        287 
Optimization     : MQL Fisher scoring             Residual df     =        281 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  362.3304316                   (1/df) Deviance =   1.289432 
Pearson          =  284.7727901                   (1/df) Pearson  =   1.013426 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u/(1-u))             [Logit] 
 
                                                  BIC             =  -1227.984 
 
------------------------------------------------------------------------------ 
             |                 EIM 
     clin_pr | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         BMI |   1.042624   .0274358     1.59   0.113     .9902142    1.097808 
        fd_2 |   .9152843   .3522441    -0.23   0.818     .4305009    1.945979 
        fd_6 |   .6717523    .316736    -0.84   0.399     .2666008     1.69261 
   OocyteAge |   .9974493   .0241534    -0.11   0.916     .9512154     1.04593 
       NrMII |   1.089135   .0269443     3.45   0.001     1.037585    1.143246 
       _cons |   .1233397    .140649    -1.84   0.066     .0131961    1.152818 
------------------------------------------------------------------------------ 
 
9.2 Site 2 
 
.  xi: binreg clin_pr BMI fd_2 fd_6 OocyteAge  NrMII if site==2, or 
 
 
Generalized linear models                         No. of obs      =        170 
Optimization     : MQL Fisher scoring             Residual df     =        164 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  145.0075243                   (1/df) Deviance =   .8841922 
Pearson          =  170.2873186                   (1/df) Pearson  =   1.038337 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u/(1-u))             [Logit] 
 
                                                  BIC             =  -697.2634 
 
------------------------------------------------------------------------------ 
             |                 EIM 
     clin_pr | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         BMI |    1.01794   .0376562     0.48   0.631     .9467476    1.094486 
        fd_2 |    3.01474   1.859843     1.79   0.074      .899766    10.10113 
        fd_6 |   1.478814   .7202162     0.80   0.422      .569323    3.841211 
   OocyteAge |   .9645469   .0470923    -0.74   0.460     .8765262    1.061407 
       NrMII |   1.027841   .0594708     0.47   0.635     .9176461    1.151268 
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